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Abstract 
Capacity to perfonn prolonged exercise is reduced in high ambient temperatures, but 
this premature fatigue is not adequately explained by peripheral mechanisms. The aim 
of this thesis was to examine some possible underlying mechanisms of central fatigue 
operating during prolonged exercise in a wann environment. 
, 
The first series of experiments investigated the effect of nutritional manipulation of 
central serotonergic activity through alterations to the plasma concentration ratio of 
free-tryptophan to branched-chain amino acids (f-TRP:BCAA). In contrast to 
previous reports, acute BCAA supplementation failed to alter perceived exertion and 
delay the onset of fatigue (Chapter 3). This response was similar when exercise was 
preceded by an exercise and diet regimen designed to reduce glycogen availability 
(Chapter 4). The ingestion of meals containing added carbohydrate and fat did not 
alter f-TRP:BCAA at rest (Chapter 5). 
Acute dopaminergic / noradrenergic reuptake inhibition with bupropion increased 
exercise perfonnance by 9 % in wann conditions (30 QC), but this effect was not 
apparent at 18 QC (Chapter 6). This response was accompanied by attainment of a 
higher core temperature and heart rate towards the end of the bupropion trial in the 
heat despite no detectable difference in perceived exertion and thennal stress. These 
data suggested that maintenance of catecholaminergic activity may dampen inhibitory 
signals from the CNS due to the attainment of a high core temperature, allowing 
power output to be maintained. 
The blood-brain barrier (BBB) regulates the exchange of substances between the 
cerebral interstitial fluid and the blood to maintain a stable environment for the CNS. 
If the BBB is compromised this may adversely influence nonnal brain function. 
Serum SI OOb, a proposed peripheral marker of BBB penneability, was increased 
following exercise in a wann environment (Chapter 7). These data indicate that 
exposure to combined exercise and heat stress may result in a loss ofBBB integrity. 
Keywords: central nervous system, serotonin, catecholamines, blood-brain barrier, 
heat stress, core temperature 
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Chapter 1 General Introduction 
1.1 - Fatigue during prolonged exercise 
The development of fatigue during prolonged submaximal exercise has featured as a 
predominant area of exercise-related research, yet a number of unanswered questions 
remain. Fatigue has been defined as the inability to maintain the required or expected 
power output that leads to a loss of performance in a given task (Edwards, 1981). This 
definition can be sub-categorised into central and peripheral components, relating to 
the location of the inhibition. Central fatigue refers to a loss of neural drive, resulting 
in a reduction in motor unit recruitment. While peripheral fatigue encompasses events 
that occur independently of central fatigue, including disturbances to neuromuscular 
transmission, sarcolemma excitability and excitation-contraction coupling (Davis, 
2000). 
Factors thought to be important in the development of peripheral fatigue during 
prolonged exercise include the depletion of muscle glycogen (Bergstrom et aI., 1967) 
limiting the rate of ADP rephosphorylation (Maughan et aI., 1997) and the loss of 
body fluids resulting in increased cardiovascular, metabolic and thermoregulatory 
strain. The latter is thought to be particularly important when exercise is performed in 
warm ambient conditions, as it elevates body heat storage, accelerating the 
development of hyperthermia (Sawka et aI., 1992). The attainment of a high core 
temperature is associated with a reduction in motivation and drive to continue 
exercise and is thought to be a key factor in the development of fatigue during 
exercise in the heat, thus serving as a form of safety mechanism limiting further heat 
production (Bruck and Olschewski, 1987; Nielsen, 1992). 
The notion that the CNS is involved in the development of fatigue is not new. Early 
work conducted by Alessandro Mosso (1904) crudely demonstrated a reduced 
capacity to perform repeated muscle contractions following a mental effort and 
resulted in the development of the term 'mental fatigue' (Mosso, 1904). Since this 
original work many advances have been made to clarify the role of the CNS in the 
development of fatigue (for a review see Gandevia, 2001). While there have been a 
number of neurobiological mechanisms proposed to explain the apparent loss of 
neural drive referred to as central fatigue, the neurotransmitter hypothesis put forward 
by Newsholme and colleagues (1987) has received the greatest academic recognition. 
2 
Chapter 1 General Introduction 
1.2 - Central Nenrotransmission 
Neurotransmitters are a group of chemicals released from nerve endings to transmit 
impulses across synapses to other neurons or across gaps that exist between the nerves 
and the muscles or glands that they supply (Cooper et aI., 2003). Four criteria have 
been proposed for a compound to qualify as a neurotransmitter (Kandel et aI., 2000): 
I) it has to be synthesised by a neuron 2) it is present in the presynaptic terminal and 
when released exerts an action on a postsynaptic neuron / effector organ 3) when 
exogenously administered it mimics the action of the endogenous transmitter 4) a 
mechanism exists to remove it from the site of action. At present around 60 biological 
substances have been classified as neurotransmitters, including acetylcholine (ACh), 
biogenic amines (serotonin, dopamine, noradrenaline), neuropeptides (endorphins, 
melatonin etc), some amino acids (glutamate, GABA etc) and gases (nitric oxide). 
Neurotransmitters act by either binding to receptors located on the post-synaptic 
membrane producing a rapid change through ion channels within the cell, whereas 
others exert an effect through the activation of secondary messenger systems 
subsequently influencing enzymatic reactions inside the cell (Cooper et aI., 2003). 
Although all neurotransmitters play important roles within the CNS, for the purpose 
of this review only serotonin (5-hydroxytryptamine; 5-HT), dopamine (DA) and 
noradrenaline (NA) will be discussed in detail, as these have been implicated in the 
genesis of central fatigue during prolonged physical exertion. 
1.2.1 - Serotonin 
Within the mammalian brain, serotonergic neurons comprise one of the smallest but 
most widely distributed neuronal systems. 5-HT cell bodies originate primarily in 
clusters found in the brainstem, with dense collections of cells present in, or near, the 
raphe nuclei (Jacobs and Azmitia, 1992). These have been divided into two 
functionally significant groups: the superior group supplying the forebrain and the 
inferior group largely projecting into the spinal cord (Jacobs and Fomal, 1997). 
Serotonergic fibres project outwards throughout the brain and spinal cord, enabling 
the innervation of almost all areas of the brain. Despite its apparent central 
importance, 5-HT has a relatively small presence in the CNS. Around I in every I 
3 
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million CNS neurons is classified as serotonergic, with only 1 - 2 % of the body's 5-
HT content present within the CNS (Cooper et aI., 2003). Many non-nervous cells, 
including the chromaffin cells of the gastrointestinal tract, mast cells and blood 
platelets are capable of synthesising and / or transporting this biogenic amine (Struder 
and Weicker, 200Ia). 
The activity of central serotonergic neurons changes throughout the sleep-wake-
arousal cycle, exhibiting a strong positive relationship with level of behavioural 
arousal (Trulson and Jacobs, 1979). The investigation of 5-HT neuronal firing rate in 
the dorsal raphe neclei (DRN) of the domestic cat has demonstrated that serotonergic 
neurons exhibit a slow regular discharge rate during quiet waking state that increases 
significantly during periods of arousal. An elevation in the firing rate of serotonergic 
neurons during periods of arousal and stress has been associated with increased brain 
5-HT content (Chaouloff et aI., 1985; Chaouloff et aI., 1986a). Whilst sleeping a 
progressive fall in neuronal discharge rate is apparent, with almost no activity 
measurable during rapid eye movement (REM) sleep. It is this characteristic pattern 
of neuronal activity that has led to the suggestion that the serotonergic system acts as 
a neuromodulator, rather than directly mediating behavioural and physiological 
responses (Gandevia, 2001; Jacobs and Azmitia, 1992; Trulson and Jacobs, 1979). 
This premise may be important to the ideas presented in this thesis, and will be 
discussed further. 
As 5-HT is charged at physiological pH (PK = 9.8), it is unable to cross the blood-
brain barrier (BBB) or readily diffuse across cell membranes from the extracellular 
space. Therefore, neurons are required to synthesize it for themselves, and it is the 
presence of enzymes required in this process that specifically characterises the 
serotonergic system (Cooper et aI., 2003). The initial step in this process is the 
cerebral uptake of the amino acid tryptophan (TRP), which acts as the substrate in the 
formation of 5-HT. TRP delivered to serotonergic neurons first undergoes 
hydroxylation by the rate-limiting enzyme tryptophan hydroxylase to form 5-
hydroxytrptophan (5-HTP). 5-HTP is then decarboxylated into 5-HT by aromatic L-
amino acid decarboxylase. This step in 5-HT synthesis occurs rapidly, so little 5-HTP 
is present within the brain at anyone time. Under resting conditions in healthy 
individuals tryptophan hydroxylase is approximately 50 % saturated. Therefore an 
4 
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Increase or decrease in TRP transport across the BBB produces a corresponding 
change in the rate of 5-HT synthesis within the CNS (Hamon et aI., 1981). The fate of 
increased 5-HT synthesis is discussed below. 
After release into the synapse from presynaptic vesicles, the action of 5-HT is 
terminated by reuptake into the presynaptic nerve terminal (Cooper et aI., 2003). 
Pharmacological agents that selectively inhibit this uptake process (selective serotonin 
reuptake inhibitors; SSRI) increase the concentration of 5-HT present at the 
postsynaptic receptors and have been widely administered in the treatment of various 
psychiatric disorders, in particular depression. Following reuptake, serotonin may 
return to the synaptic vesicles for reuse or be metabolised by monoamine oxidase A 
(MAO A) to 5-hydroxyindole acetaldehyde and then oxidised by aldehyde 
dehydrogenase to 5-hydroxyindoleacetic acid (5-HIAA). The concentration of 5-
HIAA present in the brain and CSF has been used as marker of serotonergic activity 
in psychiatric disorders. The metabolic pathways involved in the synthesis and 
metabolism of serotonin are shown in Figure 1.1. 
5 
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Tryptophan 
Tryptophan 
Hydroxylase. 
General Introduction 
COOH 
-0-WCH'-C~-NH' 
5-hydroxytryptophan 
amino acid 
decarboxylase 
H0Q:JCH'-CH,- NH, 
5-hydroxytryptamine 
(5-HT; Serotonin) 
Monoamine 
oxidase 
+ 
aldehyde 
dehydrogenase 
o 
~II HO~Nj CH,-C-OH 
5-hydroxy-indole-acetic-acid 
Figure 1.1: The metabolic pathway for synthesis and metabolism of 5-HT (Cooper et 
aI., 2003) 
The rate of 5-HT synthesis is largely dependent upon the peripheral availability of the 
essential amino acid, TRP, which is supplied from dietary proteins (e.g. meats, nuts, 
milk, eggs etc). It was initially believed that the concentration of plasma TRP was the 
only determinant of 5-HT synthesis (Fernstrom and Wurtman, 1971), but subsequent 
work has gradually revealed that the situation is complicated by additional factors 
relating to the transport of TRP across the BBB. 
A series of studies undertaken by Fernstrom and colleagues has helped clarify the role 
of competing amino acids in limiting TRP uptake across the BBB, and demonstrated 
that brain TRP content is not wholly dependent upon levels of circulating plasma TRP 
(Fernstrom and Faller, 1978; Fernstrom et aI., 1976; Fernstrom and Wurtman, 1971; 
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Femstrom and Wurtman, 1972; Leathwood and Femstrom, 1990; Pan et aI., 1982). A 
marked increase in brain 5-HT levels was reported following the ingestion of a CHO-
containing meal, resulting from a transient fall in plasma large neutral amino acids 
(LNAA) concentrations caused by the release of insulin (Femstrom and Wurtman, 
1971). This response was attenuated when protein was added to the ingested meal 
(Femstrom and Wurtman, 1972). It is now accepted that TRP uptake into the CNS 
occurs via a specific BBB transporter shared in competition with other LNAA 
(Hargreaves and Pardridge, 1988). This work led to the suggestion that the plasma 
concentration ratio of TRP to competing amino acids is important in determining the 
rate of cerebral TRP uptake, with an increase in this ratio leading to increased brain 
TRP and 5-HT content (Femstrom, 1983). 
However, this situation is further complicated by a degree of controversy regarding 
the availability of plasma TRP for uptake into the CNS by the LNAA-carrier (Bloxam 
et aI., 1980; Femstrom et aI., 1976; Knott and Curzon, 1972; Madras et aI., 1974a; 
Pardridge, 1979). Following intestinal absorption, around 80 - 90 % ofTRP circulates 
in the blood loosely bound to albumin (McMenamy and Oncley, 1958), with the 
remaining fraction circulating in a free form (free-tryptophan; f-TRP). Originally it 
was believed that albumin-bound TRP was not available for CNS uptake (Knott and 
Curzon, 1972), but subsequent findings have failed to identify a significant 
association between changes in the size of the f-TRP pool and brain TRP content 
(Femstrom et aI., 1976; Madras et aI., 1974a; Madras et aI., 1974b; Pardridge, 1979). 
While Bloxam and colleagues (1980) subsequently reported that TRP binding to 
albumin was important in determining brain TRP uptake, the balance of evidence 
suggests that under resting conditions total-TRP concentration closely reflects the 
availability ofTRP for uptake into the CNS (Femstrom, 1983; Pardridge, 1983). The 
apparent poor correlation between plasma f-TRP and brain TRP content may be 
explained by the ability of the LNAA-transporter to directly disassociate TRP from 
albumin during passage through the brain capillaries (Pardridge, 1983). Changes in 
cerebral blood flow and BBB transport may alter the kinetics of amino acid transport 
during exercise. This is considered in Section 1.3. 
While the studies described above contributed to knowledge regarding the influence 
of diet on central serotonergic neurotransmission, it is important to recognise the 
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limitations of this early work. These findings are based on the association between 
concentrations of circulating amino acids and changes in the brain TRP and 5-HT 
content, but an increase in 5-HT synthesis may not produce a comparable change in 
synaptic 5-HT release. As early studies analysed the tissue content of brain 
homogenates, what is unclear from these data is how the kinetics of transmitter 
storage and release are influenced by an upregulation of 5-HT synthesis (Meeusen et 
aI., 200la). The development of in vivo brain microdialysis has enabled the direct 
analyses of extracellular neurotransmitters and metabolites from the brain of resting 
and active animals with limited tissue trauma. Meeusen and co-workers (1996) 
demonstrated that increased TRP availability resulted in an elevation in extracellular 
5-HT and 5-HIAA concentrations in 24-hour fasted, but not fed, rats. The apparent 
discrepancy between these metabolic states has been ascribed to an increased TRP 
delivery and an upregulation in serotonergic neuron firing rate in food-deprived 
animals. It is important to note that microdialysis studies only consider changes in a 
single brain structure (e.g. hippocampus, hypothalamus etc) and these findings may 
not reflect changes in other areas of the brain. Additionally, the effect of changes in 
substratc supply on the balance between neurotransmitter storage and release may 
vary across speCIes. 
It is naIve to believe that the only regulator of 5-HT release and synthesis is the 
delivery of TRP to a serotonergic neuron. A number of subtle control factors have 
been proposed to influence 5-HT synthesis, including the availability of oxygen and 
pteridine - cofactors that are required in the hydroxylation of TRP (Cooper et aI., 
2003). Serotonin release is thought to be influenced by the activity of serotonergic and 
other neurotransmitter systems, including DA and GABA as well as cerebral glucose 
availability (Bequet et aI., 2002). Additionally, increases in extracellular 5-HT 
concentrations have been demonstrated to activate 5-HT1A (and potentially 5-HT1BIlD) 
autoreceptors producing a negative feedback, normalising 5-HT levels due to a 
reduction in the firing rate of the neuron (Artigas et aI., 1996). This response this 
thought to be largely responsible for the delayed therapeutic response observed 
following the administration of SSRI in the treatment of symptoms of depression. 
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1.2.2 - Dopamine and Noradrenaline 
The pnmary catecholaminergic neurotransmitters important to the study of brain 
neurochemistry are dopamine (DA) and noradrenaline (NA). While the existence of 
dopamine has long been known, its function as a neurotransmitter and distribution 
within the brain has only been explored relatively recently. Dopaminergic neurons 
within the brain originate from the ventral tegmental area (VTA) and substantia nigra 
in the midbrain and project to areas of the striatum, frontal cortex and the limbic 
system (Cooper et aI., 2003). The cells of the NA system are found in clusters around 
the brain stem, originating from the locus ceruleus and lateral brain stem tegmentum. 
These nerve fibers give rise to the five major NA tracts that innervate almost every 
part of the brain, including the cerebral cortex, thalamus, hypothalarnus, cerebellum, 
midbrain and the spinal cord. Noradrenaline is also released by sympathetic neurons 
of the autonomic nervous system, playing an important role in regulation vascular 
tone (Astrand et aI., 2003). 
The catecholaminergic neurotransmitters are synthesised through a shared metabolic 
pathway, with the amino acid tyrosine (TYR) acting as the precursor (Figure 1.2). 
TYR is found in protein-rich dietary sources, including chicken and milk, but unlike 
TRP it is a non-essential LNAA that can also be synthesised from phenylalanine in 
the liver. Cerebral uptake of TYR is subject to competitive transport across the BBB 
by the LNAA-carrier system, which is shared with TRP and the other LNAA as 
discussed above (Fernstrom, 1983). The first step in the synthesis of DA and NA is 
the conversion of TYR to dihydroxyphenylalanine (DOPA) by tyrosine hydroxylase. 
This is the rate-limiting step, with the other enzymes in the biosynthetic pathway 
possessing an activity 100 - 1000 times greater than tyrosine hydroxylase (Cooper et 
aI., 2003). Tyrosine hydroxylase is thought to be fully saturated with substrate under 
resting conditions (unlike tryptophan hydroxylase), so an increase in TYR delivery 
into the CNS would produce little effect on rates of dopamine synthesis (Davis and 
Bailey, 1997; Nestler et aI., 2001). Although there is some evidence from studies 
employing in vivo micro dialysis that extracellular DA concentrations are responsive 
to increased precursor supply at rest (During et aI., 1989). DOPA is then converted to 
DA by DOPA decarboxylase. Noradrenergic neurones are characterised, and differ 
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from dopaminergic neurons, by the presence of dopamine l3-hydroxylase, which is 
responsible for the hydroxylation ofDA to NA. 
Tyrosine 
H ydroxylase ~ 
Tyrosine 
HOOCH,COOH Monoamine Oxidase + 
HO~ ~ 
Aldehyde 
3,4-dihydroxyphenylacetic dehydrogenase 
acid (DOP AC) 
OH 
Monoamine CH'OO~H-COOH Oxidase + HO~ I • Catechol-O-
3-methoxy-4-
methyltransferase 
hydroxymandelic acid 
(VMA) 
COOH 
(lrCH'-~H-NH' 
HO~ 
OH 
Dihydroxyphenylalanine (DOPA) 
DOPA 
decarboxylase 
HO 
,o-CH,-CH,-NH, 
OH 
Dopamine 
Dopamine-~-
hydroxylase 
OH 
HO 
,0- ~H-CH'-NH' 
OH 
Noradrenaline 
Figure 1.2: The metabolic pathway for synthesis and metabolism of DA and NA 
(Cooper et aI., 2003) 
The action of both DA and NA are terminated by reuptake into the presynaptic nerve 
terminal (Cooper et aI., 2003). Once inside the axon terminal the catecholamines may 
return to the synaptic vesicles for reuse or be metabolised. DA is metabolised to 3,4-
dihydroxyphenylacetic acid (DOPAC) by MAO and aldehyde dehydrogenase, which 
can be further reduced to homovanillic acid (BV A) by catechol-O-methyltransferase 
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(not shown in Figure 1.2). In a similar manner to 5-HIAA, the accumulation of HV A 
in the brain and CSF has been employed as an indirect index of the activity of the 
dopaminergic neurons. The enzymes MAO, aldehyde dehydrogenase and catechol-O-
methyl transferase are responsible for the catabolism of NA to its metabolite 3-
methoxy-4-hydroxymandelic acid (VMA). 
The synthesis and turnover of both DA and NA are highly dependent on neuronal 
discharge activity (Cooper et aI., 2003). Catecholamine synthesis is significantly 
upregulated during arousal and stress where a marked increase in catecholaminergic 
activity is apparent (Milner and Wurtman, 1986). Prolonged exposure to stress is 
thought to result in a partial depletion of catecholamines in some brain regions, 
including the hippocampus, striatum and midbrain (Bailey et aI., 1992; Owasoyo et 
aI., 1992; Palkovits et aI., 1975). This reduction in extracellular catecholamine 
concentrations may be important in the loss of motor control often observed under 
these conditions (Davis, 2000). The regulation of catecholamine synthesis appears to 
be largely mediated by a change in the activity of tyrosine hydroxylase through end 
product inhibition, negative feedback from presynaptic dopamine receptors and the 
activity of the catecholaminergic neurons (Cooper et aI., 2003). 
1.3 - Behavioural Responses to Changes in Central Neurotransmission 
Physiological and behavioural responses modulated or mediated through changes in 
central serotonergic and / or catecholaminergic neurotransmission are triggered by 
ligand binding to postsynaptic receptors (Dinan, 1996). To date more than ten 5-HT 
receptors (5-HT 1-7) have been classified, distributed in different areas of the brain. 
There are fewer subtypes of catecholamine receptors (Dopamine - DI, D2; 
Noradrenaline - ai, a2, ~). 
Serotonergic neurones play a key role in various behavioural and autonomic functions 
such as the sleep-wake-arousal cycle, feeding, temperature regulation, nociception, 
sexual activity, activation of the hypothalamic-pituitary-adrenal axis and locomotion 
(Jacobs and Fomal, 1997). Neurotransmitters, in particular 5-HT, have been 
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implicated in the aetiology of a wide variety of psychiatric disorders, and the 
pharmacological manipulation of central monoamine activity forms the basis of many 
modem treatments. A large body of evidence supports a role of nutrition in mediating 
changes in arousal, mood, mental function and perception of fatigue (Spring et aI., 
1986; Young, 1991). While these responses were thought to be mediated through 
manipulation of serotonergic neurotransmission, it is likely that changes in brain 
glucose availability may also be important (Bequet et aI., 2002). While, 5-HT is often 
implicated in almost all behavioural or physiological responses, evidence usually 
suggests that it is not directly responsible (Jacobs and Azmitia, 1992). This has led to 
the suggestion that 5-HT primarily acts as a neuromodulator, possessing little intrinsic 
activity, but exerting a response by influencing other neurotransmitter systems 
(Cooper et aI., 2003). 
The DA system plays an important role in motivation, memory, reward and attention 
(Davis and Bailey, 1997). Evidence suggests that animals are motivated to perform 
behaviours that stimulate DA release in the VTA (Burgess et aI., 1991) and addiction 
is common feature of a number of dopaminergic drugs. The DA activity in the 
caudate and accumbens nuclei appears to be involved in the control of voluntary 
movement and locomotion (Freed and Yamamoto, 1985). NA neurons seem to be 
important to the regulation of attention, arousal and sleep-awake cycles as well as 
leaming and memory, anxiety, pain, mood and brain metabolism (Cooper et aI., 
1994). In a similar manner to the dopaminergic system, noradrenergic mechanisms 
are involved in feelings of reward. NA has also been implicated in aetiology of 
depression (Ascher et aI., 1995). 
1.4 - Exercise, Serotonergic Neurotransmission and Newsholme's Central 
Fatigue Hypothesis 
As mentioned in Section 1.1, the notion that the CNS is involved in the development 
of fatigue during various activities including mental and visual tasks as well as 
physical activity is not a new proposition. Work conducted over the past 25 years has 
established a clear link between exercise and improved mental health, leading to the 
prescription of exercise as an alternative treatment for depression, anxiety and stress 
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(Dey, 1994; Ransford, 1982). This led to the suggestion that exercise may directly 
influence the synthesis and metabolism of central monoamines, in particular DA, NA 
and 5-HT. 
The effects of exercise on the central serotonin levels of rats was extensively 
investigated by Chaouloff and colleagues during the 1980's (Chaouloff et aI., 1985; 
Chaouloff et aI., 1986a; Chaouloff et aI., 1986b; Chaouloff et aI., 1987). This work 
demonstrated that treadmill exercise resulted in a progressive elevation in brain TRP 
and 5-HIAA content, with 5-HT also tending to increase (Chaouloff et aI., 1985; 
Chaouloff et aI., 1986b). As 5-HIAA is employed as an index of brain 5-HT activity, 
the authors concluded that exercise resulted in an increased 5-HT turnover. The vast 
majority of the available evidence suggests that whole brain 5-HT and 5-HIAA 
content is increased following exercise (Bailey et aI., 1992; Chaouloff et aI., 1985; 
Romanowski and Grabiec, 1974), but the magnitude of change varies significantly 
across cerebral structures. 5-HT and 5-HIAA levels are elevated to varying degrees in 
the brain stem, frontal cortex, hippocampus, hypothalamus, mid-brain and striatum 
during exercise (Blomstrand et aI., 1989; Brown et aI., 1979; Dey et aI., 1992; 
Gomez-Merino et aI., 2001a). The apparent discrepancy in the magnitude of response 
reported may be due to differences in the exercise protocol used and the analytical 
techniques employed to measure changes in neurotransmission (Meeusen and De 
Meirleir, 1995). 
A number of recent studies have confirmed and developed this early work, 
demonstrating that exercise results not only in an increase in TRP uptake and brain 5-
HT content, but also influences extracellular 5-HT and 5-HIAA concentrations 
(Gomez-Merino et aI., 2001a; Meeusen et aI., 1996; Wilson and Marsden, 1996). 
Progressive increases in extracellular 5-HT and 5-HIAA have been reported during 
exercise, but marked differences in the time-course of changes were apparent between 
studies. Whereas Meeusen and colleagues (1996) demonstrated a rise in 5-HT in the 
hippocampus from the onset of treadmill running, other reports suggest a delay in this 
response with a marked increase in extracellular 5-HT only evident after 60 minutes 
exercise (Gomez-Merino et aI., 2001a; Gomez-Merino et aI., 2001b). This apparent 
discrepancy in the time-course of change in serotonergic neurotransmission has been 
attributed to differences in the pre-exercise dietary conditions, with the rapid response 
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observed in 24-hour fasted animals (Meeusen et aI., 1996) compared to a delayed 
response in fed animals (Gomez-Merino et aI., 2001a; Gomez-Merino et aI., 200Ib). 
As previously described, there is limited evidence for a relationship between plasma 
f-TRP and brain TRP content under resting conditions (Femstrom et aI., 1976; 
Pardridge, 1979), but this situation appears to be altered during exercise. The 
concentration of plasma f-TRP, rather than total-TRP, was identified as a key factor in 
cerebral TRP uptake during exercise, with a strong positive relationship reported 
between changes in plasma f-TRP and brain TRP content (Chaouloff et aI., 1985). 
This led to the suggestion that exercise-induced lipolysis is directly responsible for the 
increase in brain TRP and 5-HT synthesis (Chaouloff, 1989). The apparent difference 
in the size of the TRP pool available for transport into the CNS may be result from 
changes in cerebral blood flow. Cerebral blood flow is markedly increased during 
exercise (Ide and Secher, 2000) and this increase in blood velocity may limit the 
effectiveness of the LNAA-carrier at removing TRP from albumin. 
The mobilisation of FF A from the adipose tissue by adrenaline-stimulated lipolysis 
has been proposed to be important to the development of serotonin-mediated fatigue 
during prolonged exercise (Newsholme et aI., 1987). Plasma FF A concentrations 
typically increase progressively throughout prolonged low- to moderate-intensity 
exercise, particularly following a period of food deprivation (e.g. an overnight fast). 
Although there appears to be a near linear relationship between plasma FF A and the 
rate ofFFA utilisation (Issekutz et aI., 1967), this increase occurs as the mobilisation 
of FFA from the adipose tissue often slightly exceeds uptake by the working muscles 
(Spriet, 2002). When muscle and liver glycogen stores are nearing depletion, FFA 
mobilisation can increase disproportionately over the rate of transport into the muscle, 
resulting in a marked elevation in plasma FFA concentrations (Newsholme and 
Castell, 2000). As FFA molecules bind to albumin, conformational changes occur that 
result in the liberation of TRP from its binding site (Curzon et aI., 1974), 
consequently increasing the proportion ofTRP circulating in a free form. 
Based on the literature presented above, the underlying mechanism behind the central 
fatigue hypothesis as proposed by Newsholme and co-workers (1987) can be divided 
into two interrelated sections: 
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I. Under resting conditions, the majority of TRP circulates in the blood loosely 
bound to albumin, a transporter shared with free fatty acids (FF A). The shift in 
substrate mobilisation occurring as exercise progresses causes an increase in 
plasma FFA concentration. This displaces TRP from binding sites on albumin, 
leading to a marked increase in f-TRP. Free tryptophan, unlike albumin bound 
tryptophan, is then readily available for transport across the BBB. 
2. Plasma BCAA concentrations either fall (Blomstrand et aI., 1988; van Hall et aI., 
1995a) or are unchanged (MacLean et aI., 1994) during prolonged exercise. Since 
f-TRP and BCAA share a common transporter across the BBB, a reduction in 
competing LNAA would increase the uptake ofTRP into the CNS. 
Plasma concentrations of FF A and f-TRP are typically low at the onset of exercise, so 
the rate of cerebral TRP uptake and central 5-HT synthesis are also relatively low 
(Figure 1.3A). The metabolic events described above result in an increased plasma 
concentration ratio of f-TRP to BCAA during exercise, favouring the entry of TRP 
into the CNS. As the rate of 5-HT synthesis is largely dependent upon the delivery of 
TRP into the brain (see Section 1.2.1), serotonergic activity increases as exercise 
duration progresses (Figure 1.3B). According to Newsholme's hypothesis, this change 
in brain neurochemistry results in SUbjective sensations of lethargy and tiredness, 
causing a loss of drive and motivation to continue exercise. This could provide a 
feedback link between substrate availability and the feelings of fatigue that occur 
during prolonged exercise (Newsholme and Castell, 2000). 
While the underlying tenets of this hypothesis appear biochemically sound, recent 
human work fail to support the suggestion that cerebral TRP uptake is elevated during 
prolonged exercise (Nybo et aI., 2003). These data indicate that despite a 50 % 
increase in plasma f-TRP, a net uptake of TRP was apparent in only half the subjects 
at the end of exercise. Despite this observation the authors suggest that serotonin 
levels in the brain may increase when exercise elevates the plasma f-TRP 
concentrations, based on the observation of a positive correlation between the arterial 
f-TRP concentration and the a-v difference of TRP across the brain. However, as 
there is a physiological link between arterial f-TRP and the a-v difference of f-TRP, 
this conclusion may be flawed (Atkinson et aI, 2004). 
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1.5 - Experimental support for serotonin-mediated fatigue 
Support for 5-HT-mediated fatigue arises largely from animal and human studies 
employing pharmacological agents to manipulate central serotonergic 
neurotransmission. Many modem antidepressant treatments exert their therapeutic 
effect through a modification of extracellular 5-HT concentrations in the brain, with 
SSRl widely prescribed. SSRl drugs act through the inhibition of the presynaptic 5-
HT transporter, effectively limiting the reuptake of 5-HT from the synaptic cleft and 
prolonging the action of serotonin present within the synapse. In healthy individuals 
the reuptake process prevents over stimulation of receptors in the synapse, but some 
psychiatric disorders are thought to be characterised by an altered sensitivity of the 
postsynaptic receptors (Owens and Nemeroff, 1994). In particular, clinical depression 
is thought to be characterised by an upregulation of receptor sites, which consequently 
results in a deficiency of neurotransmitter present in the synapse. The therapeutic 
benefit of antidepressant treatments are thought to arise through a chronic increase in 
extracellular 5-HT, causing a normalisation ofreceptor sensitivity. 
A series of studies by Bailey and co-workers examined the effects of pharmacological 
manipulation of brain 5-HT levels in rats through the administration of specific 5-HT 
agonists and antagonists (Bailey et aI., 1992; Bailey et aI., 1993a; Bailey et aI., 
1993b). This early work provided good evidence for a role of 5-HT in the 
development of fatigue, with a dose-dependent reduction in exercise capacity reported 
when central 5-HT activity was augmented by the acute administration of a general 5-
HT agonist (Bailey et aI., 1992). Brain 5-HT and DA content progressively increased 
during exercise, but at the point of exhaustion a marked fall in tissue DA content was 
apparent. Furthermore, exercise capacity was enhanced by a 5-HT antagonist (L Y-
53857), although this was apparent only when the highest dose was administered 
(Bailey et aI., 1993a; Bailey et aI., 1993b). These alterations to exercise capacity 
occurred without any change in core temperature, circulating metabolites or stress 
hormones (Bailey et aI., 1993a). Additionally, muscle glycogen concentrations at 
fatigue were higher when a 5-HT agonist (quipazine dimaleate) was administered, 
suggesting that the accelerated fatigue did not occur as a result of limited glycogen 
availability. 
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While these data look promISIng, the significance of these findings has been 
questioned. It is important to note that the higher doses of drugs given in these studies 
were many times greater than would normally be administered. It is probable that 
some of the animals displayed symptoms of serotonin-syndrome, including loss of 
coordination, dizziness, confusion and disorientation that would almost certainly 
negatively affect exercise capacity (Struder and Weicker, 2001b). 
Based on these observations, Davis and Bailey (1997) developed Newsholme's 
original hypothesis. Rather than the proposition that central fatigue was exclusively 
mediated through changes in 5-HT, the findings of this series of studies led to the 
suggestion that the brain content ratio of 5-HT to DA was important to the fatigue 
process. The revised central fatigue hypothesis suggests that an increase in 5-HT:DA 
is associated with feelings of tiredness and lethargy, accelerating the onset of fatigue, 
whereas a low ratio favours improved performance through the maintenance of 
motivation and arousal (Davis and Bailey, 1997). The importance of 
catecholaminergic neurotransmission to the development of fatigue will be discussed 
in Section 1.7. 
Wilson and Maughan (1992) were first to investigate the effects of an acute dose of a 
5-HT agonist on the capacity to perform prolonged exercise in humans. Paroxetine 
administration resulted in a 19 % reduction in time to exhaustion when compared to a 
placebo. In the absence of a clear drug effect on the metabolic, cardiovascular and 
thermoregulatory responses to exercise, the reduction in exercise capacity was 
attributed to an upregulation of serotonergic activity caused by the treatment. 
Subsequent work has provided support of these initial findings, with reduced exercise 
capacity reported following an acute dose of fluoxetine (Prozac; Davis et aI., 1993), 
buspirone (Marvin et aI., 1997) and paroxetine (Struder et aI., 1998). Newsholme's 
hypothesis suggested that a change in serotonergic neurotransmission might alter an 
individual's perception of effort. The work of Davis et al. (1993) and Marvin et al. 
(1997) reported a marked increase in perceived exertion, with drug ingestion in these 
studies associated with a feeling of heaviness in the legs during exercise. No effect on 
RPE was apparent following paroxetine administration, despite a reduction in exercise 
capacity (Wilson, 1994). 
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Although much of the initial phannacological manipulation work provided good 
evidence in support of the mechanisms proposed by Newsholme and colleagues 
(1987), a number of studies have failed to replicate these early findings. This includes 
studies that have sought to investigate serotonin-mediated fatigue through the 
administration of drugs to increase 5-HT neurotransmission (Meeusen et aI., 2001b; 
Piacentini et aI., 2002a; Strachan, 2002) as well as agents to reduce central 5-HT 
release (Meeusen et aI., I 997a; Pannier et aI., 1995). 
The equivocal findings of these phannacological studies may be explained by the 
complexity of the actions of the drugs employed. Although there is good evidence that 
acute doses of drugs influencing central neurotransmission can transiently influence 
neurotransmission in rodents (Bailey et aI., 1993a; Piacentini et aI., 2003a; Piacentini 
et aI., 2003b), the effect of these drugs on the human CNS is not clear at present. 
Evidence from clinical studies suggests that an acute administration of a monoamine 
reuptake inhibitor may produce little change in extracellular neurotransmitter 
concentrations, due to a reduction in cell firing rate caused by presynaptic 5-HTIA 
autoreceptor-mediated feedback inhibition (Artigas et aI., 1996). This is supported by 
the observation that there is a delayed increase in plasma prolactin concentration 
following chronic administration of paroxetine in healthy volunteers (Cowen and 
Sargent, 1997). While there is some evidence that acute SSRI ingestion can reduce an 
individual's capacity to perform prolonged exercise (Davis et aI., 1993; Struder et aI., 
1998; Wilson and Maughan, 1992), it has been suggested that this occurred due to a 
disturbance in regulatory homeostasis of the 5-HT system perhaps via a disruption in 
pre- or postsynaptic receptor function (Struder and Weicker, 200Ib), rather than an 
increase in the activity of the serotonergic neurons (Davis et aI., 1993; Wilson and 
Maughan, 1992). 
1.6 - Nutritional Manipulation of 5-HT Neurotransmission during Exercise 
Much of the attraction of the hypothesis described by Newsholme and co-workers 
(1987) was the potential for nutritional manipulation of neurotransmitter precursors to 
delay the onset of central fatigue, potentially enhancing performance. In recent years a 
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number of studies have attempted to attenuate the increase in central 5-HT levels 
through dietary supplementation with specific nutrients, including BCAA and CHO. 
BCAA are unique amongst the amino acids in that they largely avoid hepatic uptake 
and are metabolised primarily in the skeletal muscle, where they serve as an energy 
substrate and also a precursor for the synthesis of new proteins (Wagenmakers and 
van Hall, 1996). The overall contribution of protein to energy production is thought to 
be around 3 to 6 % during prolonged exercise (Gibala, 2001), and is typically 
overlooked when estimating substrate utilisation from gas exchange (Astrand et ai., 
2003). Despite the observation that exercise and BCAA ingestion independently and 
additively increase the activation of the branched-chain 2-oxoacid dehydrogenase 
complex (van Hall et ai., 1996; Wagenmakers et ai., 1991), evidence suggests that 
BCAA oxidation contributes a relatively insignificant portion of energy expenditure 
(-1 %; Wagenmakers et ai., 1991). On the basis of these findings it is unlikely that 
BCAA supplementation would benefit exercise performance through glycogen 
sparing (Wagenmakers and van Hall, 1996). 
As described in Section 1.2, a number of amino acids, collectively tenned the large-
neutral amino acids (LNAA), share a common transporter across the BBB (Femstrom, 
1983). As both TRP and BCAA compete for cerebral uptake via the same active 
transporter, the plasma concentration ratio of f-TRP to BCAA is thought to dictate the 
rate of TRP entry into the brain and the rate of 5-HT synthesis during exercise. 
Ingestion of exogenous BCAA would therefore be expected to reduce this ratio, 
through a marked increase in plasma BCAA levels, effectively blocking the cerebral 
uptake of TRP (Figure 1.4). The resulting change in brain TRP delivery has been 
proposed to limit the exercise-induced increase in 5-HT synthesis, attenuate the 
development of central fatigue and enhance exercise performance (Blomstrand et ai., 
1991a). 
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Figure 1.4: The effect of BCAA supplementation on the development of central 
fatigue as proposed by Newsholme and colleagues (1987). BCAA supplementation 
results in a marked reduction in plasma concentration ratio of f-TRP to BCAA. 
The first investigation undertaken to test the efficacy of BCAA supplementation at 
attenuating serotonin-mediated fatigue was a field study of the physical and mental 
performance of male volunteers competing in either a marathon or a 30 km cross-
country race (B1omstrand et aI., 1991a). The findings suggested that both physical 
(race time) and mental (colour and word tests) performance were enhanced in those 
receiving BCAA prior to exercise. Enhanced exercise performance was only 
witnessed in subjects completing the marathon in times slower than 3 hours 5 
minutes. The authors suggested that a lack of effect in the faster runners might have 
been due to their increased resistance to the feelings associated with central and 
peripheral fatigue. The reliability of these results has been subsequently questioned, 
largely due to a number of methodological problems (Davis and Bailey, 1997). In 
particular, fluid and CRO ingestion was not controlled during exercise, subjects were 
not matched to controls in terms of previous performance and the retrospective 
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division of subjects into groups relating to their performance in the trial has also been 
criticised as statistically incorrect. 
Work conducted by Mittleman and colleagues (1998) has provided further evidence in 
support of these early findings and the apparent role of 5-HT in the fatigue process. A 
14 % increase in capacity to perform low intensity (40 % VO, max) exercise was 
reported following BCAA supplementation when compared to a polydextrose 
placebo. No difference in peripheral markers of fatigue was reported between the two 
exercise bouts. The authors concluded that the supplementation regimen was 
successful in limiting the entry of TRP into the CNS, attenuating serotonin-mediated 
fatigue. The unique aspect of this study was that the trials were undertaken in a warm 
environment (34.4 QC), with subjects seated at rest for 2 hours before exercise in these 
conditions. BCAA supplementation began 60 minutes prior the start of exercise, 
resulting in a 2 to 3-fold reduction in the plasma concentration ratio of f-TRP to 
BCAA. The potential involvement of the CNS when exercising in warm 
environmental conditions will be discussed in detail in Section 1.11. The effect of 
chronic administration of BCAA on exercise performance has also been examined 
(Hefler et aI., 1995). Following 14-days of BCAA supplementation (16 g.dai l ) 
performance of a 40 km cycle time trial in temperate conditions was improved by 
12 % compared to the same period of placebo ingestion. Despite these apparently 
positive findings, these data do not appear to have been published as a full manuscript 
and the abstract does not provide any supporting metabolic data. These factors make it 
difficult to accept the findings. The influence of chronic BCAA supplementation on 
exercise performance warrants further investigation. 
While there is some additional evidence of BCAA ingestion influencing perceived 
exertion (Blomstrand et aI., 1997) and mental performance (Blomstrand et aI., 1991b; 
Hassmen et aI., 1994), the results of several apparently well-controlled laboratory 
studies have not demonstrated a positive effect on exercise capacity or performance. 
No ergogenic benefit has been reported during prolonged fixed intensity exercise to 
exhaustion (Blomstrand et aI., 1995; Blomstrand et aI., 1997; Galiano et aI., 1991; 
Struder et aI., 1998; van Hall et aI., 1995a), prolonged time trial performance 
(Hassmen et aI., 1994; Madsen et aI., 1996), incremental exercise (Vamier et aI., 
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1994) or intermittent shuttle-running (Davis et aI., 1999). These findings question 
whether the attenuation of TRP uptake through the provision of exogenous BCAA can 
influence central neurotransmission, but methodological differences make 
comparisons between studies difficult. With the exception of the studies conducted by 
Hefler et al. (1995) and Mittleman et al. (1998), BCAA supplements have been 
provided immediately prior to, and during exercise, in quantities ranging from 6 to 18 
g. There is some limited evidence that a delay may exist between changes in the 
plasma concentration ratio of TRP to BCAA, the uptake of TRP into the CNS and the 
resulting modification to serotonergic neurotransmission (Curzon and Knott, 1974). 
Administering BCAA supplements immediately prior to the start of exercise may 
have limited their efficacy at preventing cerebral TRP uptake from the onset of 
exercIse. 
A possible explanation for a failure to observe an ergogenic effect in many BCAA 
studies, despite a good rationale for their use, is an increase in ammonia (NH3) 
production (Davis and Bailey, 1997). During prolonged exercise, increased NH3 
production is primarily thought to result from the deamination of BCAA, rather than 
the deamination of AMP to IMP (Greenhaff et aI., 1991; van Hall et aI., 1995b; 
Wagenmakers et aI., 1991). This response appears to be amplified by reduced 
glycogen availability (Czarnowski et aI., 1995; Wagenmakers et aI., 1991), 
hyperthermia (Febbraio et aI., 1994; Marino et aI., 2001) and the ingestion of BC AA 
(MacLean et aI., 1994; van Hall et aI., 1995a). The BCAA aminotransferase reaction 
draws carbon groups from the TCA cycle by using 2-oxoglutarate as an amino group 
acceptor (Wagenmakers and van Hall, 1996). This may attenuate anaplerosis, 
potentially limiting ATP production and negatively affecting exercise performance, 
particularly when muscle glycogen availability is low (Wagenmakers et aI., 1991; 
Wagennlakers et aI., 1990). Prolonged exhaustive exercise has also been suggested to 
produce a state of 'acute NH3 toxicity' that may disrupt brain metabolism and alter the 
pH of the nervous tissue, potentially impairing motor control and coordination 
(Banister and Cameron, 1990; Davis and Bailey, 1997). The brain buffers NH3 by the 
amination of glutamate to glutamine, which is then released into the peripheral 
circulation (Struder and Weicker, 200Ia). Elevated plasma NH3 concentrations have 
also been demonstrated to alter the transport kinetics of amino acids across the BBB 
(Mans et aI., 1983). Whether this response contributes to the development of central 
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fatigue by enhancing the uptake of neurotransmitter precursors (Banister and 
Cameron, 1990) or acts as a compensatory response to normalise cerebral amino acid 
uptake despite a marked increase in blood flow through the brain microvessels is not 
clear at present. 
Following work with patients with myophosphorylase deficiency (McArdle's disease) 
(Wagenmakers et aI., 1990) suggested that BCAA supplementation under conditions 
of reduced muscle glycogen availability could result in a reduction in endurance 
performance in healthy individuals (Wagenmakers and van Hall, 1996). Recent work 
suggests, however, that BCAA ingestion does not appear to impair the increase in 
TCA intermediates during exercise in a glycogen depleted state (Gibala et aI., 1999). 
It appears that the highest concentrations of plasma NH3 observed in healthy 
individuals during prolonged exercise (-150 flmoI.L·') are not sufficient to limit 
exercise capacity through peripheral or central mechanisms (Gibala, 2001). 
While support for a benefit of BCAA ingestion in humans is limited, particularly 
when exercise is performed in temperate conditions, the response appears to be 
different in animals, where a clear increase in exercise capacity (Calders et aI., 1999; 
Calders et aI., 1997) and free running activity (Smriga et aI., 2002) has been shown. A 
study conducted by Verger and co-workers (1994) observed no difference in time to 
exhaustion following BCAA ingestion in rats when compared to a placebo condition, 
but it is not clear why these results fail to agree with those of Calders and colleagues. 
Good evidence for the role of BCAA in limiting TRP entry into the CNS and 
attenuating the increase in 5-HT has been reported in rodents using in-vivo brain 
microdialysis (Gomez-Merino et aI., 200Ib). During the placebo trial (saline infusion) 
a progressive increase in extracellular 5-HT was apparent in the hippocampus as 
exercise continued, but this elevation was abolished when exercise was preceded by 
an infusion of valine. Perhaps a difference between species in sensitivity to 
manipulation of the 5-HT system may account for these different findings. 
The opposite of supplementing with BCAA to limit 5-HT synthesis would be a 
reduction in exercise capacity following TRP ingestion. The administration of TRP in 
food-deprived rats has been reported to elevate extracellular 5-HT and 5-HIAA 
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concentrations in the hippocampus by 55 % (Meeusen et aI., 1996). TRP infusion 
before exercise resulted in an additive response, supporting the claims of Newsholme 
and co-workers (1987) by significantly amplifying the exercise-induced increase in 5-
HT. While there are reports ofTRP supplementation producing a marked reduction in 
the exercise capacity of horses (Farris et aI., 1998) and rodents (Soares et aI., 2003), 
ingestion of between 1.2 and 3.0 g of TRP immediately prior to the start of exercise 
produced no effect on exercise capacity in human subjects (Alves et aI., 1995; 
Stensrud et aI., 1992; van Hall et aI., 1995a). Paradoxically, a 49 % increase in 
exercise capacity at 80% \rO, max has been observed following TRP supplementation 
when compared to a placebo (Segura and Ventura, 1988). A non-significant reduction 
in RPE was apparent that led the authors to propose that TRP supplementation may 
attenuate nociception, increasing the tolerance of pain associated with the 
performance of strenuous exercise. The findings of Segura and colleagues (1988) are 
difficult to accept in the light of subsequent work in this area and such a large 
improvement in exercise capacity. 
Carbohydrate feeding suppresses lipolysis, consequently lowering the circulating 
concentration of plasma FF A. Recognising this, Davis and colleagues (1992) 
suggested CHO ingestion as a means of reducing cerebral TRP uptake. A five- to 
sevenfold increase in the plasma concentration ratio of f-TRP to BCAA was reported 
under placebo conditions. Supplementation with a 6 or 12 % CRO solution attenuated 
the increase in plasma FFA and f-TRP, reducing the plasma concentration ratio of f-
TRP to BCAA in a dose-dependent manner. Exercise capacity during CHO trials was 
increased over the placebo, suggesting CHO ingestion as an effective means of 
delaying the onset of central fatigue, but it is difficult to interpret the contribution of 
central factors from the widely reported benefits of CHO at attenuating peripheral 
fatigue. 
1.7 - Exercise and Catecholamergic Neurotransmission 
While the majority of work conducted in the area of exefClse and brain 
neurotransmission has focused on changes in 5-HT, many early studies were 
interested the effects of exercise on the catecholaminergic neurotransmission. The 
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primary catecholamines implicated in the development of fatigue during prolonged 
exercise are DA and NA. As mentioned in Section 1.2, DA and NA are synthesised 
from the amino acid precursor tyrosine, through a similar metabolic pathway 
(Fernstrom, 1983). Whereas increased 5-HT activity is associated with feelings of 
tiredness and lethargy, an elevation in catecholaminergic neurotransmission is linked 
to arousal, motivation and reward (Davis, 2000). A change in regional dopamine 
metabolism has also been implicated in the control of locomotion and posture in 
moving animals (Freed and Yamamoto, 1985). 
Early studies conducted by Gordon and colleagues (1966) using radiolabelled tyrosine 
reported a marked increase in NA synthesis and turnover during exercise, but no 
change in central DA synthesis. In contrast to these initial findings, subsequent work 
provides good evidence that prolonged exercise results in a progressive increase in 
tissue DA, DOPAC and HV A content in a number of cerebral regions including 
midbrain, hippocampus and striatum (Bailey et aI., 1992; Bailey et aI., 1993a; 
Chaouloff et aI., 1987; Heyes et aI., 1988). Recent data have demonstrated an 
elevation in extracellular DA (+28 - 50 %) and NA (+60 - 66 %) concentrations 
during exercise (Gerin and Privat, 1998; Meeusen et aI., 1997b). During recovery, 
extracellular DA in the stratum remained elevated above baseline levels for over 100 
minutes, whereas NA concentrations returned to resting values soon after the 
cessation of exercise (Meeusen et aI., 1997b). 
Studies investigating neurotransmission during exhaustive exercise (Bailey et aI., 
1992; Bailey et aI., 1993a) and prolonged exposure to stress (Palkovits et aI., 1975) 
have reported a fall in brain DA content. Bailey and co-workers (1992, 1993) 
observed a parallel increase in both 5-HT and DA after one hour of exercise. While 
brain 5-HT and 5-HIAA content continued to increase as exercise progressed, DA and 
DOP AC concentrations appeared to return to resting levels at exhaustion. These 
findings have led to the suggestion that the partial depletion of catecholamines in 
regions of the brain may be linked to a loss of physical and mental performance 
during prolonged exercise (Davis and Bailey, 1997) and exposure to stress (Owasoyo 
et aI., 1992; Palkovits et aI., 1975). 
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1.8 - Experimental Support for Catecholamine-Mediated Fatigue 
Early pharmacological manipulation of central neurotransmission to improve exercise 
performance focused largely on the effects amphetamines, with studies of this nature 
undertaken by German scientists during the 2nd World War (Chaouloff, 1991). 
Amphetamine is a close analogue of DA and NA, thought to act directly on 
catecholaminergic neurones to produce a marked elevation in extracellular dopamine 
concentrations. This response is believed to be mediated through the stimulation DA 
release from storage vesicles, inhibition of dopamine reuptake and the inhibition of 
DA metabolism by MAO (Cooper et a!., 2003). Amphetamines may also limit the 
synthesis of 5-HT through a reduction in tryptophan hydroxylase activity and a direct 
interaction between DA release and serotonergic neurotransmission (Breese et a!., 
1974; Chaouloffet a!., 1987). 
Studies have demonstrated a clear performance benefit following the administration 
of amphetamine to both rodents (Gerald, 1978) and humans (Chandler and Blair, 
1980). Gerald (1978) reported a dose-dependent increase in time to exhaustion, up to 
a dose of 2.5 mg.kg·', with further doses progressively reducing exercise capacity. 
The ergogenic action of amphetamine is thought to be mediated through the 
maintenance of DA release late in exercise, through the mechanisms described above. 
These positive findings have led to the widespread use of amphetamines in many 
endurance events, with a long history of abuse in cycling events in particular. Further 
evidence for a role of DA in the development of central fatigue is provided by work 
conducted by Heyes and colleagues (1985). Infusion of apomorphine (a DA agonist) 
has been shown to prolong exercise capacity, and partially restore exercise capacity 
following destruction of dopaminergic neurons with 6-hydroxydopamine (Heyes et 
a!., 1985). 
Intracranial self-stimulation (ICSS) has been employed as a model to induce exercise 
in rodents, removing the need to administer aversive electric shocks (Burgess et aI., 
1991). ICSS involves the implantation of an electrode into the ventral tegmental area 
(VTA), the origin of the dopaminergic projection, which triggers electrical stimulation 
to this area of the brain when the animal maintained a pre-determined running speed. 
The dopaminergic reward associated with ICSS has been reported to enable rats to run 
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around 50 % longer when compared to the use of electric shock (Burgess et aI., 1991), 
while producing no effect on peripheral variables relating to cardiovascular, metabolic 
or thermoregulatory function (Burgess et aI., 1993). Studies investigating changes in 
central DA using electric shock grids to stimulate running should be viewed with 
caution as the stress associated with this form of motivation has been demonstrated to 
significantly increase dopamine release (Chrapusta et aI., 1997). 
Despite the apparent link between exercise and catecholaminergic neurotransmission 
demonstrated in animals, there has been relatively little work conducted to assess the 
effects of DA and NA manipulation on exercise capacity in humans. This may relate 
to the relatively limited number of safe pharmacological agents available to influence 
central catecholamine concentrations, and the belief that the provision of tyrosine 
does not influence DA and NA synthesis due to a saturation of tyrosine hydroxylase 
(Davis and Bailey, 1997). Recently the development of a new wave of psychiatric 
treatments, including reuptake inhibitors that act on NA (reboxetine), 5-HTINA 
(venlafaxine) and DAlNA (bupropion) have enabled the role of these 
neurotransmitters in the fatigue process to be further examined. 
A series of studies conducted by Piacentini and colleagues reported no change in the 
performance of a 90 minute cycle time trial following the acute administration a NA 
reuptake inhibitor (Piacentini et aI., 2002b), a dual 5-HT and NA reuptake inhibitor 
(Piacentini et aI., 2002a) or a dual DA and NA reuptake inhibitor (Piacentini et aI., 
2004). The pituitary-hormone response to exercise was significantly altered by drug 
ingestion, leading the authors to suggest that acute administration of these agents 
resulted in the desired central effect (Piacentini, 2003). The influence of central 
neurotransmission on the regulation of pituitary-hormonal release is discussed in 
Section 1.10. It is worth mentioning at this stage that a reduction in exercise capacity 
was observed following the administration of buspirone (Marvin et aI., 1997). While 
this drug is thought to primarily act as a 5-HTIA receptor agonist, it also produces a 
limited dopaminergic D2 antagonism (Bridge et aI., 2003), which may have played a 
significant role in mediating this response. 
As stated in Section 1.2, increasing the availability of TYR for uptake into the CNS 
may not influence the rate of DA and NA synthesis at rest (Davis, 2000), but limited 
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evidence suggests that the provision of exogenous TYR can increase central DA 
synthesis under basal conditions (During et aI., 1989). Certainly exposure to stress 
results in a marked increase in catecholaminergic activity resulting in an enhanced 
activation of tyrosine hydroxylase, making these neurons more responsive to changes 
in precursor availability (Milner and Wurtman, 1986). 
The administration of L-DOPA, an intermediate in the catecholamine pathway, has 
been employed to effectively bypass the rate-limiting step in DA and NA synthesis. 
L-DOPA has been used in the management of Parkinson's disease, a disorder 
characterised by a loss of motor control and coordination, to maintain central 
dopamine neurotransmission. Meeusen and co-workers (1997) examined the effect of 
L-DOPA on exercise capacity in endurance-trained males. Ingestion of L-DOPA 24 
hours and immediately before commencing exercise had no effect on submaximal 
time to exhaustion or peripheral cardiovascular or metabolic measures during 
exercIse. 
TYR supplementation during sustained military operations exceeding 12-hours, often 
involving severe sleep deprivation and fatigue, reduced stress-related decrements in 
mood and task performance (Owasoyo et aI., 1992). Evidence of an ergogenic benefit 
of TYR supplementation during prolonged exercise, however, is limited. Work 
conducted by Struder and colleagues (1998) failed to observe any change in the 
capacity to perform prolonged exercise following the ingestion of TYR immediately 
before (10 g) and during exercise (lOg). It has been suggested that the dose of TYR 
administered in this study may have resulted in an inhibition of dopamine synthesis, 
but a recent report administering half the dose employed by Struder and colleagues 
(1998) also produced no effect on time trial performance (Chinevere et aI., 2002). 
Interestingly a marked elevation in plasma prolactin concentration was observed by 
Struder et al. (1998) throughout exercise following TYR ingestion. This is unexpected 
as DA is thought to play an inhibitory role in the regulation of prolactin release from 
the anterior pituitary gland (Checkley, 1980). 
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1.9 - The hypothalamic-pituitary-adrenal (HPA) axis and Hormone Release 
It is difficult to directly determine changes in central neurotransmission in human 
subjects, but the recent development of imaging techniques (e.g. positron emission 
tomography) has opened new avenues to monitor the effects of pharmacological, 
nutritional and physiological challenges on the brain. While these methods are 
increasingly being employed in a clinical setting, their use is restricted in exercise 
physiology due to expense, access to experienced operators and logistical problems 
associated with performing exercise in or close to the equipment. For a number of 
years the measurement of changes in circulating concentrations of peripheral 
hormones has been employed as an index of central neurotransmission (Checkley, 
1980). 
The premise that circulating hormones may be used to determine changes in central 
neurotransmission is based on the role of central monoamines in the control of 
hormone release from the anterior and posterior pituitary gland. The paraventricular 
nucleus of hypothalamus is the major integrating link between the nervous and 
endocrine systems, with inputs from several areas of the brain governing the release 
of pituitary hormones through the infundibulum stalk. Changes in the activity of 5-
HT, DA and NA neurons innervating the hypothalamus stimulates the synthesis of 
releasing and inhibiting hormones that act directly on areas of the pituitary to trigger 
the release of hormones into the peripheral circulation. Adrenocorticotropic hormone 
(ACTH) released from the pituitary also exhibits control over the adrenal gland, 
influencing cortisol release. This has led to the term the hypothalamic-pituitary-
adrenal (HP A) axis. 
While the hypothalamus receives input from a number of cerebral structures, it is 
clear that the stimulation of different receptors within the neuroendocrine control sites 
produces a differing action on hormone release (Checkley, 1980; Van de Kar, 1997). 
The application of neuroendocrine tests to disturb central neurotransmission has 
provided insight into the relative contributions of 5-HT, DA and NA in the regulation 
of pituitary hormone release, but there remains a degree of uncertainty regarding the 
coordination of the endocrine response particularly under conditions of stress (Dinan, 
1996). 
30 
Chapter I General Introduction 
1.9.1 - Serotonergic control of pituitary hormone release 
There is a considerable body of evidence to indicate a role for central serotonergic 
neurons in the regulation of prolactin (PRL), ACTH, cortisol, and growth honnone 
(GH) secretion (Checkley, 1980; Dinan, 1996; Van de Kar, 1997). 
While basal secretion of PRL is regulated by tonic inhibition by dopamine, 
serotonergic regulation originates from cells III the dorsal raphe nucleus with 
activation of 5-HT1A, 5-HT2Alc, 5-HT3 receptors thought to stimulate the secretion of 
PRL (Van de Kar, 1997). Administration of fenfluramine, a potent 5-HT releaser and 
uptake inhibitor, has been demonstrated to produce a marked increase in prolactin 
release. While BCAA ingestion does not appear to influence PRL concentrations at 
rest, except when large quantities (60 g) are ingested (CarJi et aI., 1992; Gijsman et 
aI., 2002), around 10 g BCAA attenuated the PRL response to exercise (CarJi et aI., 
1992). Early evidence demonstrated a clear relationship between serotonergic activity 
and plasma concentrations ofPRL during exercise (De Meirleir et aI., 1985; Fischer et 
aI., 1991). These findings have resulted in the widespread use ofPRL as a peripheral 
index of changes in central serotonergic activity during exercise (pitsiladis et aI., 
2002; Strachan, 2002; Struder et aI., 1998). Recently it has become clear that PRL 
release during activity is not governed solely by 5-HT, but through a complex 
interaction between a number of neurotransmitter systems (Meeusen et aI., 2001 b; 
Piacentini, 2003). Evidence also suggests that elevated brain temperature may provide 
a stimulus for PRL release during exercise (Radomski et aI., 1998). 
There is good evidence to link increased 5-HT activity with the stimulation of ACTH 
and consequently cortisol release (Dinan, 1996). The administration of TRP, 
5-hydroxytryptophan and fenfluramine have been demonstrated to elevate plasma 
concentrations of both ACTH and cortisol in healthy individuals (Siever et aI., 1984). 
The role of 5-HT in the regulation of GH release is less certain, although it is thought 
to exert an excitatory influence (Checkley, 1980). 
31 
Chapter 1 General Introduction 
1.9.2 - Catecholaminergic control of pituitary hormone release 
Prolactin release is clearly inhibited by dopamine (Checkley, 1980), with drugs that 
increase extracellular DA producing a progressive reduction in circulating PRL 
concentrations in the rat (Piacentini et aI., 2003a). Ingestion of a large dose of BCAA 
(60 g) has been reported to significantly elevate plasma prolactin: this was thought to 
be mediated through the competitive inhibition of TYR entry into the CNS, 
consequently limiting DA synthesis (Gijsman et aI., 2002). Evidence for a role ofDA 
in the control of ACTH and cortisol release is limited in humans, but DA is 
responsible for the stimulation of GH release (Checkley, 1980). 
Regulation of hormone release by NA is complicated by the type of adrenoceptor 
subtype activated, with conflicting responses produced by alpha and beta receptors. 
While ACTH release is stimulated by activation of Uj adrenoceptors, U2 and 13 
adrenoceptors have been demonstrated to inhibit ACTH secretion. Prolactin release 
does not appear to be greatly influenced by NA activity, whereas NA-stimulated U 
adrenoceptor activation enhances GH release (Checkley, 1980). 
Table 1.1: Influence of neurotransmitters on the release of hormones from the 
anterior pituitary. t represents a stimulatory influence, ,j, represents an inhibitory 
influence, ? represents a questionable / unknown influence (adapted from Checkey, 
1980 and Van de Kar, 1997). 
5-HT DA NAu NA 13 
Prolactin t ,j, ? ? 
ACTH t ? t ,j, 
Cortisol t ? t ,j, 
Growth Hormone t? t t ,j,? 
The regulation of hormone release by central neurotransmission is summarized in 
Table 1.1. Monitoring the hormonal response of individuals to a nutritional, 
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pharmacological or exercise / heat stress intervention has become an important tool in 
both a clinical setting and in exercise physiology to provide information regarding 
alterations in central neurotransmission. As all the neurotransmitter systems are 
functionally interconnected it is difficult to attribute changes in the peripheral 
concentration of a particular hormone to a single monoamine. While the 
understanding of the central control of hormone release is growing, caution should be 
exercised when interpreting hormone responses as it is unclear how the release of 
hormones is governed by neurotransmitters, particularly under conditions of stress 
including physical activity. 
1.10 - The Blood-Brain Barrier (BBB) 
1.10.1 - Structure and function of the BBB: relevance to exercise 
Under normal physiological conditions the CNS functions within a relatively stable 
environment, largely distinct from the compositional fluctuations occurring in the 
peripheral circulation. This regulation is essential to ensure normal brain function and 
the operation of the organism as a whole, as well as to protect the brain from 
pathogens and other harmful substances. As a function of this, the capillaries 
supplying the brain differ structurally from those found in the periphery (Figure 1.5), 
forming a barrier to the entry of blood-borne substances, known as the blood-brain 
barrier (BBB). The BBB is a dynamic structure formed primarily by microvascular 
endothelial cells. These are characterised by the presence of overlapping tight 
junctions and restricted vesicular transport (Kandel et aI., 2000). The foot processes of 
astrocytes surround around 99 % of cerebral vessels and along with the presence of 
pericytes these cell serve to reinforce the tight junctions (Pardridge, 2003). The BBB 
functions through these specialised structures to maintain a stable environment for the 
CNS by tightly regulating the exchange of substances between the cerebral interstitial 
fluid and the peripheral circulation. 
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Figure 1.5: A basic histology of peripheral and cerebral capillaries. 
There is also a blood-to-CSF barrier (BCSFB) that regulates the exchange of 
substances between the blood and CSF (Marchi et ai., 2003a). While both barriers 
possess tight junctions, the BCSFB consists of epithelial rather than endothelial cells. 
Despite this structural difference, both barriers tightly limit the passage of substances 
into and out of the CNS. Additionally, some areas of the brain lack the protection of 
the BBB, and are therefore subject to changes occurring in the periphery. These are 
referred to as the circumventricular organs, which include the hypothalamus, the 
pineal and pituitary glands and some other nearby structures (Kandel et ai., 2000). 
The lack of a BBB in these leaky regions largely relates to their function in the 
regulation of peripheral actions through hormone release. The circumventricular 
organs are isolated from the rest of the brain by specialised ependymal cells that limit 
the exchange between these structures and the cerebrospinal fluid (CSF). 
The relative impermeability of the BBB helps to maintain a stable environment for the 
CNS by regulating exchange between the brain / CSF and the extra-cerebral 
environment. The transport of substances across the BBB is the result of a complex 
interaction between active efflux systems, active transporters and enzymes distributed 
on the structures that comprise the BBB (Pardridge, 2003). Entry into the CNS across 
the BBB is primarily mediated through three mechanisms (Kandel et ai., 2000): I) 
Passive diffusion of lipid-soluble molecules, including lipid soluble gases such as O2 
and CO2• 2) Selective, carrier-mediated transport of specific water-soluble substances, 
including glucose (GLUT I) and amino acids (L-transporter) by Na+-K+-ATPase 
dependent exchange 3) Electrolyte transport through active ion channels. 
34 
Chapter I General Introduction 
While the BBB is largely resistant to changes in permeability there are situations 
where the function of the BBB maybe compromised. Changes in the permeability of 
this barrier may allow the entry or exit of species that can affect the metabolism of the 
brain and thus influence a wide range of homeostatic mechanisms (Shivers and 
Wijsman, 1998). Situations where the BBB may be breached include infections and 
fever (Chaudhuri, 2000), neuronal damage (Greenwood, 1991), physiological and 
emotional stress (Hanin, 1996) and prolonged exposure to hyperthermia (Sharma and 
Dey, 1987; Wijsman and Shivers, 1993). Paradoxically, there are situations where 
transient BBB disruption is desirable, to enable the delivery of drugs that would not 
otherwise cross the BBB (Rapoport, 2000). 
Prolonged exercise may lead to increased BBB permeability. Animal studies have 
established that the BBB can be widely disrupted following 30 minutes forced 
swimming, with an albumin-tracer complex detected in a number of cerebral regions 
at the end of exercise (e.g. cerebral cortex, cerebellum, hippocampus and 
hypothalamus) (Sharma et aI., 1991; Sharma et aI., 1996). These changes were found 
to be relatively short lasting, with normal BBB function restored 2 hours after the end 
of exercise. When a pharmacological agent (p-chlorophenylalanine) was administered 
prior to exercise to deplete central 5-HT, this response was abolished. As 5-HT is a 
potent vasoactive agent, it is possible that changes in BBB permeability may have 
been serotonin-mediated. Interestingly, this response was only apparent in young 
animals (8 - 9 weeks), with little change in permeability observed in rats 30 to 32 
weeks old (Sharma et aI., 1996). 
It is not clear how an increase in BBB permeability may influence exercise. A degree 
of change in the exchange of substances across the barrier is probably desirable 
during exercise, to facilitate the transport of metabolites and other substances into the 
CNS when cerebral blood flow is elevated. While there is no direct evidence for this 
suggestion at present, it is clear that adrenaline-stimulated vasodilation of brain 
capillaries (Abdul-Rahrnan et aI., 1979) and NH3 facilitated amino acid transport 
(Mans et aI., 1983) may be important in this response during prolonged exercise. 
However, a marked disturbance in BBB function during exercise may adversely affect 
normal brain function and contribute to the development of central fatigue by 
allowing increased brain-blood interfacing. This may modify the transport kinetics of 
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neurotransmitter precursors and other metabolites or allow the accumulation of 
unwanted substances in the CNS. 
While it is accepted that the BBB integrity can be altered by a wide range of 
physiological disturbances, the molecular and cellular mechanisms behind these 
changes in vivo are not clear at present (Gloor et aI., 2001). Factors that may be 
important in changes to BBB permeability during prolonged exercise include a 
persistent elevation in core temperature (Sharma and Hoopes, 2003; Shivers and 
Wijsman, 1998). Wijsman and Shivers (1993) demonstrated that BBB permeability of 
anesthetized mice was increased when subjected to 45 minutes passive heat exposure. 
Colonic temperature throughout the protocol was maintained at 40.5 QC, with brain 
temperature possibly maintained at a higher level (Nybo et aI., 2002). This is clearly a 
stressful situation that could not be ethically reproduced in humans, but the level of 
disruption resulted in considerable damage to the endothelial cells of the BBB. The 
use of an anaesthetic would have impaired thermoregulation in these animals creating 
an artificial situation, but whole-body hyperthermia can also influence BBB function 
in free living rats although a longer exposure was required to increase core 
temperature and consequently observe a response (Sharma and Dey, 1987). 
As mentioned previously, manipulation of central serotonergic neurotransmission has 
been reported to alter the BBB response to exercise, suggesting a role for 5-HT in the 
regulation ofBBB integrity during exercise (Sharma et aI., 1991; Sharma et aI., 1996). 
Increases in circulating interleukin-6 (IL-6), IL-8, IL-IO and tumour necrosis factor-a 
(TNF-a) concentrations have been reported following bouts of strenuous exercise 
(Nieman et aI., 2001). An upregulation in pro-inflammatory cytokine production has 
also been implicated in changes in BBB permeability occurring during exercise (de 
Boer and Breimer, 1998). Cytokines are cellular hormones that play important roles in 
the growth, differentiation and function of many cells, as well as mediating 
inflammation. Some cytokines have been proposed to influence BBB permeability 
through an inflammatory component (1L-1 p, IL-6, TNF-a), producing functional 
changes in the barrier. An energy sensing role has been proposed for IL-6 (Steensberg 
et aI., 2000). Increased muscle IL-6 production during exercise, modulated by the 
muscle glycogen content, has been shown to stimulate lipolysis and increase fat 
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oxidation (pedersen et aI., 2003). In this way, IL-6 may act as a negative feedback 
mechanism to the CNS contributing to the development of central fatigue (Gleeson, 
2000). Additionally, there is a growing body of evidence to support the idea that 
feelings of tiredness and fatigue are triggered by the production of pro-inflammatory 
cytokines (Dantzer, 2004). This communication between the periphery and the brain 
has been tenned sickness behaviour and is thought to be a natural homeostatic 
reaction to promote recovery from infection by limiting non-essential activities. 
Strenuous exercise (pals et aI., 1997) and hyperthennia (Lambert et aI., 2002) have 
also been reported to produce a loss of tight junction control in the gastrointestinal 
(Gl) tract, resulting in an increase to gut penneability. Impaired GI tract penneability 
result in inflammatory events that alter gut structure and function that may manifest in 
intestinal bleeding and feelings of bloating and nausea (Gisolfi, 2000). It is important 
to note, however, that the histology of the intestinal mucosa differs markedly from 
that of the cells comprising the BBB, and changes in penneability control are likely to 
be mediated through different molecular and cellular mechanisms. 
1.10.2 - S100b: A proposed peripheral marker of BBB permeability 
As the protein content of the CSF is relatively low compared to that of the plasma, 
diagnostic methods of assessing BBB integrity often rely on the detection of plasma 
proteins in the CSF following disruption. This typically requires the use of 
sophisticated equipment (e.g. gadolinium-enhanced MRI), specialist operators and 
often invasive procedures (e.g. lumbar puncture). Recently it has been proposed that 
the appearance of CSF-specific proteins, including S 100b, in the circulation may be 
used as a peripheral marker of BBB function (Karuner et aI., 2003; Kapural et aI., 
2002; Marchi et aI., 2003b). SIOOb (also referred to as SIOO~, SIOObeta) is a low 
molecular weight protein (21 kDa) expressed predominantly within the CNS by 
astrocytes and Schwarun cells. It is typically found in low concentrations in the 
circulating serum, with a CSF (-1.5 Ilg.L·1) to serum (-0.08 Ilg.L·1) ratio of 
approximately 18:1 (Reiber, 2001). While the role of S100b is not clear at present, it 
is thought is to regulate protein phosphorylation, cell proliferation and it may be 
important in the regulation of cerebral energy metabolism (Zimmer et aI., 1995). 
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Serum SI OOb concentrations markedly increase following brain tumours, strokes, 
head injury and multiple sclerosis, leading to the widespread use of this protein as a 
peripheral marker of brain damage. These events result in a marked release of S 100b 
from the cytosol of damaged astrocytes, causing an up to 3- to 5-fold elevation in CSF 
concentrations (Petzold et ai., 2003). As most neurological disorders are accompanied 
by BBB disruption, markers used to indicate neuronal damage may actually indicate 
changes in BBB function (Marchi et ai., 2003b). In fact, when brain damage is 
induced in pig while the BBB was intact, no change in serum S 100b was apparent, 
despite a marked elevation in CSF SI OOb concentrations. 
Recently, Kapural et ai. (2002) demonstrated that a significant elevation in serum 
S100b occurred in the absence of structural neuronal/brain tissue damage following 
osmotic opening of the BBB by intra-arterial mannitol infusion (lA M). The authors 
proposed that SI OOb present in the perivascular space moves into the systemic 
circulation in areas of BBB disruption. Thus, an elevation in serum SI OOb may be an 
important marker of changes in BBB function. Mathematical modelling conducted by 
Marchi et ai. (2003) established a serum SIOOb concentration of -0.34 Jlg.L-1 as a cut 
off following an opening of the BBB in the absence of neuronal damage. This appears 
to fit well as serum SI OOb concentrations of greater than 0.7 Jlg.L-1 are typically 
associated with poor patient recovery in clinical settings (Ali et ai., 2000). 
BBB Opening 
I 
Figure 1.6: A graphical representation of the use of SI OOb as a peripheral marker of 
BBB disruption. 
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To confirm these initial findings, Kanner and co-workers (2003) examined the 
relationship between changes in serum SI OOb and the assessment of BBB function 
using gadolinium-enhanced MRI following osmotic opening of the BBB. Changes in 
serum SI OOb were directly associated with the extent and time-course of BBB 
disruption determined using neuroimaging, suggesting that SI OOb is a suitable marker 
of changes in BBB permeability under these conditions. 
S100 proteins circulating in the periphery are cleared by the kidneys and appear in the 
urine, with a serum half-life of around two hours (Ali et aI., 2000). The beta subunit 
of this protein is highly specific to the CNS, it is also expressed in small quantities in 
peripheral tissues including bone, heart and adipose tissue (Zimmer et aI., 1995). 
While peripheral sources have been identified, evidence suggests that the expression 
of SI OOb in these sites is around 5 % of the astrocytic production (Marchi et aI., 
2003b). Additionally, recent work suggests that SI OOb is liberated into the circulation 
only when significant trauma occurs to these tissues, for example the tissue damage 
encountered during surgery (Anderson et aI., 2001; Pelinka et aI., 2003). At present a 
peripheral role of S 1 OOb is not apparent. 
As there are clearly logistical and ethical problems associated with the use of 
imagining and lumbar-puncture techniques to monitor changes in BBB function 
during exercise. The recent identification of serum SI OOb as a peripheral marker of 
BBB permeability may provide useful information regarding potential changes in 
barrier function during exercise. 
1.11 - Exercise in a warm environment 
The capacity to perform prolonged exercise is reduced in a warm environment 
(Galloway and Maughan, 1997; Parkin et aI., 1999). Galloway and Maughan (1997) 
reported that the exercise capacity of non-heat acclimated males was greatest at 11 QC, 
with a progressive fall in time to fatigue as ambient temperature was increased. 
Similar findings have been reported by subsequent work, with an inverse relationship 
reported between ambient temperature and exercise capacity (parkin et aI., 1999). 
Additionally, a 6.5 % reduction in mean power output during a cycle time trial was 
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reported when the ambient temperature was increased from 23°C to 32 °C (Tatterson 
et aI., 2000). This response occurred despite little difference in rectal temperature 
between trials. Despite an understanding of the influence of ambient conditions on 
prolonged exercise capacity, the underlying mechanisms behind the deleterious 
effects of heat stress are not clear at present. 
During exercise, muscle contraction required to produce locomotion results in heat 
production. In cool-moderate ambient conditions, body temperature is typically 
maintained at a relatively constant level (within 1°C), by the dissipation of excess 
heat through a number of routes of heat loss (e.g. radiation, conduction, convection 
and evaporation). As ambient temperature rises, the effectiveness of these routes 
becomes compromised, and heat loss becomes increasingly dependent upon the 
evaporation of sweat from the skin's surface. The water that forms the majority of 
sweat is derived primarily from the blood plasma, with fluid mobilised from 
intracellular fluid compartments to maintain the circulating blood volume (Nose et aI., 
1988). High rates of sweat loss, typically encountered when exercising in hot and 
humid conditions, can result in a progressive reduction in blood volume and stroke 
volume, consequently limiting muscle blood flow. This situation is confounded by the 
need to supply an increased skin blood flow, required to transport heat away from the 
deep tissues to the periphery (Rowell, 1974). 
The loss of fluids occurring through increased sweat losses, results in a steady-state 
condition of decreased body water content, termed hypohydration (Greenleaf, 1992). 
Body water losses have been demonstrated to result in elevated exercise heart rate and 
the impairment of thermoregulation during exercise (Sawka et aI., 1985; Sawka et aI., 
1992), leading to an elevation in core temperature at the same absolute intensity. 
Hypohydration during exercise in the heat is also associated with a reduction in stroke 
volume, cardiac output and blood pressure (Gonzalez-Alonso et aI., 1997) as well as a 
marked decline in blood flow to the working muscles (Gonzalez-Alonso et aI., 1998). 
Undertaking prolonged exercise III the heat appears to increase the reliance upon 
carbohydrate oxidation, accelerating muscle glycogen utilisation and resulting in a 
greater accumulation of intramuscular lactate (Febbraio et aI., 1994). These metabolic 
alterations appear to result from changes in muscle temperature influencing the 
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activity of key enzymes responsible for energy production and elevated plasma 
catecholamine concentrations (Febbraio, 2001). While fatigue during prolonged 
exercise (65 - 85% VO, max) in temperate conditions is largely associated with the 
depletion of muscle glycogen (Bergstrom et ai., 1967), this relationship is not 
apparent at high ambient temperatures. There appears to be an inverse relationship 
between muscle glycogen concentration at fatigue and ambient temperature (Parkin et 
ai., 1999), suggesting that CHO availability is not limiting during prolonged exercise 
in the heat. 
While it appears that fat oxidation remams relatively unchanged in response to 
exercise in a warm environment (Febbraio, 2001), there is some evidence that protein 
metabolism may be increased. Elevated intramuscular (Febbraio et ai., 1994) and 
plasma (Marino et ai., 2001) ammonia accumulation has been reported during 
exercise is the heat. During prolonged exercise ammonia production is thought to 
arise from the oxidation of BCAA rather than purine catabolism (Greenhaff et ai., 
1991; van Hall et ai., 1995b). Although the contribution of protein oxidation to energy 
production is typically small, around 3 - 6 % of total energy expenditure (Gibala, 
2001), this may be elevated when exercising in warm ambient conditions (Febbraio, 
2001). An increased skeletal muscle uptake and utilisation of BC AA during exercise 
in the heat may have implications in the development of central fatigue through the 
mechanisms discussed previously (see Section 1.4). 
These peripheral changes do not adequately explain the reduction in performance, 
leading to the suggestion that the CNS may be involved (Nielsen, 1992; Nielsen and 
Nybo, 2003; Strachan and Maughan, 2002). Fatigue during prolonged exercise in a 
warm environment may coincide with the attainment of a critical core temperature 
(Gonzalez-Alonso et ai., 1999; Nielsen et ai., 1993; Waiters et ai., 2000), suggesting 
that there may be a thermal limit to exercise performance. Nielsen and co-workers 
(1993) first proposed this concept following a comprehensive investigation of the 
effects of the physiological adaptations associated with repeated exposure to the heat. 
Following a period of heat acclimation exercise capacity at 60% VO, max was 
increased by 40 %, with fatigue occurring at a similar oesophageal temperature of 
39.7 ± 0.15 QC. The period of acclimation attenuated the rate at which core 
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temperature increased and appeared to lower resting levels, allowing performance to 
be extended prior to the attainment of this critical value. This concept has been 
supported by recent findings in humans (Gonzalez-Alonso et aI., 1999) and rodents 
(Waiters et aI., 2000), although Sawka and colleagues (1992) observed that around 
75 % of individuals appear to fatigue at a rectal temperature of 39.1 QC. While it is 
currently unclear how an elevated body temperature contributes to the development of 
fatigue, it seems possible that a critical core temperature may serve as a protective 
mechanism preventing potential damage to the body by limiting further heat 
production. 
Recent work suggests that hyperthermia may have a direct affect on the CNS (Nielsen 
et aI., 2001; Nybo and Nielsen, 200la; Nybo and Nielsen, 2001b; Nybo and Nielsen, 
2001c; Nybo et aI., 2002). Neilsen and co-workers (2001) demonstrated that 
prolonged exercise in the heat was characterised by a progressive reduction in 
electroencephalogram (EEG) activity from the prefrontal cortex (Nielsen et aI., 2001), 
with an increase in the ratio of a to J3 frequency bands. This shift towards lower-
frequency a-bands is associated with feelings of tiredness and fatigue and is observed 
during the transition from waking to sleep. Whether exercise-induced hyperthermia 
influences neuromuscular function is not clear at present, with studies reporting a 
marked reduction (Nybo and Nielsen, 200la) or little change (Ftaiti et aI., 2001; 
Nielsen et aI., 1993) in force generation capacity. This discrepancy appears to relate to 
differences in the duration of contraction, with the fall in voluntary activation 
occurring faster when body temperature is elevated (Nybo and Nielsen, 200la). In 
addition, a decline in cerebral blood flow has been reported during exercise with 
hyperthermia (Nybo and Nielsen, 200lb). Perceived exertion is also significantly 
elevated by high core temperature compared to exercise at the same intensity under 
normothermic conditions (Armada-Da-Silva et aI., 2004; Nybo and Nielsen, 200lc). 
This has been demonstrated to occur despite little change to peripheral indices of 
fatigue, suggesting that a high body temperature may reduce motivation and drive to 
continue exercise (Bruck and Olschewski, 1987; Nielsen, 1992). The underlying 
neurobiological mechanisms for these responses are not clear at present. 
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Thennoreceptors in the preoptic anterior hypothalamus are responsible for regulation 
of body temperature, with changes in body temperature detected through inputs from 
peripheral osmoreceptors and pressure receptors as well as the temperature of blood 
flowing to the brain (Gleeson, 1998). As serotonergic and catecholaminergic 
projections innervate areas of the hypothalamus, a change in the activity of these 
neurons may be expected to contribute to fatigue when core temperature is elevated 
(Gandevia, 2001). The suggestion that serotonin-mediated fatigue is important during 
exercise in the heat is partially supported by the work of Mittleman and colleagues 
(1998). The findings of this study are outlined in Section 1.6, but it is important to 
note that core temperature at fatigue « 38 QC) was significantly below values 
suggested as limiting. There is also limited evidence that combined exercise and heat 
stress results in an increase in serotonergic neurotransmission (Pitsiladis et aI., 2002). 
Additionally, high levels of dopaminergic activity have been correlated with an 
increased tolerance to exercise in the heat (Bridge et aI., 2003). On the basis of these 
findings it is possible to speculate that the central ratio of 5-HT to DA may be 
important to the development of fatigue during prolonged exercise in a warm 
environment. 
Serotonin and dopamine have been implicated in the control of thennoregulation at 
rest (Lin et aI., 1998; Lipton and Clark, 1986) and during exercise (Hasegawa et aI., 
2000; Strachan, 2002). Pharmacologically-induced increases in serotonergic activity 
have been demonstrated to transiently elevate core temperature in free living rats, 
with the pattern of change in hypothalamic 5-HT and 5-HIAA concentrations 
mirroring almost exactly the change in body temperature (Lin et aI., 1998). Strachan 
(2002) reported a marked elevation in core temperature at rest and during exercise 
following pizotifen (a 5-HT2C receptor antagonist) administration, suggesting a role 
for the 5-HT2C receptor in the regulation of core temperature. Dopamine has also been 
implicated in thennoregulation, with a clear relationship reported between 
dopaminergic activity in the preoptic anterior hypothalamus (POlAR) and changes in 
core temperature during exercise (Hasegawa et aI., 2000). 
While many investigations have contributed to our understanding of the increased 
thennoregulatory and metabolic demands experienced during prolonged exercise in 
the heat, it is clear that the causes of fatigue are yet to be fully understood. While 
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early work focused primarily on the increase in circulatory and thermoregulatory 
strain, there is now a considerable body of evidence to suggest that central fatigue 
may be accelerated when exercise is performed in a warm environment. An overview 
of the factors currently thought to be important in the development of fatigue during 
prolonged exercise in a warm environment is illustrated in Figure 1.7. 
Metabolism 
Muscle Function 
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Exercise and Heat 
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Circulation 
Fluid Balance 
CNS 
Motor Centres? 
? 
Figure 1.7: Potential interaction between hyperthermia, physiological function and 
performance during exercise in the heat (Hargreaves and Febbraio, 1998). 
1.12 - Summary and Aims 
Support for a central component of fatigue mediated through changes to central 
neurotransmission is relatively poor under temperate environmental conditions. It 
appears likely that the development of fatigue during prolonged exercise can be 
largely explained by mechanisms peripheral to the eNS, including the depletion of 
muscle glycogen (Bergstrom et aI., 1967), and the development of hypohydration 
(Maughan and Shirreffs, 1997). This is not to suggest that the brain has no role in 
fatigue whilst exercising in temperate conditions, as psychological aspects 
significantly influence exercise performance and ultimately an individual has to make 
a conscious decision to cease exercise (Kayser, 2003). 
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Evidence is accumulating for a role of the CNS in the development of fatigue during 
prolonged exercise in a warm environment (Nielsen and Nybo, 2003). Perhaps this 
acts as a protective mechanism to limit tissue and cellular damage resulting from 
hyperthermia, but the neurobiological mechanism behind this response is not clear at 
present. The aim of this series of studies was to examine the potential role of central 
neurotransmitter systems and changes in blood-brain barrier function in the 
development of fatigue during prolonged exercise in a warm environment. 
The studies described in chapters 3 and 4 examined the effects of acute BCAA 
supplementation on the capacity to perform prolonged exercise In a warm 
environment. These studies were undertaken to further investigate the role of 
serotonin-mediated fatigue during prolonged exercise in the heat. The work in chapter 
5 was undertaken to determine the magnitude and time-course of changes in the 
plasma concentration ratio of f-TRP to BCAA at rest, following meals containing 
added CRO and fat. The work described in Chapter 6 investigated the effect of acute 
dopamine / noradrenaline reuptake inhibition on exercise performance in temperate 
and warm environments. Finally, the effect of water immersion and prolonged 
exercise under temperate and warm conditions on BBB function was considered in 
Chapter 7. 
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2.1 - Ethical approval 
All work described in Chapters 3, 4 and 5 received ethical approval from the 
Grampian Research Ethics Committee. The Loughborough University Ethical 
Advisory Committee approved the experimental protocol employed in Chapter 7. The 
bupropion study (Chapter 6) was approved by the Research Council of the Vrije 
Universiteit Brussel, Belgium. Prior to the start of each investigation all potential 
volunteers were first approached either in person, or contacted via email or poster. 
Those expressing an interest in taking part received written details outlining the 
background to the study, information regarding the protocol and any possible 
discomfort that may arise during the investigation. Following an opportunity to ask 
any questions, those interested in volunteering signed a written statement of consent. 
All subjects were fully aware from the outset that they were free to withdraw from the 
study at any time without providing any reason for doing so. 
2.2 - Subjects 
Subjects were typically recruited from the University staff and student populations as 
well as local sports clubs. Due to the physically demanding nature of the 
investigations described in Chapters 3, 4, 6 and 7, subjects were familiar with the 
sensation of strenuous exercise, and had regularly taken part in prolonged exercise for 
a number of years. Subjects recruited to take part in the studies investigating 
responses to exercise in a warm environment were unaccustomed to exercise in the 
heat at the time of the investigation. Due to the nature of this series of studies, those 
with a history of psychiatric illness and I or metabolic disease were excluded. Those 
individuals that did not fit the inclusion criteria were thanked for their interest and 
politely told that their help would not be required. 
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2.3 - Experimental design and standardisation of experimental conditions 
The studies described in Chapters 3, 4 and 6 were placebo-controlled trials. Trials 
were randomised using a Latin-square crossover design to minimise any order effect 
and administered in a double-blind manner. The studies investigating the effect of 
meals with added CHO and fat (Chapter 5), and potential changes in blood-brain 
barrier permeability during exercise (Chapter 7) were randomised crossover trials. 
Trials were performed at the same time of day to minimise the influence of circadian 
variation and were also performed on the same day of the week wherever possible to 
further standardise the pre-exercise conditions. Prior to the start of the experimental 
trials, at least one familiarisation trial was undertaken to ensure the subjects were 
accustomed to the procedures employed during the investigations and to minimise any 
potential learning or anxiety effects. This followed the exact protocol used in the 
experimental trials. In Chapters 3, 4 and 6, the placebo treatment was administered 
during the familiarisation. During the BCAA supplementation trials (Chapters 3 and 
4) a single expired gas collection was made following 15 minutes of exercise to verify 
the workload was correct to elicit the desired percent V0 2 peak. 
To help ensure metabolic conditions were similar before each experimental trial, 
subjects were instructed to record all food and fluid intake (household measures 
technique), as well as any exercise performed, in a diary over the 2 days prior to the 
first trial. This dietary intake and physical activity was replicated as closely as 
possible during the 2 days before subsequent trials. Subjects were also asked not to 
perform any strenuous exercise or consume alcoholic beverages in the 24 hours prior 
to all trials. 
All trials outlined in this thesis were performed following an overnight fast, with the 
exception of the study described in chapter 6. In the study investigating the influence 
of bupropion administration on exercise performance, subjects were instructed to 
ingest a standardised breakfast 90 minutes before entering the lab. Subjects in all 
investigations were asked to consume 500 mL of plain water around 90 minutes 
before entering the lab. 
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The environmental conditions for exercise trials were controlled usmg a climatic 
chamber. Thermostat-controlled floor standing heaters were used to elevate the 
ambient temperature to the desired level prior to each trial. The room temperature was 
monitored throughout the protocol using a dry-bulb ambient temperature probe (YSI 
OK Ltd, Hampshire, OK or Gram Corp. LT-SA, Saitama, Japan), with any deviation 
in temperature corrected to maintain the temperature within at least ± 0.5 °C of the 
desired temperature. Relative humidity was also determined at regular intervals using 
a hygrometer. When subjects were required to remain seated at rest, the ambient 
temperature was maintained within a comfortable range (24 - 25°C). Trials 
I 
investigating prolonged exercise in a warm environment (Chapters 3, 4, 6 and 7) were 
separated by at least 7 days to limit the development of heat acclimation (Barnett and 
Maughan, 1993). 
2.4 - M~asurement of peak oxygen uptake CV0 2 peak) 
To determine the workloads subjects were required to exercIse at during the 
experimental protocols, the determination of peak oxygen uptake (V0 2 peak) was 
first necessary. This was undertaken using either a discontinuous (Chapters 3, 4 and 
7) or continuous (Chapter 6), incremental graded exercise test on an electrically 
braked cycle ergometer. The discontinuous protocol required subjects to complete 
between 4 to 6 discrete 3 minute increments, beginning at an initial workload of 100 
watts (W). Depending upon the subject's performance in the previous stage (e.g. was 
fatigue evident, heart rate close to age-predicted maximum?), the workload was 
increased by either 50 or 25 W. Between each bout, a supervised rest period of 3 to 5 
minutes was observed, during which the subject was able to walk around and drink 
plain water, if desired. The test continued until the subject retired through volitional 
exhaustion. The continuous protocol required subjects to began exercise at an initial 
workload of SO W, with the intensity increased by 40 W every 3 minutes until 
volitional exhaustion. Maximum workload (W max) was determined using the 
following equation: Wmax = WOU! + (t/ISO) x 40 where 'WOU!' is the workload of the 
last completed stage and 't' is the time in seconds of the final stage (Jeukendrup et aI., 
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1996). The experimenters provided verbal encouragement during both protocols to 
help ensure a maximal effort. 
Expired gas was collected during the last 120 seconds of the first, and the final 60 
seconds of the remaining stages of the discontinuous protocol, using the Douglas bag 
method (described by Astrand et aI., 2003). Throughout the continuous test, expired 
gas was analysed using an automated spirometry system (Metamax, Cortex, 
Biophysik GmbH, Germany). At the end of each increment in both protocols, heart 
rate was recorded using telemetry (Polar Beat, Kempele, Finland). 
The expired gas collected using Douglas bags was analysed for oxygen (02) and 
carbon dioxide (C02) composition by drawing gas through a Servomex paramagnetic 
02 transducer (Sussex, UK) and medical CO2 analyser (Beckman LB-2, Illinois, 
USA). Both analysers were calibrated prior to each test using appropriate gases of 
known concentrations (BOC Gases, Surrey, UK). The remaining expired gas in the 
Douglas bag was then evacuated using a Harvard dry gas meter (Harvard Apparatus 
Ltd, Kent, UK), to determine gas volume and temperature (Comark, Sussex, UK). All 
expired gas volumes were corrected to standard temperature and pressure dry (STPD) 
prior to integration into further analysis. 
The expired gas data were used to calculate oxygen uptake (VO,), carbon dioxide 
production (VCO,), ventilation rate (VE ), and respiratory exchange ratio (RER) for 
each stage of the protocol. These data were then used to calculate the workloads 
corresponding to an appropriate percentage of a subject's VO, peak. Measurement of 
expired gas composition was also used during experimental trials to estimate rates of 
substrate oxidation (Peronnet and Massicotte, 1991) and energy expenditure (Chapters 
4 and 7). 
2.5 - Exercise trials 
All the exercise-based investigations outlined in this thesis used cycle exercise on a 
stationary, electrically braked cycle ergometer as an experimental model (Gould 
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Corival 300 or Lode Excalibur Sport, Groningen, Holland). This type of ergometer 
was used as a preset workload can be maintained by the subject independent of pedal 
frequency (hyperbolic ergometry). During the preliminary incremental test to 
exhaustion, subjects were instructed to set up the cycle ergometer, as desired (e.g. 
saddle height etc). These details were recorded and the ergometer was set to their 
specifications prior to the start of each trial. Wherever possible subjects were 
supervised by the same experimenters for all experimental trials to minimise the 
influence of social facilitation. 
Trials investigating the effect of BCAA supplementation on exercise capacity 
(Chapters 3 and 4), used exercise time to volitional exhaustion, defined as an inability 
to maintain a pedal cadence of;:" 60 revolutions.min-', as the outcome measure. To 
help ensure the achievement of a maximal effort, the experimenters provided verbal 
encouragement, particularly during the later stages of each trial. To assess the 
influence of pharmacological manipulation of central dopamine and noradrenergic 
systems on exercise performance (Chapter 6), a time trial (TT) protocol was 
employed. The TT required the subjects to complete an amount of work equal to 30 
minutes at 75% Wm• x as quickly as possible (Jeukendrup et ai, 1996). Subjects began 
the TT at a workload corresponding to 75% W max and were free to increase or 
decrease their power output as desired. During the TT a computer program displayed 
a bar indicating the percentage of total work completed to give the subject an 
indication of their progress. No feedback was provided regarding time lapsed, power 
output, pedal cadence or heart rate. 
Throughout the thesis, before and after exercise post-void nude body mass was 
measured to the nearest 10 g, using a beam balance (Marsdens, London, UK). When 
body mass was measured following exercise, the subject first towelled them self dry 
to remove any sweat lying on the skin surface. The difference in body mass before 
and after exercise, corrected for any urine output and fluid ingestion, was used as an 
index of sweat losses that had occurred. These data were not corrected for immiscible 
fluid losses (e.g. respiratory water and losses due to substrate oxidation). 
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To monitor core body temperature whilst at rest and during exercise, subjects inserted 
a flexible rectal thermistor (YSI UK Ltd, Hampshire, UK or Gram Corp. LT-8A, 
Saitama, Japan) 10cm beyond the anal sphincter. Surface skin thermistors (YSI UK 
Ltd, Hampshire, UK or Gram Corp. LT-8A, Saitama, Japan) were positioned at four 
sites (chest, upper arm, thigh and calf). Thermisters were held securely in contact with 
the skin using transpore medical tape (3M, Loughborough, UK). Weighted mean skin 
temperature was calculated using the methods described by Ramanathan (1964). 
Throughout the work described in this thesis perceived exertion (RPE) was assessed 
at regular intervals during exercise using the standard 15-point Borg scale (Borg, 
1982). To provide an indication of perceived thermal stress, a 21-point thermal 
sensation scale was also used (see Appendix Ill). Heart rate was measured whilst at 
rest and during exercise using short-range telemetry (Polar Beat, Kempele, Finland). 
Where studies involved the ingestion of set meals (Chapters 4 and 5), the nutritional 
composition of the meals was determined using a computer-based dietary analysis 
program based on the food composition tables of McCance and Widdowson 
(Windiets Professional, Robert Gordon University, Aberdeen, UK). The amino acid 
composition of the meals ingested in Chapter 5 were determined using USDA 
National Nutrient Database (http://www.nal.usda.gov/fuic/foodcomp). When fluids 
were provided at regular intervals during exercise (Chapters 3, 4 and 6), these were 
maintained at a temperature of approximately 21 QC by immersing the drinks bottles 
in a water bath prior to ingestion. 
2.6 - Blood collection, handling and analysis 
To enable serial blood samples to be drawn whilst at rest and during exercise, a 21 g 
butterfly cannula (Terumo, Leuven, Belgium) was introduced into a superficial vein 
found in either the forearm or back of the hand. Blood was drawn through a three-way 
tap into dry syringes, except during the bupropion study were vacutainer tubes were 
used (see Chapter 6). To ensure the cannula remained patent between blood samples, 
it was flushed with a small volume of heparinised saline after sampling. Where 
arterialised venous blood was required whilst seated at rest, the subject's forearm was 
immersed in warm water (40 - 42 QC) for approximately 10 minutes prior to sampling 
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(Nauck et aI., 1992). Collected blood was immediately dispensed into plain tubes or 
tubes containing an anticoagulant (e.g. K2EDT A or lithium heparin) depending on its 
intended analytical use. Assays used widely throughout this thesis are described 
below, with assays common to a single study described in the methods section of the 
appropriate chapter. All biochemical analyses performed throughout this thesis were 
performed in duplicate, unless otherwise stated. 
In all investigations, with the exception of the bupropion study, 2.5 mL of whole 
blood was dispensed into tubes containing K2EDT A. Duplicate 1 00 ~L aliquots of 
blood were rapidly deproteinised in 1000 ilL of ice-cold 0.3 N perchloric acid. These 
were centrifuged, and the resulting supematant was used for spectrophotometric 
determination of blood glucose on the day of the trial using a commercially available 
assay kit (God-Perid, Sigma Diagnostics, Poole, UK or God-PAP, Randox, 
Co. Antrim, UK). Blood lactate was determined fluorimetrically within 48 hours of 
each trial using the methods outlined by Maughan (1982). 
The remammg EDT A-treated whole blood was used for the spectrophotometric 
determination of haemoglobin (Hb) by the cyanmethaemoglobin method. Packed cell 
volume (PCV) was measured in triplicate using microcentrifugation (Hawksley, 
Sussex, UK). Both Hb and PCV were determined within 2 hours after each 
experimental trial. Using the Hb and PCV values obtained, percentage changes in 
blood, plasma and red cell volumes relative to the first sample were estimated using 
the methods proposed by Dill and Costi11 (1974). 
K2EDTA or lithium heparin treated whole blood was centrifuged at 1500 g for 15 
minutes at 4 QC, with the visible plasma transferred into plain eppendorf tubes ready 
for storage at -20 QC. Plasma free-fatty acids (FFA) were analysed using a 
commercially available test kit (Roche Diagnostics, Mannheim, Germany). Changes 
in circulating plasma amino acids were determined using enzymatic fluorimetric 
method5. To isolate plasma free-tryptophan (f-TRP) from albumin bound tryptophan, 
a 0.5 mL aliquot of plasma was centrifuged at 4 QC for 120 minutes at 400 g through a 
12 kDa cellulose tri-acetate membrane (Whatman VectaSpin Micro, Kent, UK). 
Plasma and ultrafiltrate samples were stored frozen at -20 QC ready for the analysis of 
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total-TRP and f-TRP concentrations (see Appendix II). Plasma branched-chain amino 
acid concentrations were determined through the oxidative deamination of L-leucine, 
L-isoleucine and L-valine by leucine dehydrogenase. NADH is produced 
stoichiometrically from the oxidation of BCAA in an alkaline reaction medium 
(Gleeson and Maughan, 1987). 
2.7 - Statistical analysis 
The statistical analyses of the physiological data collected throughout this series of 
investigations were performed using Minitab v13.3 for Windows (Minitab Inc. PA, 
USA). Normality was first determined using the Ryan-Joiner correlation test. All 
normally and non-normally distributed results are presented as means ± standard 
deviation and median ± range respectively, unless otherwise stated. Data presented in 
figures throughout the thesis are also contained in Appendix I as numerical values. To 
identify differences in normally distributed results, one and two-way (time-by-trial) 
repeated measures analysis of variance (ANOVA) were employed. Where a 
significant interaction was apparent, pair-wise differences were evaluated using 
Tukey's post hoc procedure. Non-normal data were examined using Kruskal-Wallis 
tests where appropriate. For the purpose of hypothesis testing, the 95 % level of 
confidence was predetermined as the minimum criterion to denote a statistical 
difference (P < 0.05). 
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2.8 - Coefficients of variation (CV) of assays 
Intra-assay coefficient of variation (SD/mean* I 00) was determined for the 
biochemical assays used throughout this thesis (Table 2.1) using at least 20 samples. 
Table 2.1: Intra-assay coefficient of variation of biochemical assays used throughout 
this thesis 
Assay Method Mean CV(%) 
Haemogloblin Cyanmethaemoglobin 146 g.L-1 0.6 
Packed Cell Volume Microcentrifugation 45.0% 0.6 
Blood Glucose GOD-Perid (Sigma) 5.1 mmol.L-1 1.1 
Blood Glucose GOD-PAP (Randox) 5.1 mmol.L-1 1.3 
Blood Lactate Maughan (1982) 1.47 mmol.L-1 0.8 
PlasmaBCAA Gleeson and Maughan (1987) 372 J.lmoI.L-1 1.3 
Plasma free-tryptophan See Appendix I 4.6 J.lmoI.L-1 1.6 
Plasma total-tryptophan See Appendix I 43 J.lmoI.L-1 1.9 
Plasma free fatty acids Half-micro test kit 0.36 mmol.L-1 2.3 
Plasma ammonia Glutamate dehydrogenase 90.4 J.lmoI.L-1 6.6 
Plasma ACTH Immulite 2000 (DPC) 23.7 ng.L-1 13.1 
Serum sodium Flame photometry 143 mmol.L-1 0.7 
Serum potassium Flame photometry 5.4 mmol.L-1 1.7 
Serum chloride Coulometric Titration 104mmolr l 1.1 
Serum osmolality Freezing point depression 295 mOsm.kg-1 0.9 
Serum pro lactin Architect (Ab bott) 6.3 ng.mL-1 5.8 
Serum cortisol Immulite 2000 (DPC) 32.5 ng.mL-1 8.3 
Serum growth hormone Immulite 2000 (DPC) 3.3 mill.L-1 8.0 
Serum SIOOb Microplate ELISA 0.06 J.lgT1 6.7 
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3.1- Abstract 
Eight healthy males were recruited to examine the influence of BCAA ingestion on 
prolonged exercise capacity in a warm environment. Subjects entered the lab in the 
morning following an overnight fast. 500 mL of a BCAA+CHO solution (12 g.L·1 
BCAA, 65 g.L·1 CHO) or CHO placebo (65 g.L·1 CHO) was ingested 45 minutes prior 
to exercise. Subjects remained seated in a comfortable environment for 45 minutes, 
before cycling to volitional exhaustion at 60 % VO, peak in climatic chamber 
maintained at 35.0 °C. An additional 250 mL of the appropriate solution was consumed 
at 15 minute intervals throughout exercise. No difference in time to exhaustion was 
apparent between the BCAA (62.8 ± 15.7 min) and placebo (60.8 ± 18.8 min) trials (P 
= 0.583). The addition of BCAA to the ingested solutions produced a marked increase 
in plasma BCAA immediately prior to exercise (+843 ± 229 !-!moI.L·1; P < 0.001), with 
this difference maintained throughout. Consequently, a significantly lower 
f-TRP:BCAA was observed during the BCAA trial compared with the placebo 
(P < 0.001). Core temperature was similar throughout both trials (P = 0.855), with 
temperatures of 39.2 ± 0.6 °C and 39.1 ± 0.6 °C respectively recorded at exhaustion. 
Weighted mean skin temperature was also unaffected by the supplementation 
(P = 0.522). The subjects' RPE (P = 0.496) and perceived thermal stress (P = 0.668) 
was not different between trials. No effect of BCAA supplementation on blood glucose 
(P = 0.063) or lactate (P = 0.498) concentrations was apparent during the trials. These 
results suggest that ingestion of a BCAA+CHO solution does not enhance the capacity 
to perform prolonged exercise in a warm environment over that of a CHO placebo. 
3.2 - Introduction 
It has been suggested that changes to the synthesis and metabolism of central 
neurotransmitters may contribute to the genesis of fatigue during prolonged exercise 
(Newsholme et aI., 1987). While changes in the central synthesis of 5·HT have long 
been associated with alterations to mood, arousal, lethargy and sensory perception, 
Newsholme and colleagues (1987) were first to propose that fatigue during exercise 
may result from changes in the activity of serotonergic neurons. The authors suggested 
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that the shift in substrate utilisation that occurs as exercise progresses would result in a 
greater cerebral uptake of f-TRP, with the increased delivery of this amino acid 
precursor thought to be directly responsible for determining the rate of 5-HT synthesis 
(Femstrom, 1983). See Chapter 1 for a detailed description of mechanism behind 
Newsholme's central fatigue hypothesis. 
The acute administration of pharmacological agents thought to manipulate extracellular 
5-HT concentrations has provided some support for this hypothesis (Davis et aI., 1993; 
Struder et aI., 1998; Wilson and Maughan, 1992), but nutritional manipulation of 
plasma amino acids have produced inconsistent results despite a good rationale. The 
positive tindings of an early field study conducted by (Blomstrand et aI., 1991) 
supporting an ergogenic benefit of BC AA have not been reproduced in apparently well-
controlled laboratory studies conducted in temperate environmental conditions 
(Blomstrand et aI., 1995; Madsen et aI., 1996; Struder et aI., 1998; van Hall et aI., 
1995). Although evidence in humans is sparse, rodent studies have demonstrated 
BCAA administration to be effective at attenuating 5-HT synthesis during exercise 
(Gomez-Merino et aI., 2001) and prolonging exercise capacity (Calders et aI., 1999; 
Calders et aI., 1997). 
It is widely accepted that the capacity to perform prolonged exercise is significantly 
reduced in a warm environment (Galloway and Maughan, 1997; Parkin et aI., 1999), 
but the mechanism for the deleterious effects of heat stress remain unclear. While it 
appears that performance is primarily limited by thermoregulatory and fluid balance 
factors (Hargreaves and Febbraio, 1998), it has been proposed that hyperthermia may 
result in an acceleration of central fatigue (Bruck and Olschewski, 1987; Nielsen, 
1992). Subsequent work has provided support for this proposal, with elevated core 
temperature demonstrated to impair maximal muscle activation (N ybo and Nielsen, 
200Ia), alter brain activity (Nielsen et aI., 2001) and increase perceived exertion (Nybo 
and Nielsen, 200Ic). These recent findings suggest that the CNS is important in the 
development of fatigue during prolonged exercise in a warm environment, but the 
underlying neurobiological mechanism(s) behind these responses are currently 
unknown. 
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Work conducted by Mittleman and colleagues (1998) has provided some evidence in 
support of the importance of serotonergic neurotransmission in the development of 
central fatigue during exercise in a warm environment (34.4 0c). BCAA 
supplementation was reported to improve exercise capacity by 14 % when compared to 
a polydextrose placebo (BCAA 153.1 ± 13.3 min, placebo 137.0 ± 12.2 min; P = 0.04). 
The ingestion of the BCAA solution resulted in a marked elevation in circulating 
BCAA and consequently a 50 % reduction in the plasma concentration ratio of f-TRP 
to BCAA. The authors reported no differences in cardiovascular, thermoregulatory or 
substrate responses between trials, suggesting that the supplementation regimen may 
have been successful at attenuating the development of serotonin-mediated central 
fatigue. It is worth highlighting that a relatively low exercise workload was employed 
during this investigation (40 % V0 2 peak). Additionally, as a consequence of the low 
exercise intensity, the subjects' core temperature at fatigue (37.3 - 37.7 0c) was 
considerably lower than the critical core temperature suggested to be important in the 
acceleration of central fatigue in a warm environment (-40°C; Nielsen et aI., 1993). 
The aim of the present investigation was to re-examine the findings of Mittleman et al. 
(1998), by determining the effects of BCAA ingestion on exercise capacity during 
prolonged exercise in a warm environment. The present investigation employed a 
workload corresponding to 60 % VO, peak, which is closer to the intensity of exercise 
typically undertaken during athletic training and would elicit whole-body hyperthermia. 
In order to allow comparisons with the work of Mittleman et al. (1998) a similar 
supplementation regimen was followed, with BCAA administered at a similar time 
prior to the start of exercise and in similar quantities. 
3.3 - Methods 
Subjects. Eight healthy male subjects were recruited (age 30.9 ± 8.6 y; height 1.77 ± 
0.05 m; mass 77.4 ± 8.4 kg; VO, peak 4.3 ± 0.3 L.minol). All volunteers were 
recreationally active and regularly participated in endurance exercise, but were not 
accustomed to exercise in a warm environment at the time of the study. Prior to the 
start of the investigation all subjects received written details outlining the nature and 
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purpose of the study, after which a statement of informed consent was signed. The 
protocol received ethical approval from the Grampian Research Ethics Committee. 
Experimental protocol. All subjects completed an incremental exercise test to 
determine VO, peak, a familiarisation trial and two experimental trials. The 
incremental test is described in Chapter 2, and was used to determine the exercise 
intensities undertaken by each subject during the remainder of the study. 
Approximately one week later, the subjects completed a familiarisation trial that 
mirrored exactly the protocol employed in the experimental trials. This was included to 
ensure the subjects were accustomed to the exercise protocol and environmental 
conditions and to minimise any leaming or anxiety effects which may serve to 
confound the results of the study. Subjects received an appropriate quantity of the 
placebo solution during the familiarisation trial (see below), but were unaware of which 
solution was being administered. The standardisation of pre-trial conditions is outlined 
in Chapter 2. 
Experimental trials were randomised and undertaken in a double-blind, crossover 
manner. Subjects reported to the laboratory in the morning (-9 am), following an 
overnight fast. Upon arrival, post-void, nude body mass was recorded before a rectal 
thermister was inserted 10 cm beyond the anal sphincter. Surface skin thermisters were 
placed at four sites (upper arm, chest, thigh and calf), and a heart rate monitor was 
positioned. Whilst seated in a comfortable environment (25.9 ± 0.2 QC), a 21 g butterfly 
cannula was introduced into a superficial forearm vein and remained in place 
throughout the experimental period to allow blood sampling whilst at rest and during 
exerCise. 
Following the collection of a 10 mL baseline blood sample (-45 minute), 500 mL of 
either a placebo (65 g.L·' CHO) or BCAA solution (65 g.L-' CHO, 6 g.L-' leucine, 3 
g.L-' isoleucine, 3 g.L-' valine) was ingested. Both solutions comprised a commercially 
available sports drink powder (Gatorade Thirst Quencher, Chicago, IL), prepared to the 
manufacturers' guidelines, with or without the addition of the BCAA. During the rest 
period heart rate, rectal and skin temperatures were recorded at 5 minute intervals. A 
second blood sample was then drawn 45 minutes following the baseline collection. 
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Subjects then entered a climatic chamber, maintained at 3S.0 ± 0.3 QC (initial relative 
humidity 30 ± 3 %), and commenced cycle exercise at a workload corresponding to 60 
± 2 % V0 2 peak. The experimental trials required the subject to continue to volitional 
exhaustion, defined as an inability to maintain a pedal cadence of~ 60 rev.min· l despite 
verbal encouragement from the experimenters. Measurements of core and skin 
temperatures, as well as heart rate, were recorded at S minute intervals throughout the 
exercise period. Ratings of perceived exertion and thermal stress were assessed at 10 
minute intervals. Venous blood samples were drawn every IS minutes during the first 
hour of exercise, and at the point of exhaustion. In addition to the initial bolus of fluid 
given whilst at rest, subjects also received 2S0 mL of appropriate solution (placebo or 
BCAA) in sports drink bottles every IS minutes during exercise. 
Immediately following the cessation of exercise, subject were removed from the 
climatic chamber into a comfortable environment, where the heart rate monitor, skin 
and rectal temperature probes and cannula were removed. A second nude body mass 
was then recorded to enable the estimation of the sweat losses incurred during exercise. 
Blood handling and analysis. The 10 mL blood samples collected throughout the 
protocol were drawn into dry syringes and immediately dispensed into tubes containing 
an anticoagulant. 2.S mL was dispensed into a tubes containing K2EDTA, 2.S mL was 
added to tubes containing ice-cold fluoride oxalate, with the remaining S mL placed 
into a tube containing lithium heparin. Samples treated with fluoride oxalate or lithium 
heparin were centrifuged to yield plasma, which was stored at -20 QC until analysis. 
Duplicate 100 I-lL aliquots of EDTA-treated whole blood were rapidly deproteinised in 
I mL of ice-cold 0.3 N perchloric acid. These were centrifuged and the resulting 
supernatant used for determination of blood glucose and lactate concentrations. Whole 
blood was also used for the determination of haemoglobin (Hb) and packed cell volume 
(PCV), allowing percentage changes in blood, plasma and red cell volumes relative to 
the first resting sample to be estimated (Dill and Costill, 1974). f-TRP was separated 
from albumin bound TRP, as described in chapter 2. Plasma and ultrafiltrate samples 
were then kept frozen a-20 QC ready for the determination ofFFA, BCAA and f-TRP. 
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3.4 - Results 
The subjects' individual times to exhaustion in each trial are presented in Figure 3.1A. 
The ingestion of a BCAA + CHO solution resulted in no change to exercise capacity 
when compared to the CHO placebo, with mean times of 62.8 ± 15.7 min and 60.8 ± 
18.8 min recorded respectively (P = 0.583). This represents a 3.1 ± 13.0 % difference 
between trials, but there was no apparent trend in the change in exercise capacity 
following the ingestion of BCAA (Figure 3.IB). There was no evidence of an order 
effect during the experimental trials (Wkl 62.7 ± 16.7 min, Wk2 61.0 ± 17.9 min; P = 
0.637). 
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Figure 3.1: Individual exercise times to exhaustion (A) and percent changes in exercise 
capacity (B) between the placebo and BCAA trials. The dark lines represent the mean 
changes in exercise capacity. 
The ingestion of BCAA prior to the start of exercise resulted in a elevation in plasma 
BCAA c~ncentrations (+843 ± 229 ~moI.L-l; P < 0.001), with this level maintained 
throughout exercise (Figure 3.2). During the placebo trial there was a tendency for a 
reduction in circulating BCAA concentration as time progressed, but this failed to reach 
significance (P = 0.111). 
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Figure 3.2: Plasma BCAA concentration at rest and during exercise. a and b denote a 
significant difference from -45 min time point in the placebo and BCAA trials 
respectively (P < 0.05). * (P < 0.05) and ** (P < 0.0 I) denote a significant difference 
between the BCAA trial and the corresponding time point on the placebo trial. 
Table 3.1: Changes in plasma f-TRP concentrations (IlmoI.L·1) and the plasma 
concentration ratio of f-TRP to BCAA (no units). a and b denote a significant 
difference from the -45 time point in the placebo and BCAA trials respectively (P < 
0.05), * denotes a significant difference from the corresponding time-point (P < 0.01). 
-45 0 Ex 
f-TRP Placebo 6.8 ± 2.5 5.5 ± 1.2 7.5 ± 2.0 
BCAA 6.0 ± 3.7 5.5 ± 2.6 8.6 ± 5.0 
f-TRP: BCAA Placebo 0.015 ± 0.004 0.014 ± 0.003 0.022 ± 0.006 a 
BCAA 0.014 ± 0.010 0.005 ± 0.002 b* 0.009 ± 0.007 b* 
Changes in plasma f-TRP and the plasma concentration ratio of f-TRP to BCAA are 
presented in Table 3.1. No difference in circulating f-TRP was apparent between 
experimental trials (P = 0.906). Baseline (-45 min) f-TRP:BCAA values were similar 
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(P = 0.846), with a marked reduction in this ratio observed immediately prior to 
exercise and at the point of exhaustion following the ingestion of the BCAA+CHO 
solution (P < 0.001). At the point of exhaustion f-TRP:BCAA was elevated over the 
-45 minute time point in the placebo trial. 
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Figure 3.3: Change in core (A) and weighted mean skin (B) temperature at rest and 
during exr.:rcise. a and b denote a significant difference from the pre-exercise value in 
the placebo and BCAA trials respectively (P < 0.05). 
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Core temperature was not different during the two trials (P = 0.855) with a progressive 
rise observed throughout the exercise period (Figure 3.3A). At 35 minutes of exercise, 
and beyond, core temperature was significantly elevated over resting values (P < 0.05). 
Core temperature increased similarly during both trials reaching 39.1 ± 0.6 QC and 39.2 
± 0.6 QC at the point of exhaustion in the placebo and 8CAA trials respectively (P = 
0.534). Weighted mean skin temperature was not different between trials whilst seated 
at rest prior to commencing exercise (P = 0.194). Skin temperature increased rapidly in 
both trials during the initial 15 minutes of exercise, after which the temperature 
continued to rise at a slower rate (Figure 3.38). 
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Figure 3.4: The heart rate response at rest and during exercise. a and b denote a 
significant difference from the pre-exercise value in the placebo and BCAA trials 
respectively (P < 0.05). 
Heart rate was significantly elevated above resting values throughout the exercise bout 
in both trials (P < 0.001; Figure 3.4), but 8CAA ingestion produced no change whilst at 
rest or during exercise (P = 0.823). From the onset of exercise RPE progressively 
increased throughout both trials, with no detectable difference between the 8CAA and 
placebo (P = 0.496; Figure 3.5A). There was a tendency for an elevated RPE at the 
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point of exhaustion during the placebo trial (P = 0.078). No difference in thennal stress 
was observed between the two trials (P = 0.668; Figure 3.5B). The perceived sensation 
of thennal stress was significantly elevated above the initial exercise time point 
following 40 minutes of exercise in both experimental trials. 
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Figure 3.5: Change in RPE (A) and thennal stress (B) during the placebo and BCAA 
trials. a and b denote a significant difference from the 10 minute time point in the 
placebo and BCAA trials respectively (P < 0.05). 
66 
Chapter 3 BCAA Supplementation I 
8 
-+-BCM 
-o-Placebo 
7 
~ 
~ 
0 6 E 
E 
-Cl> 
III 
0 5 u 
:::I 
Cl 
4 
3 
A 
ab 
7 
a 
6 
5 
ab 
4 
3 a 
2 
1 
o+-----~----~----,-----,-----,----. 
B -45 o 15 30 45 Ex 
Time (minutes) 
Figure 3.6: Blood glucose (A) and lactate (B) concentrations at rest and during 
exercise. a and b denote a significant difference from the -45 minute time point in the 
placebo and BCAA trials respectively (p < 0.05). 
There was a clear tendency for a difference in blood glucose concentration between 
trials, but this was not significant (P = 0.063). Following a small rise in glucose post-
ingestion, a transient fall was apparent during the initial 15 minutes of exercise in both 
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the placebo (P = 0.023) and BCAA (P < 0.001) trials. Blood glucose concentrations 
were restored to resting levels as exercise progressed. BCAA supplementation 
produced no effect on the blood lactate concentration (P = 0.498; Figure 3.6B). Lactate 
levels increased progressively during both trials, reaching peak values of 4.7 ± 2.4 
mmoI.L-' and 4.5 ± 2.0 mmoI.L-' at exhaustion in the placebo and BCAA trials 
respectively. Plasma FFA were not different between trials, but tended to be lower 
following BCAA ingestion (P = 0.264). Ingestion of both placebo and BCAA solutions 
produced a marked reduction in FFA immediately prior to commencing exercise, 
increasing to 0.38 ± 0.10 mmoI.L-' and 0.32 ± 0.10 mmolr' at exhaustion. To 
determine the relationship between changes in plasma FFA and plasma f-TRP observed 
in the placebo and BCAA trials, the difference between baseline and exhaustion values 
were correlated. The correlation coefficients were calculated as -0.22 (P = 0.596) for 
the placebo and -0.04 (P = 0.927) for BCAA trial. 
Table 3.2: Percentage changes in blood, plasma and red cell volumes relative to the 
-45 minute sample at rest and during exercise. a and b denote a significant difference 
from the -45 minute time point in the placebo and BCAA trials respectively (P < 0.05). 
0 15 30 Ex 
Blood Volume Placebo 2.4 ± 2.3 -5.3 ± 2.0 • -5.8 ± 2.5 • -5.5 ± 3.0 a 
BCAA 2.4 ± 3.7 -4.0 ± 2.2 b -4.2 ± 3.4 b -3.9 ± 4.5 b 
Plasma Volume Placebo 3.5 ± 3.4 -9.2 ± 3.6' -7.1 ±9.0' -9.1 ± 5.8 a 
BCAA 3.8 ± 5.4 -7.4±3.2 b -9.0 ± 3.7 b -9.3 ± 3.6 b 
Cell Volume Placebo 0.9 ± 1.5 -0.4 ± 1.I -0.6 ± 1.6 -0.5 ± 1.9 
BCAA 0.7 ± 2.4 0.4 ± 2.3 0.2 ±2.6 0.3 ± 3.0 
Percentage changes in blood, plasma and red cell volumes relative to the first resting 
sample are presented in Table 3.2. Reductions in blood (P < 0.001) and plasma (P < 
0.001) volumes were observed during exercise, but there was no difference between 
experimental trials apparent at any point during the protocol. 
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3.5 - Discussion 
There appears to be an Inverse relationship between exercise time to fatigue and 
ambient temperature (Galloway and Maughan, 1997; Parkin et aI., 1999). Limited 
evidence suggests that central 5-HT activity may be an important factor in the early 
onset of fatigue during prolonged exercise in the heat. The aim of this investigation was 
to further investigate the effects of BCAA supplementation on exercise capacity during 
prolonged exercise in a warm environment. 
The results of the present study demonstrate that the ingestion of a solution containing 
BCAA and CHO offers no additional ergogenic benefit over the ingestion of a CHO 
placebo during prolonged exercise performed in a warm environment (Figure 3.1; 
P = 0.583). These findings fail to support previous data from Mittleman and co-workers 
(1998) reporting a marked (14 %; P = 0.04) improvement in time to exhaustion when 
cycle exercise was performed at 40 % VD, peak in a warm environment following the 
ingestion of BCAA. While the authors where cautious in attributing a mechanism 
behind this positive observation, the main focus of the study was directed at the use of 
BCAA in limiting the development of serotonin-mediated central fatigue. 
Although a number of studies investigating the efficacy of BCAA supplementation on 
exercise capacity in temperate conditions (-20 QC) have failed to identify an ergogenic 
benefit, despite a marked reduction in the plasma concentration ratio of f-TRP to 
BCAA (Blomstrand et aI., 1995; Madsen et aI., 1996; Struder et aI., 1998; van Hall et 
aI., 1995), it has been suggested that central fatigue may be accelerated by the 
development of hyperthermia. This may go some way to explaining the marked 
reduction in exercise capacity observed in a warm environment. While recent work 
undertaken by Nielsen's research group in Copenhagen have established that 
hyperthermia results in a reduction in maximal muscle activation (Nybo and Nielsen, 
200Ia), altered brain activity (Nielsen et aI., 2001) and increased perceived exertion 
(Nybo and Nielsen, 200Ic), the biochemical mechanism(s) underlying these changes 
remains unknown at present. 
The measured changes in plasma BCAA, f-TRP and the plasma concentration ratio of 
f-TRP to BCAA apparent in the present investigation were comparable to those 
69 
Chapter 3 BCAA Supplementation I 
reported by Mittleman and colleagues (1998) and other studies examining the effect of 
BCAA supplementation. In accordance with the recommendations of Newsholme and 
Castell (2000) and to mirror the supplementation protocol employed by Mittleman et al. 
(1998), BCAA were administered as a number of small boli, before and during 
exercise, rather than a single pre-exercise dose. The ingestion of 6g BCAA prior to the 
start of exercise resulted in a marked elevation in plasma BCAA concentrations (+843 
± 229 I-lmoI.L-'; P < 0.001), with this level maintained throughout the exercise bout 
through the repeated consumption of small boluses (3 g / IS min). Subjects ingested 
between 6 and 18 g BCAA during exercise, due to variations in exercise duration. 
During the placebo trial the mean circulating BCAA concentration decreased 
progressively throughout exercise, although failing to reach significance. While there 
was no difference in f-TRP levels between trials, a marked reduction in the ratio of f-
TRP to BCAA was observed during the BCAA trial due to the presence of exogenous 
BCAA. 
It has been proposed that changes in the availability of amino acid precursors and 
competing large neutral amino acids of the magnitude reported in this, and other BCAA 
supplementation studies, may be insufficient to produce functional changes in central 
monoamine synthesis (Femstrom, 2000). While a 13- to 26-fold increase in the plasma 
concentration ratio of TRP to BCAA has been reported to be necessary to induce a 
change in the tissue content of 5-HT and its metabolite 5-HIAA in the brain stem of 
monkeys (Leathwood and Femstrom, 1990), recent brain microdialysis studies do not 
support this suggestion. Both Meeusen et al. (1996) and Gomez-Merino et al. (2001) 
have reported marked changes in extracellular 5-HT in the hippocampus following TRP 
or valine infusion. These changes were apparent following a similar alteration to 
plasma amino acid concentrations as observed during the present investigation. 
Core temperature at the point of fatigue during the placebo and BCAA trials was 39.1 ± 
0.6 DC and 39.2 ± 0.6 DC respectively (P = 0.534). These mean values were around 
0.5 DC lower than the critical core temperature of 39.7 ± 0.5 DC proposed by Nielsen et 
aI., 1993), thought to result in an acceleration of central fatigue. While the concept of a 
critical core temperature has been subsequently supported by both human (Gonzalez-
Alonso et aI., 1999) and animal (Waiters et aI., 2000) based investigations, there are 
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reported instances where fatigue during prolonged exercise in the heat occurs at lower 
core temperatures (Sawka et aI., 1992). If the attainment of a critical core temperature 
does act to accelerate central fatigue, potentially serving as a protective mechanism, the 
underlying cause of fatigue remain unclear at present. Although it has recently been 
demonstrated that exercise-heat induced hyperthermia results in altered brain activity, 
with a shift from higher frequencies (~-bands) to slower (a) wave bands (Nielsen et aI., 
2001). This increase in the a/~ index late in exercise was proposed to represent a 
reduced state of arousal, which may contribute to the development of fatigue. 
It has been demonstrated that the permeability of the blood-brain barrier (BBB) may 
become temporarily compromised during exposure to sub-lethal hyperthermia (Sharma 
and Dey, 1987; Wijsman and Shivers, 1993), potentially altering the transport kinetics 
of amino acid uptake into the CNS. It is possible to speculate that during the present 
investigation the whole body hyperthermia observed towards the end of exercise may 
have induced disturbance to the permeability of the BBB potentially comprising the 
efficacy of BCAA supplementation. During the Mittleman et al. (1998) study the core 
temperatures of the subjects were not elevated above 38 QC, largely due to the low-
moderate exercise intensity employed. The influence of exercise on BBB function, 
using a proposed peripheral marker of permeability, is explored in Chapter 7. 
A reduction in perceived exertion has been previously reported with the ingestion of 
BCAA (Blomstrand et aI., 1997), and might be expected as changes in central S-RT 
activity have been associated with feelings of reduced arousal, tiredness and lethargy. 
This response was not observed in the present investigation, although a difference 
between trials became more apparent as the exercise progressed and approached 
significance at the point of exhaustion (Figure 3.SA; P = 0.078). No difference in 
perceived thermal stress was recorded throughout the study. Previous investigations 
have also failed to observe changes in RPE or thermal stress despite a marked change 
in core temperature following the acute pharmacological manipUlation of central S-RT 
levels with pizotifen (Strachan, 2002). It is possible that the sensitivity of these 
perception scales may not be sufficient to detect subtle changes in exertion or thermal 
stress resulting from manipulation of central monoamine synthesis or that no such 
differences exist. 
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During both treatments, cardiovascular and substrate responses were similar at rest and 
during exercise. As previously demonstrated in a number of investigations (Blomstrand 
et aI., 1995; Madsen et aI., 1996; Mittleman et aI., 1998; van Hall et aI., 1995), the 
ingestion of BCAA produced no difference in the glucose and lactate response to 
exercise when compared to the placebo (Figure 4.5). In the present investigation there 
was no evidence that carbohydrate availability was limiting, with blood glucose 
concentrations maintained throughout exercise following an initial transient fall. 
Additionally, while it is accepted that CHO oxidation is elevated during exercise in a 
warm environment (Febbraio et aI., 1994), fatigue during prolonged exercise does not 
appear to correspond with a depletion of muscle glycogen stores (Parkin et aI., 1999). 
As a result of the CHO content of the ingested solutions, FFA and consequently f-TRP 
concentrations were not significantly elevated during exercise. It is widely reported that 
a strong positive relationship exists between plasma FFA concentrations and levels of 
circulating f-TRP (Curzon et aI., 1974). No such relationship was apparent in the 
present investigation, but marked increase in plasma FF A is thought to be required 
before TRP is displaced from albumin, and perhaps a threshold exists before a 
significant change in f-TRP can be measured (Struder and Weicker, 2001). 
The work conducted by Mittleman and colleagues (1998) remams to date the only 
convincing published investigation to observe an ergogenic benefit of BCAA 
supplementation. This study employed low-intensity exercise (40% VO, max) and 
consequently time to exhaustion was between 130 and 170 minutes, whereas other 
investigations undertaken to investigate the efficacy of BCAA supplementation have 
prescribed exercise at higher relative intensities (e.g. 60 - 80% VO, max). It has been 
proposed that the development of serotonin-mediated central fatigue may become 
important only after 2 - 3 hours of exercise have passed (Nybo et aI., 2003b). This 
hypothesis is supported by animal studies employing in vivo microdialysis techniques 
to monitor changes in extracellular 5-HT (Bequet et aI., 2001). The results of these 
investigations demonstrated that there appears to be a delayed elevation in extracellular 
5-HT, with no change in hippocampus and cortical 5-HT concentrations apparent until 
60 minutes of exercise had passed. This may explain the failure to observe an ergogenic 
effect in the present study where the exercise time was only around 60 minutes. 
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It is possible that a failure to observe a benefit from BCAA ingestion may arise from a 
disturbance in catecholaminergic neurotransmission. The rationale behind BCAA 
supplementation is to block the uptake of TRP, but the possibility that BCAA ingestion 
will limit the transport of TYR into the CNS and consequently attenuate central DA 
and NA synthesis has not been considered. As central catecholamines are thought to be 
important mediators of motivation and arousal during exercise (Davis and Bailey, 
1997) limiting central TYR availability may adversely impact on exercise performance. 
In a number of investigations where no change in exercise capacity has been reported, 
BCAA supplements have been administered along with CHO (Galiano et aI., 1991; 
Madsen et aI., 1996; van Hall et aI., 1995). It is possible to suggest that in the present 
investigation, any potential ergogenic effect of BCAA may have been masked by the 
administration of BCAA and CHO together. This was recently demonstrated in rats 
with performance enhanced following the infusion of either CHO or BCAA, but no 
further improvement was apparent when both were administered together (Calders et 
aI., 1999). While the role of BCAA in limiting f-TRP transport across the BBB is 
accepted as important, this is secondary to the role of FFA. Liberation of FF A from the 
adipose tissue and the subsequent displacement of TRP from albumin forms the core of 
the central fatigue hypothesis proposed by Newsholme et al. (1987). The insulinogenic 
effect of CHO ingestion has been reported to attenuate the increase in the plasma 
concentration ratio of f-TRP to BCAA during prolonged exercise in a dose dependent 
manner (Davis et aI., 1992). In addition to its widely reported peripheral benefits 
(Coyle, 1992) and potential effect on central glucose metabolism (Nybo et aI., 2003a), 
CHO appears to be a far more attractive ergogenic supplement for prolonged exercise. 
The results of the present investigation fail to support the positive findings of 
Mittleman et al. (1998). Despite a large increase in plasma BCAA and consequently a 
marked reduction in the plasma concentration ratio of f-TRP to BCAA, 
supplementation did not influence exercise capacity in a warm environment compared 
to a CHO placebo. Failure to observe an ergogenic effect may have been caused by the 
administration of BCAA along with CHO or the relatively short duration of exercise 
completed by the subjects. 
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Chapter 4 
Branched-chain amino acid supplementation during 
prolonged exercise in a warm environment after a 
regimen designed to reduce muscle glycogen 
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4.1 - Abstract 
Eight healthy males were recruited to examine the effect of BCAA supplementation 
on exercise capacity in a warm environment following a regimen designed to reduce 
glycogen availability. Subjects remained seated for 2 hours, before cycling to 
volitional exhaustion at 50 % \rO, peak in a warm environment (30.0 ± 0.2 0c). 
250 mL of a 12 g.L·1 BCAA solution or placebo was ingested at 30 minutes intervals 
prior to exercise, with an additional ISO mL consumed every IS minutes throughout 
exercise. BCAA ingestion (111.0 ± 29.2 min) had no effect on exercise capacity 
(placebo 103.9 ± 26.9 min; P = 0.129). No difference in HR (P = 0.345), core 
temperature (P = 0.628), or weighted mean skin (P = 0.114) temperatures was 
apparent between the trials. The ingestion of the BCAA solution produced a marked 
increase in plasma BCAA immediately prior to exercise (+1126 ± 158 J.!moI.L·1; P < 
0.001) with this difference maintained throughout. Consequently, a significant 
reduction in f-TRP:BCAA was observed during the BCAA trial when compared to the 
placebo (P < 0.001). Plasma ammonia was significantly elevated during exercise 
throughout the BCAA trial (P < 0.001), with no difference apparent during the 
placebo (P = 0.608). Blood glucose (P = 0.114) and lactate (P = 0.836) concentrations 
were not different between trials. Ingestion of a BCAA solution prior to, and during, 
prolonged exercise did not significantly influence exercise capacity in a warm 
environment, but evidence of variations in the individual sensitivity to the 
supp lementation regimen was apparent. 
4.2 - Introduction 
It is clear that an individual's capacity to perform prolonged exercise is significantly 
reduced when exercise is undertaken in warm conditions (Galloway and Maughan, 
1997). While it appears that performance is primarily limited by thermoregulatory and 
fluid balance factors (Hargreaves and Febbraio, 1998), hyperthermia may also result 
in an acceleration of fatigue processes residing in the central nervous system (CNS) 
leading to a reduced drive to continue exercise (Nielsen, 1992). 
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Changes in the synthesis and metabolism of central neurotransmitters, in particular 
serotonin (5-HT), have been suggested to contribute to the genesis of fatigue during 
prolonged exercise (Newsholme et aI., 1987). See Chapter 1 for a detailed description 
of Newsholme's central fatigue hypothesis. Oral supplementation of the BCAA has 
been suggested to limit the entry of f-TRP into the CNS, reducing the rate of 5-HT 
synthesis and potentialJy enhancing exercise capacity (Blomstrand et aI., 1991). In 
rats, valine administration has been demonstrated to be effective in limiting TRP 
uptake into the CNS and consequently attenuating the increase in extraceIJular 5-HT 
observed during prolonged exercise (Gomez-Merino et aI., 2001). These findings, 
considered in conjunction with animal studies demonstrating a clear improvement in 
exercise capacity when BCAA were infused (Calders et aI., 1999; Calders et aI., 
1997), provide good evidence for the central fatigue hypothesis and an ergogenic 
benefit of BC AA supplements. 
Attempts to enhance exercise capacity in humans through BCAA supplementation 
have been largely inconclusive when exercise has been performed in temperate 
conditions (Blomstrand et aI., 1991; Madsen et aI., 1996; Struder et aI., 1998; van HaIJ 
et aI., 1995). However, an apparently well-controlJed laboratory study reported a 
marked improvement in exercise capacity (+14 %) when low-moderate intensity 
exercise was performed in a warm environment (34 DC) following the ingestion of 
BCAA (Mittleman et aI., 1998). These data potentialJy support the premise that 5-HT 
mediated central fatigue is accelerated when performing exercise in warm conditions. 
Furthermore, there is indirect evidence that central serotonergic activity may be 
upregulated during combined exercise and heat stress (Pitsiladis et aI., 2002). 
However, this data may be misleading as prolactin release from the pituitary gland is 
governed through an complex interaction between a number of neurotransmitters 
rather than by serotonin alone (Meeusen et aI., 2001; see Chapter I). 
The aim of the present investigation was to develop the work described in Chapter 3 
to further examine the effect of BCAA ingestion on exercise capacity in a warm 
environment. Treatments were administered without the addition of CHO and trials 
were undertaken following a regimen designed to reduce glycogen availability. This 
was intended to simulate the metabolic conditions experienced during the latter stages 
of prolonged exercise, and effectively accelerate exercise-induced changes in 
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serotonergic neurotransmission. Exercise was performed at a low-moderate intensity 
with an extended pre-exercise supplementation period to allow sufficient time for 
changes in peripheral amino acids to significantly alter CNS concentrations and 
influence central neurotransmission. 
4.3 - Methods 
Subjects. Eight healthy male subjects were recruited (age 28.5 ± 8.2 y; height 1.76 ± 
0.04 m; mass 74.5 ± 6.7 kg; VO,peak 4.1 ± 0.5 L.min·'). All subjects took part in 
regular endurance exercise, but were not accustomed to exercise in a warm 
environment at the time of the study. Prior to the start of the investigation all subjects 
received written details outlining the content of the study. Following any questions 
regarding the protocol, a written statement of consent was signed. The protocol 
employed received ethical approval from the Grampian Research Ethics Committee. 
Experimental protocol. To calculate the workloads used during the investigation, 
each subject first completed an incremental cycle ergometer test to 
determine VO, peak, as described in chapter 2. Prior to the start of the experimental 
trials, two preliminary trials were undertaken. During the first preliminary trial 
subjects completed up to two hours of cycle exercise in the environmental conditions 
employed throughout the investigation, with the second preliminary trial mirroring the 
complete experimental protocol. Each subject then completed 2 experimental trials 
(placebo and BCAA), randomised and administered in a double-blind crossover 
manner, separated by at least 7 days. Standardisation of pre-trial conditions is outlined 
in Chapter 2. 
All experimental trials commenced in the evening (5 - 6 pm) following a 4 hour fast, 
other than the ingestion of 500 mL of plain water 2 hours before the start of each trial. 
Upon arrival in the laboratory, post-void nude body mass was measured, and subjects 
then completed a bout of exercise on a cycle ergometer (Gould Corival 300, 
Groningen, Holland) corresponding to approximately 75 % VO, peak for 60 minutes 
in temperate conditions (18 - 20 QC). During exercise, expired gas was collected and 
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analysed at 15 minute intervals. These data were used to estimate rates of substrate 
oxidation and energy expenditure (Peronnet and Massicotte, 1991). Following the 
cessation of exercise, subjects showered and were re-weighed. Subjects then 
consumed 50 kJ.kg,1 body mass ofa low carbohydrate, high fat meal (cheese omelette 
and pork pie; 6 % CRO, 73 % fat, 21 % protein), along with a quantity of sugar-free 
fruit drink with electrolytes (Robinsons Special R, Chelmsford, UK) equal to 150 % 
of the body mass lost, to help ensure the adequate replacement of sweat losses 
(Shirreffs et aI., 1996). A similar protocol has been employed previously to produce a 
significant reduction in muscle glycogen stores (Lemon and Mullin, 1980). 
The next morning at 8 am, following an overnight fast other than ad libitum intake of 
plain water, subjects returned to the laboratory. Post-void nude body mass was 
recorded, and subjects were then asked to insert a rectal thermister 10 cm beyond the 
anal sphincter for the measurement of core temperature. Surface skin temperature 
probes were attached to four sites (chest, upper arm, thigh and calf) and a heart rate 
monitor (polar Beat, Kempele, Finland) was positioned. SUbjects were then seated in 
a comfortable environment (25 - 26 QC), and a 21 g cannula was inserted into a 
superficial forearm vein. A baseline blood sample (7.5 mL) was drawn, after which 
subjects consumed 250 mL of either a placebo (sugar-free fruit drink) or BCAA 
(sugar-free fruit drink with 6 g.L'1 leucine, 3 g.L,1 isoleucine, 3 g.L·1 valine; SRS 
International Ltd, Liverpool, UK) solution. A further 250 mL of the appropriate drink 
was ingested at 30 minute intervals throughout the 2 hour rest period. Heart rate and 
core and skin temperatures were recorded at IS minute intervals at rest with two 
further blood samples drawn at 60 and 120 minutes. 
Subjects then entered a climatic chamber, maintained at 30 ± 0.2 QC (relative humidity 
38 ± 8 %), and commenced cycle exercise at a power output corresponding to 50 % 
VO, peak. During exercise, heart rate, skin and core temperatures, and RPE and 
perceived thermal stress were recorded every 10 minutes. In addition, 7.5 mL blood 
samples were drawn at IS minute intervals, as well as at the point of exhaustion. 150 
mL of the appropriate solution (placebo or BCAA) was ingested by the subjects every 
15 minutes during exercise. Exercise continued until volitional exhaustion, defined as 
an inability to maintain a pedal cadence of ~ 60 rev.min'l despite verbal 
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encouragement from the experimenters. Following the cessation of exercise, the 
subject returned to a comfortable environment where all probes and the cannula were 
removed. Subjects were then asked to shower, and were reweighed to allow the 
estimation of sweat losses occurring during exercise. 
Blood handling and analysis. Blood samples collected throughout the experimental 
protocol were drawn into dry syringes with 2.5 mL dispensed into tubes containing 
K2EDT A. Duplicate 100 ilL aliquots of whole blood were rapidly deproteinised in 
I mL of ice-cold 0.3N perchloric acid. These were centrifuged, and the resulting 
supernatant was used for determination of blood glucose and lactate concentrations. 
1.5 mL ofEDTA treated whole blood was immediately extracted and spun in a micro-
centrifuge before the plasma was transferred to a plain tube and frozen in liquid 
nitrogen. Samples were kept in liquid nitrogen ready for analysis of ammonia (NH3; 
Sigma Diagnostics, Poole, UK) and free fatty acids using commercially available 
assay kits. Whole blood was also used for the determination of haemoglobin (Hb) and 
packed cell volume (PCV), allowing percentage changes in blood, plasma and red cell 
volumes relative to the first resting sample to be estimated (Dill and Costill, 1974). 
The remaining 5 mL was added to a tube containing lithium heparin and centrifuged 
to obtain plasma. f-TRP was separated from albumin bound TRP, as described in 
Chapter 2. Plasma and ultrafiltrate samples were then kept frozen at -20°C ready for 
the determination of BC AA and f-TRP. 
4.4 - Results 
The data collected during the glycogen depletion protocol are displayed in Table 4.1. 
During the 60 minute cycle exercise subjects expended approximately 3.6 ± 0.5 MJ 
and 3.7 ± 0.5 MJ on the placebo and BCAA trials respectively (P > 0.05). 
Approximately 82 % of the total energy demand on each of the trials was derived 
from CRO oxidation, corresponding to the oxidation of around 178 g of CRO. An 
increase in oxygen uptake was observed in both trials as the exercise bout progressed, 
but no difference in VO, was apparent between trials (P > 0.05). The respiratory 
exchange ratio fell progressively throughout exercise, becoming significantly lower 
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than the corresponding 15 minute time point after 30 minutes in the BCAA trial and 
45 minutes in the placebo. Again, no difference in RER was apparent between trials 
(P = 0.578). Both heart rate (P < 0.001) and RPE (P < 0.001) increased significantly 
during the 60 minutes of exercise in both experimental trials. 
Table 4.1: Summary of the glycogen depletion exercise results (mean ± SD). 
a and b denote a significant difference from the 15 minute time point in the placebo 
and BCAA trials respectively (P < 0.05). 
15 30 45 60 
V0
2 
(L.min-I) Placebo 2.77 ± 0.34 2.90 ± 0.36' 2.98 ± 0.37 a 2.97 ± 0.32 a 
BCAA 2.84 ± 0.37 2.90 ± 0.33 3.00 ± 0.39 b 3.02 ± 0.35 b 
VC0
2 
(L.min-I) Placebo 2.68 ± 0.31 2.68 ± 0.30 2.75 ± 0.31 2.69 ± 0.25 
BCAA 2.79 ± 0.33 2.68 ± 0.31 2.78 ± 0.31 2.77 ± 0.27 
RER (no units) Placebo 0.97 ± 0.05 0.93 ± 0.03 0.93 ± 0.04' 0.91 ± 0.05 ' 
BCAA 0.99 ± 0.07 0.93 ± 0.03 b 0.93 ± 0.03 0.92 ± 0.03 b 
HR (beat.min-I) Placebo 149 ± 10 156± 10' 160 ± 9' 165 ± 9 a 
BCAA 147 ± 7 152 ± 6 b 158 ± 7 b 162 ± 7 b 
RPE (no units) Placebo 14± 2 15 ± 2 15 ± 2 16 ± 2' 
BCAA 14 ± 1 l4± 2 15 ± 2' 16 ± 2 b 
Mean exercise time to exhaustion was 111.0 ± 29.2 min on the BCAA trial and 103.9 
± 26.9 min on the placebo trial (P = 0.129). This represents a mean difference of7.1 ± 
11.6 min, or 6.4 ± 12.9 %, between trials, with 4 subjects demonstrating a clear 
improvement in exercise capacity with BCAA, 3 subjects with little or no difference 
between trials and 1 subject clearly exercising for longer on the placebo trial (Figure 
4.1 A + B). No treatment order effect was apparent over the course of the 
investigation (P = 0.844). 
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Figure 4.1: Individual exercise times to exhaustion (A) and percent changes in 
exercise capacity (B) between the placebo and BCAA trials. The dark lines represent 
the mean changes in exercise capacity. 
All subjects received 1 litre of test solution (250 mU30 min) during the 2 hour rest 
period prior to exercise. This provided 12.0 g BCAA during the BCAA trial. Ingestion 
of this quantity of BCAA resulted in a mean increase in circulating plasma BCAA 
concentration of 1126 ± 158 flmoI.L·' (Figure 4.2A; P < 0.001). The quantity of 
BCAA ingested during exercise ranged between 5.4 g and 18.0 g due to variations in 
performance time. Following an initial reduction in BCAA concentration during the 
first 15 minutes of exercise, a progressive increase in plasma BCAA was apparent, 
returning to pre-exercise levels at the point of exhaustion. During the placebo trial, 
plasma BCAA remained stable with no change observed during either rest or exercise 
(P > 0.964). 
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Figure 4.2: Plasma BCAA (A; mean ± SD) and f-TRP (B; median, range omitted for 
clarity, see Appendix I) concentrations at rest and during exercise. a and b denote a 
significant difference from the -120 min time point in the placebo and BCAA trials 
respectively (P < 0.05). * (P < 0.05) and ** (P < 0.01) denote a significant difference 
between the BCAA trial and the corresponding time point on the placebo trial. 
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Ingestion of the BCAA solution resulted in consistently lower f-TRP concentrations 
when compared to the placebo trial (Figure 4.2B; P < 0.003). A progressive increase 
in f-TRP was observed on both trials, but this reached significance over baseline only 
at the point of exhaustion (P < 0.05). The median plasma concentration ratio of f-TRP 
to BCAA was similar during the placebo (0.0086 range 0.0055 - 0.0105) and BCAA 
trials (0.0104 range 0.0047 - 0.0153) prior to the ingestion of first bolus of solution 
(Figure 4.3). BCAA ingestion resulted in a 4-fold reduction in the f-TRP:BCAA 
immediately prior to the start of exercise (P < 0.001), with no change apparent whilst 
at rest in the placebo trial. This difference was maintained throughout exercise, with 
median values at exhaustion of 0.0267 (0.0163 - 0.0527) on the placebo trial and 
0.0069 (0.0060 - 0.0119) on the BCAA trial (P < 0.001). 
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Figure 4.3: Changes in the plasma concentration ratio of f-TRP to BCAA (median ± 
range) at rest and during exercise. a and b denote a significant difference from the 
-120 min time point in the placebo and BCAA trials respectively (P < 0.05). • (P < 
0.05) and *. (P < 0.01) denote a significant difference between the BCAA trial and 
the corresponding time point on the placebo trial. 
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Figure 4.4: Change in core (A) and weighted mean skin (B) temperature at rest and 
during exercise. a and b denote a significant difference from the pre-exercise time 
point in the placebo and BCAA trials respectively (P < 0.05). 
No difference in basal core or weighted mean skin temperature was apparent between 
trials (Figure 4.4A + B). The drink treatment had no effect on core temperature during 
the experimental trials (P = 0.628). Core temperature progressively increased 
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throughout exercise to 38.9 ± 0.5 °C on the placebo trial and 38.9 ± 0.5 °C on the 
BCAA trial at the point of exhaustion (P = 0.785). Following an increase during the 
initial 20 minutes of exercise, mean skin temperature remained relatively stable 
through to the point of exhaustion. 
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Figure 4.5: Heart rate at rest and during exercise. a and b denote a significant 
difference from the pre-ingestion time point in the placebo and BCAA trials 
respectively (P < 0.05). 
Heart rate was elevated from the onset of exercise, with a steady increase apparent 
throughout the exercise period (Figure 4.5). At exhaustion heart rates of 156 ± 15 
beat.min'! (placebo) and 159 ± 13 beat.min'! (BCAA) were recorded (P = 0.122). No 
difference was observed between the experimental trials (P = 0.345). 
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Figure 4.6: Rating of perceived exertion (A) and thermal stress (B) during exercise. a 
and b denote a significant difference from the 10 minute time point in the placebo and 
BCAA trials respectively (P < 0.05). 
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A progressive increase in RPE was recorded during both experimental trials, but this 
was significantly greater than the initial measurement only after 50 minutes of 
exercise and at the point of exhaustion (Figure 4.6A). Perceived exertion was not 
influenced by the drink treatment, with no difference between trials at any time point 
(P = 0.840). Perceived thermal stress also tended to increase throughout exercise, 
becoming significantly elevated over the 10 minute time point following 50 minutes 
of exercise in the placebo trial and only at exhaustion in the BCAA trial (Figure 4B). 
Again, no difference in perceived thermal stress between trials was apparent 
(P = 0.351). 
Changes in blood (P = 0.464) and plasma (P = 0.547) volumes were not different 
between trials (Table 4.2). Plasma volume was significantly reduced throughout 
exercise on both trials than at rest (P < 0.05), but remained stable throughout the 
exercise period. The ingestion of BCAA produced no change in red cell volume 
(P = 0.134), with no significant difference apparent during exercise in either trial 
(P > 0.05). 
Table 4.2: Percentage changes in blood (BV), plasma (PV) and red cell (CV) 
volumes relative to the -120 min value at rest and during exercise. a and b denote a 
significant difference from the -120 min time point in the placebo and BCAA trials 
respectively (P < 0.05). 
-60 0 15 30 45 60 Ex 
Placebo 1.4 ± -1.1 ± -4.1 ± -3.3 ± -3.8 ± -4.2 ± -5.4 ± 1.6 1.5 1.4" 1.6" 1.4" 2.0 3.0 
BV 
BCAA 0.4± 0.1 ± -3.4 ± -3.5 ± -3.2 ± -3.6 ± -5.0 ± 1.8 1.9 1.7b 1.5b l.lb 2.0b 3.3 
Placebo 2.2 ± -1.4 ± -6.3 ± -4.7 ± -5.3 ± -6.3 ± -7.8 ± 3.3 2.3 2.4" 2.7" 2.2 2.3" 4.3" 
PV 
BCAA 0.4 ± -0.8 ± -5.9 ± -5.6± -4.9 ± -5.6 ± -8.0 ± 2.5 2.6 2.7b 2.2b 1.9b 2.8b 4.3b 
CV Placebo 0.3 ± -0.7 ± -1.2 ± -1.6 ± -1.9 ± -1.4 ± -2.3 ± 1.5 1.1 1.8 1.8 1.7 2.3 3.6 
BCAA 0.9± l.3± O.O± -0.6 ± -0.8 ± -1.0 ± -1.2 ± 1.8 2.7 1.9 2.6 1.6 2.6 2.5 
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TABLE 4.3: Blood and plasma metabolite data at rest and during exercise in the 
placebo and BCAA trials. a and b denote a significant difference from the -120 min 
time point in the placebo and BCAA trials respectively (P < 0.05). * (P < 0.05) and ** 
(P<O.Ol) denote a significant difference between the BCAA trial and the 
corresponding time point in the placebo trial. 
-120 0 15 30 45 60 Ex 
Glucose Placebo 4.1 ± 3.9 ± 4.3 ± 4.5 ± 4.4 ± 4.2± 4.1 ± 
(mmoI.L·1) 0.8 0.7 0.8 0.8 0.8 1.0 1.0 
BCAA 4.0 ± 3.5 ± 4.0 ± 4.2 ± 4.2 ± 4.0± 4.1 ± 
0.4 0.6 0.4 0.5 0.6 0.6 0.6 
Lactate Placebo 0.53 ± 0.78 ± 0.67 ± 0.66± 0.68 ± O.79± 1.51 ± 
(mmoI.L·1) 0.23 0.36 0.25 0.23 0.22 0.30 0.59 
BCAA 0.59 ± 0.77± 0.66± 0.65 ± 0.67± O.72± 1.53 ± 
0.25 0.25 0.26 0.26 0.24 0.29 0.65 
FFA Placebo 0.58± 0.58± 0.61 ± 0.80± 0.81 ± O.86± 1.27 ± 
(mmoI.L·1) 0.09 0.14 0.13 0.18 0.15 0.22 0.39 a 
BCAA 0.47 ± 0.32± 0.45 ± 0.66± 0.70± O.70± 1.17 ± 
0.08 0.10** 0.14* 0.17* 0.16* 0.19 0.29 b 
Blood glucose and lactate and plasma free-fatty acid data are presented in Table 4.3. 
The pre-exercise ingestion of BCAA resulted in a progressive non-significant 
reduction in the blood glucose concentration prior to start of exercise. Circulating 
blood glucose concentrations were stable throughout exercise, with no difference 
between trials recorded (P = 0.114). Blood lactate concentrations were unaffected by 
the ingestion of BC AA (P = 0.836). Plasma FFA concentration was reduced following 
BCAA ingestion, with levels consistently lower throughout exercise than during the 
placebo trial (P < 0.01). Figure 4.7 illustrates the relationship between changes in 
plasma FFA and plasma f-TRP observed in the placebo and BCAA trials. The 
correlation coefficients were calculated as 0.82 (P = 0.012) for the placebo and 0.59 
(P = 0.120) for BCAA trial. 
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Figure 407: The relationship between the change in plasma FFA and plasma f-TRP 
during the placebo and BCAA trials. 
No difference in baseline plasma NH3 concentrations (n = 6) was apparent between 
experimental trials (Figure 4.8; P = 0.512), with ingestion of BCAA prior to exercise 
resulting in a slight, but non-significant, increase in the plasma NH3 concentration (P= 
0.179). The BCAA solution resulted in a significant elevation in plasma NH3 
throughout exercise when compared to the placebo treatment (P < 0.001). Values at 
the point of exhaustion were 94.7 ± 17.7 f\mo1.L01 and 134.7 ± 6.8f\moI.L01 for the 
placebo and BCAA trials respectively. Circulating plasma prolactin was significantly 
elevated above resting values at the point of exhaustion in both trials (P = 0.004; 
Figure 4.9). No difference between trials was apparent at rest before (P = 0.485) or at 
the point of exhaustion (P = 0.578). 
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Figure 4.8: Plasma NH3 concentration during the placebo and BCAA trials. a and b 
denote a significant difference from the -120 min time point in the placebo and BCAA 
trials respectively. * (P < 0.05) and ** (P < 0.01) denote a significant difference 
between the BCAA trial and the corresponding time point on the placebo trial. 
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Figure 4.9: Plasma prolactin concentration at rest and at the point of exhaustion 
during the placebo and BCAA trials. a and b denote a significant difference from the 
pre-ingestion time point in the placebo and BCAA trials respectively. 
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4.5 - Discussion 
Accelerated central fatigue resulting in a reduced drive to continue exercise has been 
proposed as an important mechanism mediating the reduction in exercise capacity 
observed when exercising in warm environmental conditions (Nielsen, 1992). Recent 
data go some way to supporting this suggestion: high core temperatures have been 
demonstrated to impair maximal muscle activation (Nybo and Nielsen, 200Ia), alter 
EEG brain activity (Nielsen et aI., 2001) and increase perceived exertion (Nybo and 
Nielsen, 200Ib), but the underlying neurobiological mechanism(s) behind these 
responses are not clear at present. Indirect support for the hypothesis that the early 
onset of fatigue in the heat results from an increased activity of central serotonergic 
neurones comes from evidence that BCAA supplementation can prolong exercise 
capacity when low-moderate intensity exercise is performed in the heat (Mittleman et 
aI., 1998). The purpose of the present study was to develop the work described in 
chapter 3 to further investigate the effect of BCAA supplementation on exercise 
capacity in a warm environment following an exercise and diet regimen designed to 
reduced glycogen availability. 
Despite a 4-fold reduction in the plasma concentration ratio of f-TRP to BCAA, 
exercise capacity, determined by time to volitional exhaustion, was not influenced by 
ingestion of a BCAA solution (111.0 ± 29.2 min) when compared to a placebo 
treatment (103.9 ± 26.9 min). Although the findings of Mittleman and colleagues 
(1998) support an effect of BCAA ingestion on exercise performance, the available 
evidence is not entirely convincing. A number of investigations have failed to 
demonstrate an improvement in exercise capacity following BCAA supplementation 
under temperate environmental conditions (Blomstrand et aI., 1995; Blomstrand et aI., 
1997; Madsen et aI., 1996; Struder et aI., 1998; van Hall et aI., 1995). 
Despite a 4-fold reduction in the plasma concentration ratio of f-TRP to BCAA, 
exercise capacity was not influenced by ingestion of BCAA, but there was a large 
inter-individual variation in the subjects' response to the supplementation regimen 
(see Figure 1). This apparent variation may be explained by recent data demonstrating 
that net uptake of tryptophan across the brain was increased in only 50 % of subjects 
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following 2 hours moderate-intensity exercise, despite a marked elevation in plasma f-
TRP (Nybo et al. 2003). Additionally, a number of studies employing different 
markers of 5-HT receptor function suggest that differences in the sensitivity of the 5-
HT system to manipulation may exist between individuals. Marked differences in 
platelet 5-HT transporter density (Strachan and Maughan, 1998; Struder et aI., 1999) 
and in the prolactin response to a buspirone challenge (Bridge et aI., 2003; Jakeman et 
aI., 1994) are reported in the published literature. Additionally, patients suffering from 
chronic fatigue syndrome appear to possess an altered sensitivity of central 
serotonergic receptors (Bakheit et aI., 1992). This variability may also extend to other 
neurotransmitter systems implicated in the development of fatigue (e.g. dopamine, 
noradrenaline), but evidence for this is not clear at present. 
Studies conducted by Blomstrand et al. (1991) and Mittleman et al. (1998), both of 
which involved exercise of a long duration performed at a low-moderate intensity, are 
the only published human investigations to date reporting an ergogenic effect of 
BCAA supplementation in humans. It is possible that central fatigue, resulting from 
increased serotonergic neurotransmission, may become important only after a 
significant duration of exercise has passed (Nybo et aI., 2003). This may go some way 
to explaining a failure to observe an ergogenic benefit in studies where the exercise 
time was substantially less than 180 minutes (Blomstrand et ai, 1995; Madsen et ai, 
1996; van Hall et ai, 1995). The present study employed a glycogen depletion 
protocol completed the evening prior to the main trials in an attempt to simulate 
metabolic conditions found later in exercise, therefore potentially accelerating the 
onset of central fatigue. The relatively low blood glucose concentrations and elevated 
plasma FF A whilst at rest suggest the regimen was successful in reducing CHO 
availability, although no direct measure of changes in muscle glycogen was made. 
Therefore, the duration of exercise in the present investigation should be have been 
sufficient for serotonin-mediated fatigue to become important, as suggested by Nybo 
and co-workers (2003). 
As reported in previous studies investigating BCAA ingestion during exercise in a 
warm environment (Mittieman et aI., 1998), the ingestion of BCAA produced no 
difference in heart rate or in blood glucose or lactate concentrations at rest and during 
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exercise compared with the placebo trial. The circulating plasma FF A concentration 
was significantly reduced at the end of the seated rest period and during the initial 30 
minutes of exercise, presumably due to the insulinogenic effect of BCAA ingestion. 
Subjective ratings of exertion (P = 0.840) were also unaffected by the treatment 
(Figure 4A). If the supplementation regimen had resulted in an altered rate of 5-HT 
synthesis, and the central fatigue hypothesis holds true, a reduction in RPE may be 
expected. A previous study conducted by (Blomstrand et aI., 1997) reported a 
significant reduction in RPE during exercise at 70 % Y0 2 max, but work by 
Mittleman and colleagues (1998) failed to identify such a difference despite a marked 
improvement in exercise capacity. It is also possible that the standard 15-point Borg 
RPE scale (Borg, 1982) may be not sensitive enough to detect subtle differences in 
perceived exertion resulting from alterations in central neurotransmission or that no 
such differences resulted from BCAA feeding. 
Oral ingestion of BCAA also failed to produce any clear difference in measures of 
thermoregulation during both rest and exercise, including core (P = 0.628) and 
weighted mean skin (P = 0.114) temperature as well as perceived thennal stress (P = 
0.351). Such changes may have been expected as central neurotransmitter systems 
including 5-HT and dopamine are intrinsically involved in the regulation of body 
temperature (Hasegawa et aI., 2000; Lee et aI., 1985; Lin et aI., 1998). 
Pharrnacologically-induced alterations in central 5-HT neurotransmission may modify 
thermoregulatory function in rats (Lin et aI., 1998) and humans (Strachan, 2002). 
Therefore if the supplementation regimen was indeed successful at limiting 5-HT 
synthesis, a change in core temperature might have been expected. Core temperature 
at exhaustion in the present study was below the 39.7 °C threshold considered to be 
limiting (Gonzalez-Alonso et aI., 1999; Figure 3A). This suggests that the 
thermoregulatory stress encountered may not have been sufficient to accelerate central 
fatigue, but this is in marked contrast to the improvement in exercise capacity 
demonstrated by Mittleman et al (1998) despite lower core temperatures observed at 
fatigue (37.3 - 37.7 0C). 
Elevated production of ammonia (NH3) is widely cited as a possible explanation for 
the failure of BCAA supplements to attenuate the development of central fatigue and 
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consequently enhance exercise capacity (Davis and Bailey, 1997; Wagenmakers and 
van Hall, 1996). In the present investigation a marked increase in plasma NH3 
concentration was evident throughout exercise following the ingestion of BCAA 
(Figure 5; P < 0.001). During the low-moderate intensity exercise undertaken in this 
study, increased production ofNH3 is thOUght to result primarily from the oxidation of 
BCAA (Gibala, 2001). Taken together with the reduction in circulating BCAA 
observed from the onset of exercise, it seems probable that BCAA oxidation was 
elevated, but no measurement of BCAA utilisation was undertaken to confirm or 
refute this suggestion. 
It is possible that a failure to observe a benefit from BCAA ingestion may arise from a 
disturbance in catecholaminergic neurotransmission. The rationale behind BCAA 
supplementation is to block the uptake of TRP, but the possibility that BCAA 
ingestion will limit the transport of TYR into the CNS and consequently attenuate 
central DA and NA synthesis has not been considered. As the catecholaminergic 
neurotransmitters are thought to be important mediators of motivation and arousal 
during exercise (Davis and Bailey, 1997) limiting central TYR availability may 
adversely impact on exercise performance and negate any possible benefit of 
attenuating the exercise-induced increase in central 5-HT. 
Wagenmakers and van Hall (1996) suggested that BCAA supplementation under 
conditions of reduced muscle glycogen availability might result in a reduction in 
endurance performance in healthy individuals. The authors proposed that elevated 
ammonia accumulation would result in the depletion of TCA cycle intermediates, but 
subsequent evidence has demonstrated that exercise under conditions of reduced 
glycogen availability may have no effect on TCA cycle anaplerosis (Gibala et aI., 
1999). Elevated circulating NH3 concentrations have also been suggested to 
negatively affect CNS function leading to impaired motor control and lethargy (Davis 
and Bailey 1997) and alter the transport characteristics of the blood-brain barrier 
(Mans et aI., 1983) see Chapter 7 for further discussion of the effects of exercise and 
the blood-brain barrier. It seems likely the levels observed in the present investigation, 
and other BCAA supplementation studies using healthy human subjects (Madsen et 
aI., 1996; Mittleman et aI., 1998; Struder et aI., 1998) would be insufficient to produce 
such an effect (Gibala, 2001). 
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Circulating plasma prolactin was significantly elevated above resting values at the 
point of exhaustion (P = 0.004). This finding is consistent with a number of previous 
studies investigating the honnonal response to prolonged exercise in a warm 
environment (Pitsiladis et aI., 2002; Radomski et aI., 1998). A curvilinear relationship 
between plasma prolactin and core temperature has been proposed (Radomski et aI., 
1998; Strachan, 2002), suggesting the thennal response to exercise may be related to 
the induction of honnone release during exercise. The failure to observe a difference 
between trials at exhaustion (P = 0.578), raises the question whether the 
supplementation regimen produced a functional change in 5-HT neurotransmission as 
prolactin is widely employed as a peripheral marker of central serotonin activity 
(Struder and Weicker, 2001), but this assumption is not entirely accurate as the 
regulation of prolactin secretion is also under the control of the dopaminergic system 
(Checkley, 1980; Meeusen et aI., 2001; Strachan and Maughan, 2002). 
In conclusion, the results of the present study demonstrate a failure of acute BCAA 
ingestion to significantly influence exercise capacity in a warm environment, 
following a regimen designed to reduce glycogen availability. The large variation of 
exercise capacity change observed between subjects in response to BCAA ingestion 
raises the question of differences in individual sensitivity to nutritional manipulation 
of the 5-HT system. It may be that the effect of nutritional supplementation is simply 
too small to produce a functional change in central neurotransmission in some 
individuals (Femstrom, 2000). In contrast to the suggestion of Wagenmakers and van 
Hall (1996), BCAA ingestion under conditions of low glycogen availability did not 
produce a reduction in exercise capacity despite a marked elevation in plasma NH3 
concentrations. This increase in plasma NH3 observed during exercise following 
BCAA ingestion is probably not sufficient to result in a marked effect on metabolism 
or CNS function in healthy individuals. 
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Chapter 5 
Acute changes to the plasma concentration ratio of 
f-TRP to BCAA following the ingestion of 
carbohydrate and fat rich meals in man 
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5.1 - Abstract 
Eight healthy volunteers (5 males and 3 females) completed two trials to examine 
transient changes to the plasma concentration ratio of f-TRP to BCAA at rest 
following the ingestion of meals. Subjects consumed 34 kJ.kg BM-1 of a fruit 
flavoured smoothie containing either added CRO or fat. The response to the meals 
was monitored at 30, 60, 120, 180, 240 minutes after ingestion. The CRO meal 
produced a significant elevation in blood glucose concentrations during the first 60 
minutes post-ingestion (P < 0.001). Plasma FFA was suppressed below pre-ingestion 
levels after the CRO meal and remained significantly lower than the fat trial 
throughout the trial (P < 0.001). Plasma f-TRP was not affected by the CRO 
(P = 0.231) or fat (P = 0.073) meals. Ingestion of the CRO meal resulted in a 
reduction in plasma BCAA concentrations (P = 0.022), with levels significantly 
higher in the fat trial (P < 0.05). Despite the change in circulating BCAA, no effect on 
the plasma concentration ratio of f-TRP to BCAA was apparent following the CRO 
meal (P = 0.871). The fat meal altered the plasma concentration ratio of f-TRP to 
BCAA (P = 0.034), with the ratio significantly lower than the CRO trial at 60 minutes 
after ingestion (P < 0.01). The meals did not influence subjective feelings of tiredness, 
alertness, concentration and headache during the experimental time-scale. The 
ingestion of meals containing added CRO and fat resulted in no change to the plasma 
concentration ratio of f-TRP to BCAA relative to pre-ingestion values over the time-
course of the investigation. 
5.2 - Introduction 
The potential involvement of central monoammes in the development of fatigue 
during prolonged exercise has been the subject of increasing interest in recent years. 
One particular model suggests that the shift in substrate mobilisation that occurs 
during prolonged exercise results in an upregulation of central 5-HT synthesis, 
producing feelings of tiredness that may contribute to the development of fatigue 
(Newsholme et aI., 1987). The details of this hypothesis are described in Chapter 1. 
The key relationship in this mechanism of fatigue is the plasma concentration ratio of 
f-TRP to BCAA. This ratio determines the rate of TRP uptake into the CNS, and 
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consequently the rate of 5-HT synthesis during exercise (Chaouloff et aI., 1985; 
Chaouloff et aI., 1986). A particular attraction of Newsholme's hypothesis is the 
potential for nutritional manipulation of neurotransmitter precursors to delay the 
development of central fatigue. In recent years a number of investigations have been 
undertaken to alter the ratio of f-TRP:BCAA during exercise through both acute 
(Blomstrand et aI., 1995; Blomstrand et aI., 1991; Davis et aI., 1992; Madsen et aI., 
1996; Mittleman et aI., 1998; Struder et aI., 1998; van Hall et aI., 1995) and chronic 
(Hefler et aI., 1995) supplementation of BC AA or CHO. 
The purpose of pre-exercise nutritional strategies is to ensure glycogen stores are 
optimised and euhydration is achieved, while avoiding gastrointestinal distress 
(Hargreaves, 2001). Many studies have sought to investigate changes in exercise 
metabolism resulting from the manipulation of the composition and timing of the pre-
exercise meal (Coyle et aI., 1985; Horowitz and Coyle, 1993; Montain et aI., 1991). 
This work has established that CHO and fat feeding prior to exercise can markedly 
influence rates of substrate utilisation, and may have profound effects on exercise 
performance. To date only one study has investigated the influence of pre-exercise 
meal ingestion on the metabolic indices thought to be important to the development of 
central fatigue (Paul et aI., 1996). This examined changes in the plasma concentration 
ratio of total-TRP to LNAA in response to relatively small (-1340 kJ) corn, wheat 
and oat-based meals, containing increasing quantities of protein, ingested 90 minutes 
before exercise. These cereal-based meals produced no change in TRP:LNAA relative 
to pre-ingestion values, but this plasma amino acid ratio was lower during exercise 
and recovery following the corn meal compared to the other treatments. Despite this 
reduction in circulating amino acids, apparently due to the lower protein content of 
this meal, performance of a 6.4 km cycle time trial preceded by 60 minutes fixed-
intensity submaximal exercise was not different between trials. 
While there is considerable debate regarding the availability of plasma TRP for 
cerebral uptake (see Chapter 1), it appears that brain TRP content is closely related to 
plasma f-TRP rather than total-TRP whilst at rest (Bloxam et aI., 1980) and during 
exercise (Chaouloff et aI., 1985). Paul and colleagues (1996) failed to report changes 
in f-TRP, despite the ingested meals producing marked changes in circulating FF A. 
Changes in the plasma concentration ratio of f-TRP to BCAA are thought to more 
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accurately represent changes in TRP delivery into the CNS and consequent changes in 
5-HT synthesis. The aim of this investigation was to examine the magnitude and time-
course of changes in the plasma concentration ratio of f-TRP to BCAA following 
meals containing added CHO or fat. If changes in circulating amino acids in response 
food ingestion have implications for the development of central fatigue, the timing 
and composition of the pre-exercise meal may be important for achieving optimum 
performance during prolonged exercise. 
5.3 - Methods 
Subjects. To test the hypothesis, eight healthy subjects (5 males, 3 females; age 24.6 
± 4.1 y; height 1.74 ± 0.11 m; mass 78.9 ± 14.9 kg) were recruited. Prior to the start 
of the investigation all subjects received written details outlining the nature of the 
study. Following any questions regarding the experimental protocol, a written 
statement of informed consent was signed. The protocol employed during this 
investigation received ethical approval from the Grampian Research Ethics 
Committee. 
Experimental protocol. Subjects completed two experimental trials in a randomised 
order, separated by at least seven days. The standardisation of pre-trial conditions is 
outlined in chapter 2. Subjects entered the lab in the morning (between 8 and lOam), 
following an overnight fast. Upon arrival, a post-void body mass was recorded when 
wearing minimal clothing. Whilst seated in a comfortable environment (24 - 26 QC), a 
21g butterfly cannula was introduced into a superficial forearm vein to allow repeated 
blood sampling throughout the experimental period. After sitting quietly for 15 min to 
allow equilibrium of body fluids to be reached, two 5 mL baseline blood samples 
were drawn 5 min apart (-5 and 0 min). Subjects were then given 15 min to ingest 34 
kJ .kg BM- l of a meal containing either added CHO or fat. This quantity was chosen as 
it was felt that a meal of this energy content might typically be consumed prior to 
taking part in an athletic event. In order to standardise the nature of the meal 
administered to the subjects, a fruit flavoured smoothie was prepared to which either 
sucrose (CHO trial; 86 % CHO, 7 % fat, 7 % protein) or double cream (fat trial; 12 % 
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CHO, 81 % fat, 7 % protein) was added. The two meals were similar in volume and 
appearance, although there was a noticeable difference in the taste and texture. The 
subjects' response to the ingested meals was then monitored over the subsequent four 
hours, with blood samples taken at 30, 60, 120, 180 and 240 minutes post-ingestion. 
During the post-ingestion period subjects remained seated except for essential 
movements. Subjective feelings of tiredness, alertness, concentration and headache 
were assessed at 60 min intervals using lOO mm visual analogue scales (see Appendix 
IV). 
Blood handling and analysis. The 5 mL blood samples collected during the 
investigation were dispensed into two labelled tubes containing K2EDT A. 
Deproteinised whole blood was used to determine blood glucose concentration using 
a commercially available assay kit (Sigma Diagnostics, Poo\e, UK). Percentage 
changes in blood, plasma and red cell volumes relative to the first sample were 
estimated using the methods proposed by Dill and Costill (1974), using haemoglobin 
and packed cell volume values. The remaining 2.5 mL of whole blood was 
centrifuged and the plasma transferred into plain eppendorf tubes. Plasma f-TRP was 
separated from albumin bound TRP as described in Chapter 2. All plasma and 
ultrafiltrate samples were then kept frozen at -20 DC ready for analysis. Fluorimetric 
analysis of plasma BCAA (Gleeson and Maughan, 1987) and total- and f-TRP (see 
Appendix IT) were undertaken. Plasma FF A concentrations were determined 
enzymatically (Half-micro test, Roche Diagnostics, Mannheim, Germany). 
5.4 - Results 
The nutrient content of the ingested meals is presented in Table 5.1. The mean energy 
content of the meal ingested was 2.7 ± 0.5 MJ (range 1.8 - 3.4 MJ). The relatively 
large range was due to variation in the subjects' body mass. The experimental meals 
provided around 2.5 ± 0.6 g of BC AA and 0.2 ± 0.1 g ofTRP. 
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Table 5.1: The nutrient content ofthe meals ingested by the subjects during the study. 
El (MJ) CHO (g) Fat (g) Protein (g) ~BCAA(g) TRP (g) 
CHO 2.7 ± 0.5 136 ± 26 5±1 11 ± 2 2.55 ± 0.62 0.17 ± 0.05 
Fat 2.7 ± 0.5 19±4 57 ± 11 11 ± 2 2.51 ± 0.68 0.19 ± 0.06 
The blood glucose and plasma free-fatty acid responses to the meals are presented in 
Table 5.2. The CHO meal produced a marked elevation in circulating blood glucose 
reaching a peak 30 minutes following meal ingestion (+2.6 ± 0.6 mmoI.L'!; P < 
0.001) and returning to near pre-ingestion levels after 120 minutes. The Fat meal did 
not alter circulating blood glucose concentrations throughout the 4 hour experimental 
period (P = 0.270). A small increase above pre-ingestion values was apparent at 240 
minutes post-ingestion during the fat trial. Glucose was higher during the 2 hour post-
ingestion in the CHO trial when compared to the Fat trial (P < 0.01). Plasma FFA 
concentrations were similar prior to the ingestion of the meals (P = 0.236), with a 
marked difference between trials apparent throughout the post-ingestion period (P < 
0.001). A progressive fall in FFA was witnessed during the initial 120 min of CHO 
trial, with values failing to return to pre-ingestion levels at 240 min. Following an 
initial fall, plasma FFA increased following the ingestion of the meal containing 
added fat, reaching significance at 240 min post-ingestion (P < 0.05). 
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Table 5.2: Resting blood glucose (mmoI.L-1) and plasma free-fatty acid (FFA; 
mmoI.L-1) responses to the CHO and fat meals. a and b denote a significant difference 
from the 0 time point in the CHO and fat trials respectively (P < 0.05). * (P<0.05) and 
** (P<O.OI) denote a significant difference between the CHO trial and the 
. corresponding time point in the fat trial. 
Glucose CHO 
Fat 
FFA CRO 
Fat 
o 
4.2 
±0.4 
4.1 
±0.3 
0.46 
± 0.12 
0.39 
± 0.07 
30 
4.2 
±0.4 
4.1 
± 0.3 
0.24 
± 0.10"* 
0.33 
± 0.09 
60 120 180 
6.8 5.4 4.9 
± 0.6 "** ± 0.8 "** ± 0.6 ** 
4.3 4.1 4.1 
± 0.4 ± 0.5 ± 0.4 
240 
4.7 
±0.4 
4.3 
± 0.6 
0.13 0.08 0.11 0.28 
± 0.06"** ± 0.03"** 
0.25 
±0.08 
0.39 
± 0.14 
± 0.09"** ± 0.17"** 
0.54 
± 0.14 
0.64 
± 0.11 b 
There was no difference in plasma BCAA between trials before the ingestion of the 
meals (P = 0.581; Figure 5.IA). A reduction in BCAA concentrations was apparent 
during the CRO trial (p = 0.022), but levels were not significantly different to the pre-
ingestion value at any point. The meal with added fat failed to alter BCAA during the 
4 h post-ingestion period (P = 0.112). Plasma f-TRP was not influenced by the 
experimental meals over the time course of the study (CHO, P = 0.231; Fat, P = 
0.073), with no difference between trials apparent at any point (P = 0.849). 
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Figure 5.1: Resting plasma BCAA (A) and f-TRP (B) responses to the CHO and fat 
meals. * (P < 0.05) and ** (P < 0.01) denote a significant difference between the 
CHO trial and the corresponding time point in the fat trial. 
While the plasma concentration ratio of f-TRP to BCAA did not change after 
consuming the CHO meal (P = 0.871; Figure 5.2), the fat meal resulted in a modest 
reduction in f-TRP:BCAA during the 4 h post-ingestion period (P = 0.034). The ratio 
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of these amino acids was significantly greater during the CHO trial when compared to 
the fat trial between 60 and 120 minutes after meals ingestion. 
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Figure 5.2: Changes in the plasma concentration ratio of f-TRP to BCAA in response 
to the CHO and fat meals. * (P<0.05) and ** (P<O.OI) denote a significant difference 
between the CHO trial and the corresponding time point in the fat trial. 
Plasma total-TRP concentrations were not influenced by the CHO (P = 0.777) or fat 
(P = 0.071) trials (Figure 5.3). The ingestion of the experimental meals produced 
differing responses in the plasma concentration ratio of total-TRP to BCAA (P = 
0.004). While the CHO (P = 0.046) and fat (P = 0.018) meals influenced the total-
TRP : BCAA over the time course of the investigation, they failed to significantly 
alter this ratio relative to pre-ingestion values. Sixty minutes after the meals were 
consumed total-TRP : BCAA was significantly higher during the CHO trial compared 
to the fat trial (+0.05 ± 0.03; P = 0.008), with this difference maintained to the end of 
the 4 h experimental period. 
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Figure 5.3: Resting plasma total-TRP (A) and changes in the plasma concentration 
ratio of total-TRP to BCAA (B) in response to the CRG and fat meals. • (P<0.05) and 
** (P<O.OI) denote a significant difference between the CRO trial and the 
corresponding time point on the fat trial. 
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Table 5.3: Percentage changes in blood (BV), plasma (PV) and red cell (CV) 
volumes relative to the first sample (-5 min). 
0 30 60 120 180 240 
BV CHO 1.9 ± 1.5 2.2 ± 2.2 0.3 ± 1.5 0.7 ± 2.0 1.8 ± 2.0 1.8 ± 1.8 
Fat 1.7±1.3 0.3 ± 1.4 0.5 ± 2.2 0.7 ± 2.6 -0.2 ± 2.8 -0.4 ± 2.7 
PV CHO 3.1 ± 2.5 3.7 ± 3.9 1.5 ± 2.3 2.0 ± 3.0 3.3 ± 3.5 2.9 ±4.2 
Fat 2.8 ± 2.4 1.1 ± 2.6 1.5 ± 3.5 1.9 ± 3.9 0.5 ± 4.8 0.3 ± 4.5 
CV CHO 0.2 ± 1.5 0.4 ± 1.7 -1.0 ± 2.6 -0.8 ± 1.9 -0.2± 1.7 0.1 ± 1.4 
Fat 0.3 ± 0.9 -0.8 ± 1.7 -0.5 ± 1.5 -1.0 ± 1.6 -1.1 ± 1.9 -1.3 ± 2.4 
Changes in blood, plasma and red cell volumes are displayed in Table 5.3. There were 
no main effects for the meal on blood (P = 0.157), plasma (P = 0.170) or red cell (P = 
0.138) volumes during the 4 h post-ingestion period. 
Subjective feelings of tiredness, alertness, concentration and headache were assessed 
at 60 min intervals throughout the experimental protocol (Table 5.4). The ingestion of 
meals containing added CHO or fat did not alter perceived tiredness (P = 0.663). 
During the 4 h period after the meals, the subjects' reported feelings of alertness (P = 
0.425) or concentration (P = 0.172) did not change. There was no difference in 
subj ective feelings reported between trials. 
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Table 5.4: Changes in subjective feelings of tiredness, alertness, concentration and 
headache in response to the CHO and fat meals. 
0 60 120 180 240 
Tiredness CHO 25 ± 17 43 ±24 41 ± 26 38 ± 25 29±20 
Fat 39±24 41 ± 19 39 ± 19 32 ± 20 36 ± 26 
Alertness CHO 72±20 57 ± 21 61 ± 20 67 ± 23 71 ± 10 
Fat 57±26 49 ± 13 59 ± 24 59 ± 25 62 ±28 
Concentration CHO 71 ± 21 58 ±25 62 ± 16 67 ± 20 76 ± 5 
Fat 70±23 54 ± 16 66 ± 17 71 ± 21 65 ± 25 
Headache CHO 17 ± 17 18 ± 18 26 ± 18 20 ± 18 22 ± 19 
Fat 22±24 23 ± 17 24± 17 22 ± 18 28±27 
5.5 - Discussion 
The aim of the present investigation was to examine the time-course and magnitude of 
changes in plasma amino acids thought to be important to the development of 
serotonin-mediated central fatigue following the ingestion of meals containing added 
CHO and fat. Changes in the plasma concentration ratio of f-TRP to BCAA in 
response to CHO (Femstrom and Wurtman, 1971) and fat (Femstrom et aI., 1975) 
meals have been demonstrated to alter brain TRP and 5-HT content and may be 
important to the development of fatigue during prolonged exercise (Newsholme et aI., 
1987). 
There is a considerable degree of controversy regarding the availability of TRP for 
uptake into the CNS by the L-transporter (see Chapter 1). Originally it was believed 
that total TRP was readily available for uptake (Femstrom et aI., 1976; Madras et aI., 
1974; Pardridge, 1979), but subsequent work has suggested that only plasma f-TRP 
availability is closely associated with brain TRP tissue content whilst at rest (Bloxam 
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et aI., 1980) and during exercise (Chaouloff et aI., 1985; Chaouloff et aI., 1986). This 
premise resulted in the development of Newsholme's central fatigue hypothesis 
(Newsholme et aI., 1987), and forms the basis of the underlying metabolic 
mechanism. As the present study examined changes in plasma amino acids at rest, 
both plasma concentration ratios of f-TRP to BCAA and total-TRP to BCAA were 
considered due to the relative uncertainty regarding cerebral TRP uptake. 
Despite significantly altering circulating concentrations of blood glucose and plasma 
FF A and a reduction in plasma BCAA in the CRO trial, the meals failed to 
significantly alter the plasma concentration ratio of f-TRP to BCAA or total-TRP to 
BCAA compared to pre-ingestion values. Previous work has examined the influence 
of cereal-based meals on plasma amino acids during prolonged exercise (Paul et aI., 
1996). The authors reported that the plasma concentration ratio oftotal-TRP to LNAA 
was lower during exercise and recovery following the meal with the smallest protein 
content (the corn meal) than in the other trials, but failed to observe any change 
relative to pre-ingestion values. The energy content of the meals provided in the Paul 
study was somewhat small (-1340 kJ) and no reference to the importance of f-TRP in 
determining the rate of entry of TRP into the CNS was made. 
The effect of CRO ingestion on plasma amino acids, brain TRP uptake and central 
serotonin synthesis has been widely investigated. Original studies conducted by 
Fernstrom and Wurtman (1971) demonstrated a marked increase in brain 5-RT 
content following the ingestion of CRO or the peripheral infusion of insulin. 
Subsequent work established the role of other LNAA in determining the rate of TRP 
delivery into the CNS, and the influence of insulin secretion on the concentrations of 
competing amino acids (Femstrom and Wurtman, 1972). Oral doses of glucose have 
been reported to produce dose-dependent reductions in the plasma concentration ratio 
of TRP to LNAA, with a 40 % reduction in plasma BCAA following the ingestion of 
50 g of glucose (Pan et aI., 1982). While it is reasonable to assume that the CRO load 
(136 ± 26 g) provided in the present investigation produced a marked insulin 
response, only a modest change in circulating amino acid concentrations and was 
measured. Although the CRO present in the CRO-containing meal was primarily 
sucrose, with the hydrolysis of this disaccharide into glucose and fructose required at 
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the intestinal brush boarder before absorption can take place. The insulin response to a 
bolus of sucrose is around half that expected following the ingestion of the same 
quantity of glucose (Macdonald et aI., 1978), suggesting that the amino acid response 
following this meal would not be as pronounced as observed in previous studies 
employing a glucose load (Pan et aI., 1982). 
Following a transient fall, the fat meal increased circulating plasma FF A above pre-
ingestion levels, but this was statistically significant only at 4 h post-ingestion. It has 
been suggested that the ingestion of meals containing fat will raise circulating levels 
of triacylglycerol to a greater extent than FF A, but work conducted by Femstrom and 
co-workers (1975) reported marked dose-dependent increases in plasma FFA soon 
after the ingestion of fat -containing meals. This animal work demonstrated that the 
ingestion of meals containing significant quantities of fat would produce a marked 
increase in f-TRP, consequently reducing the plasma concentration ratio of f-TRP to 
BCAA (Femstrom et aI., 1975). No such change in plasma amino acids was apparent 
in the present investigation following the ingestion of a meal containing 81 % fat. It is 
important to note, however, that the increase in serum free tryptophan caused by fat 
ingestion in the F emstrom study was not accompanied by significant changes in brain 
tryptophan content. 
Since previous work has clearly demonstrated an effect of CRO and fat ingestion on 
circulating plasma amino acids (Femstrom et aI., 1975; Femstrom and Wurtman, 
1971; Pan et aI., 1982), it is possible to suggest that the protein content of the meals 
ingested in the present investigation limited such changes. The amino acid content of 
the meals, whilst relatively small compared to the contributions of CHO and fat (see 
Table 5.2) and those employed in previous investigations (Femstrom and Wurtman, 
1972; Paul et aI., 1996), may have significantly influenced the observed plasma amino 
acid response. Additionally, it is possible that changes in the plasma concentration 
ratio of f-TRP to BCAA were limited as the meals did not sufficiently alter circulating 
FFA and consequently result in changes to f-TRP concentrations. It does not appear 
that a linear relationship exists between levels of circulating FF A and the liberation of 
f-TRP from the binding sites on albumin (Struder and Weicker, 2001), with the 
findings of Chapters 3 and 4 suggesting that a threshold may exist beyond which FFA 
readily displace TRP. 
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The ingestion of mixed meals and single macronutrients at rest have been reported to 
produce transient changes in mood, mental function and perception of fatigue (Craig, 
1986; Spring et aI., 1986; Young, 1991). The experimental meals failed to alter 
sUbjective feelings of tiredness, alertness, concentration and headache assessed using 
visual analogue scales. This observation may not be surprising since little change to 
the plasma concentration ratio of both f-TRP and total-TRP to competing amino acids 
was measured during the post-ingestion period. While these reported changes in mood 
followir.g meal ingestion have been associated with changes to central serotonergic 
neurotransmission, evidence is accumulating that alternative mechanisms involving 
brain glucose availability and interactions with other monoamine systems may be 
more important (Bequet et aI., 2001; Cooper et aI., 2003). 
In summary, the ingestion of meals containing added CHO and fat resulted in little 
change to the plasma concentration ratio of f-TRP to BCAA over the time-course of 
the investigation. It is likely that the changes were not of a sufficient magnitude to 
influence the development of central fatigue during a subsequent exercise bout. 
Alterations to circulating plasma amino acids were probably limited by the relatively 
small quantity of protein present in both experimental meals and the use of sucrose 
rather than glucose in the CHO trial. In contrast to previous reports, the ingestion of 
meals produced no effect on subjective feelings of tiredness, alertness and 
concentration. 
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6.1 - Abstract 
Nine healthy endurance-trained males were recruited to examine the effect of a dual 
dopamine / noradrenaline reuptake inhibitor on performance, thermoregulation and 
the hormonal responses to exercise. Subjects performed 4 trials, ingesting either a 
placebo (pIa) or 2x300mg bupropion (bup), prior to exercise in temperate (18 QC) or 
warm (30 QC) conditions. Trials consisted of 60 min cycle exercise at 55% W max 
(Ex 1) immediately followed by a time trial (TT) to measure exercise performance. TT 
performance in the heat was significantly improved by bupropion (pIa 39.8 ± 3.9 min, 
bup: 36.4 ± 5.7 min; P = 0.046), but no difference between treatments was apparent in 
temperate conditions (pIa 30.6 ± 2.2 min, bup 30.6 ± 1.9 min; P = 0.954). During Ex1 
core and skin temperatures, heart rate, blood lactate, perceived exertion and thermal 
stress were not influenced by bupropion in either temperate or warm conditions. Time 
trial power output was not different between treatments at 18 QC. While power output 
was consistently lower during the TT in warm than in temperate conditions, this 
decrement was attenuated throughout the bupropion trial in the heat. At the end of the 
TT both core temperature (pla30 39.7 ± 0.3 QC, bup30 40.0 ± 0.3 QC; P = 0.017) and 
HR (pla30 178 ± 7 beats.min·I, bup30 183 ± 12 beats.min· l ; P = 0.039), were higher 
in the bup30 trial than in the pla30. Serum prolactin, cortisol, growth hormone and 
plasma ACTH concentrations increased throughout exercise in all trials. Plasma 
ACTH was higher following the ingestion of bupropion (P = 0.001). Circulating 
serum prolactin was elevated above temperate levels during exercise In a warm 
environment (P < 0.001). These data indicate that performance in wann conditions is 
enhanced by acute administration of a dual DA / NA reuptake inhibitor. No such 
effect was apparent under temperate conditions. It appears that bupropion enabled 
subjects to continue to maintain a high power output in the heat, despite the 
attainment of core temperatures suggested to accelerate central fatigue. 
6.2 - Introduction 
An individual's capacity to perform prolonged exercise is clearly impaired in high 
ambient temperatures (Galloway and Maughan, 1997; Parkin et aI., 1999; Tatterson et 
aI., 2000). While fatigue during prolonged exercise in temperate conditions is largely 
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associated with the depletion of muscle glycogen (Hennansen et aI., 1967), factors 
contributing to fatigue when exercising in a wann environment are not entirely clear. 
While exercise capacity is thought to be primarily limited by thennoregulatory and 
fluid balance factors (Hargreaves and Febbraio, 1998), it has been suggested that the 
CNS may become important in the development of fatigue when body temperature is 
significantly elevated (Bruck and Olschewski, 1987; Nielsen, 1992). Hyperthennia 
has been proposed to accelerate central fatigue, resulting in a reduction in maximal 
muscle activation (Nybo and Nielsen, 2001a), altered EEG brain activity (Nielsen et 
aI., 2001) and increased perceived exertion (Nybo and Nielsen, 2001b). 
As outlined in Chapter 1, Newsholme's original central fatigue hypothesis proposed 
that prolonged exercise results in an increased activity of central serotonergic neurons, 
producing feelings of tiredness and lethargy that may contribute to the development of 
fatigue (Newsholme et aI., 1987). While early evidence was supportive of this 
suggestion (Wilson and Maughan, 1992), many subsequent studies designed to 
manipulate central 5-HT have failed to replicate these positive findings (Meeusen et 
aI., 2001b; Pannier et aI., 1995; Strachan, 2002). The relatively small (-1 in every 1 
million neurons), but widespread distribution of serotonin throughout the CNS, has 
led to the suggestion that this monoamine acts largely as a neuro-modulator 
influencing other neurotransmitter systems within the brain, rather than directly 
regulating physiological responses (Jacobs and Azmitia, 1992; Trulson and Jacobs, 
1979). 
The opposite aspect to the serotonin-fatigue hypothesis is the catecholamine-
arousal/motivation axis (Davis and Bailey, 1997). Dopamine (DA) and noradrenaline 
(NA) have been implicated in arousal, motivation, reinforcement and reward, the 
control of motor behaviour and mechanisms of addiction (Nestler et aI., 2001). The 
depletion of central catecholamines has been linked to CNS fatigue by a number of 
research groups (Chaouloff, 1989; Davis, 2000; Owasoyo et aI., 1992). A series of 
studies conducted by Bailey and co-workers (1992, 1993 ab) demonstrated that brain 
5-HT and DA activity were elevated during exercise, but at the point of exhaustion a 
marked fall in tissue DA content was apparent. This observation resulted in the 
suggestion that the ratio of 5-HT to DA activity may be important for the 
development of central fatigue, with a high ratio of 5-HT to DA associated with 
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feelings of tiredness and reduced motivation (Davis and Bailey, 1997). Additionally, 
intracranial stimulation of the ventral tegmental area (VT A), the origin of the 
dopaminergic projections, motivated rats to run without the need for aversive electric 
shocks (Burgess et aI., 1991; Burgess et aI., 1993). 
While there is good evidence that amphetamine, which acts as a potent DA releaser, 
reuptake inhibitor, and MAO inhibitor (Cooper et aI., 2003), can enhance capacity to 
perform prolonged exercise (Gerald, 1978), little evidence from other strategies to 
manipulate catecholaminergic neurotransmission supports a performance benefit 
(Chinevere et aI., 2002; Meeusen et aI., 1997; Piacentini et aI., 2002a; Piacentini et aI., 
2004; Piacentini et aI., 2002b; Struder et aI., 1998). In particular, Piacentini and 
colleagues (2004) recently examined the effects of bupropion, a dual DA / NA 
reuptake inhibitor, on performance and hormonal responses to exercise in temperate 
conditions. Although bupropion failed to alter exercise performance when compared 
to a placebo treatment, a marked difference in the hormonal response to exercise was 
reported. As pituitary hormone release is largely governed though changes in 
extracellular hypothalamic neurotransmitter concentrations, these hormones have 
been widely employed as peripheral markers of central neurotransmission (Checkley, 
1980; Van de Kar, 1997). 
As exercise-induced hyperthermia is thought to result in a reduced drive and a loss of 
motivation (Bruck and Olschewski, 1987; Nielsen, 1992), maintenance of central 
catecholamine levels may attenuate the loss of performance apparent when exercise is 
undertaken in a warm environment. Dopamine has also been implicated in the control 
of body temperature (Hasegawa et aI., 2000; Lee et aI., 1985; Lipton and Clark, 1986) 
and tolerance to exercise in the heat (Bridge et aI., 2003). The aim of the present study 
was to investigate the influence of an acute dose of bupropion, a dual dopaminergic 
and noradrenergic reuptake inhibitor, on exercIse performance and on 
thermoregulatory and hormonal responses to exercise in temperate and warm 
environmental conditions. 
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6.3 - Methods 
Subjects. Nine healthy males (age 22.7 ± 4.3 y; Ht I.S3 ± 0.07 m; mass 75.2 ± 6.7 kg; 
Wm• x 372 ± 36 W; VO, peak 5.1 ± 0.5 L.min- I ) participated in this investigation. All 
subjects were well-trained cyclists or triathletes, with a long history of endurance-
training, but were not accustomed to exercise in a warm environment at the time of 
the study. Prior to the start of the study all volunteers received written information 
regarding the nature and purpose of the experimental protocol. Following an 
opportunity to ask any questions, a written statement of consent was signed. The 
protocol employed in the present study was approved by the Research Council of the 
Vrije Universiteit Brussel, Brussels, Belgium. 
Experimental protocol. All subjects completed a preliminary maximal exercise test, 
a familiarisation trial and 4 experimental trials. The preliminary trial is described in 
Chapter 2, and was used to determine the power output required to elicit 55 % and 
75 % W max. A familiarisation trial was undertaken to ensure the subjects were 
accustomed to the procedures employed during the investigation and to minimise any 
potential learning or anxiety effects. This trial was performed in temperate 
environmental conditions with the placebo treatment administered in a single-blind 
manner and was identical to the experimental trials in all respects (see below). 
Experimental trials were undertaken in either temperate (Tmp; IS QC) or warm (Wrm; 
30 QC) conditions, with relative humidity maintained between 50 - 60 % in both 
conditions. The experimental jrials were separated by at least 7 days to minimise the 
development of heat acclimation and to ensure drug washout (Holm and Spencer, 
2000). The standardisation of pre-trial conditions is outlined in Chapter 2. 
Subjects entered the laboratory in the mormng approximately 90 minutes after 
consuming a standardised breakfast that included 500 mL of plain water prior to the 
start of each trial (-150 min before the start of exercise). Nude post-void body mass 
was measured and an indwelling venous cannula was introduced into a superficial 
forearm vein to enable repeated blood sampling at rest and during exercise. Subjects 
inserted a rectal thermister (Gram Corporation LT-SA, Saitama, Japan) 10 cm beyond 
the anal sphincter for the measurement of core temperature. Surface skin temperature 
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probes (Gram Corporation LT-SA, Saitama, Japan) were attached to four sites (chest, 
upper arm, thigh and calf) and a heart rate telemetry band (Polar Accurex plus, 
Kempele, Finland) was positioned. Subjects were dressed in only cycling shorts, 
socks and shoes for all trials. 
Subjects then entered a climatic chamber maintained at the appropriate 
environmental conditions and rested in a seated position for 15 minutes. During this 
period temperatures and heart rate were recorded at 5 minute intervals and a resting 
venous blood sample was drawn immediately before the start of exercise. The 
exercise protocol consisted of 60 minutes constant load exercise at a workload 
corresponding to 55 % W max, followed by a time trial (TT) to measure performance. 
There was a 1 to 2 minute delay between the end of the constant load exercise and the 
beginning of the TT, to program the ergometer (Lode Excalibur Sport, Groningen, 
Holland) and computer software. The TT required the subjects to complete a 
predetermined amount of work equal to 30 minutes at 75 % Wmax as quickly as 
possible (Jeukendrup et aI., 1996). Subjects began the TT at a workload 
corresponding to 75 % W max, but were free to increase or decrease their power output 
as desired from the outset. During the TT a computer program displayed a bar 
indicating the percentage of total work completed to give the subject an indication of 
their progress. Throughout the protocol no feedback was provided regarding time 
lapsed, power output, pedal cadence or heart rate. During exercise subj ects had ad 
libitum access to plain water. 
Core and skin temperatures and heart rate were recorded at 5 minute intervals during 
exercise. Ratings of perceived exertion and thermal stress were assessed every 15 
minutes during the initial 60 minutes and at 10 minute intervals during the TT. 
Venous and capillary blood samples were drawn after 30 and 60 minutes of constant 
load exercise and at the end of the TT. Following the completion of the TT, subjects 
returned to a seated position where recovery was monitored for 15 minutes and a 
further blood sample was obtained. The probes and cannula were then removed and 
nude body mass was then re-measured to allow the estimation of sweat losses. 
Drugs. SUbjects ingested 600 mg bupropion (bup: Zyban TM, GSK, Middlesex, UK) or 
a placebo (pIa: lactose) spread over two doses: one ingested at night immediately 
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before sleeping, with the other taken upon waking on the morning of the trial (2 x 300 
mg). This is equivalent to the maximum daily therapeutic dose administered during 
the treatment of depression or to assist in the cessation of cigarette smoking (Holm 
and Spencer, 2000), and has been demonstrated to alter the hormonal response to 
prolonged exercise (piacentini et aI., 2004). The treatment was randomised and 
administered in double-blind crossover manner. Drug and placebo capsules were 
prepared by an independent pharmacy to appear indistinguishable with regard to 
dimensions, weight and colour. 
Blood collection and analysis. Venous blood samples were drawn directly into pre-
cooled vacutainer tubes (BD Vacutainer, Plymouth, UK). 10 rnL samples were 
collected into a plain tubes and left to clot for -1 hour at room temperature before 
centrifugation. The resulting serum was stored at -20 QC for the determination of 
prolactin (Roche Diagnostics, Mannheim, Germany), cortisol (Diasorin, Still water, 
USA) and growth hormone (pharmacia & Upjohn Diagnostics, Uppsala, Sweden). 
Samples for plasma adrenocorticotropic hormone (ACTH; Nichols Institute 
Diagnostics, CA, USA) were collected into 4.5 mL tubes containing KJEDTA. A 0.5 
mL aliquot of whole blood was extracted and used for the determination of 
haemoglobin (Hb) and haematocrit (Hct). Hb and Hct values were used to estimate 
percent changes in plasma volume relative to the pre-exercise sample using the 
methods described by Dill and Costill (1974). The remaining EDTA-treated blood 
was spun, with the resulting plasma stored at -80 QC. Capillary blood (20 ilL) drawn 
from the earlobe was analysed for blood lactate immediately following the completion 
of each trial (EKF Biosen 5030, Magdeburg, Germany). 
Statistical Analysis. Data are presented as means ± standard deviation (SD). To 
evaluate differences in TT performance, 2-factor (temp x drug) repeated measures 
ANOVA were employed. Data collected over time were analysed using 3-factor 
(temp x drug x time) ANOVA with repeated measures, Pairwise differences were 
identified using Tukey's post-hoc test as appropriate. To improve the clarity of 
figures, differences present between environmental conditions are described in the 
text. 
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6.4 - Res u Its 
All subjects completed all trials. Some minor side-effects were reported (e.g. mild 
insomnia, headaches), but these were not consistent with bupropion. Throughout the 
text the trials are referred to as: placebo trial at 18 QC (plaI8), bupropion trial at 18 QC 
(bup 18), placebo trial at 30 QC (p1a30) and the bupropion trial at 30 QC (bup30). 
Mean time trial performance is displayed in Figure 6.1, with individual percent 
changes in performance shown in Figure 6.2. Exercise performance was significantly 
influenced by the ambient temperature, with subjects taking longer to complete the 
target amount of work in the warm than in the temperate trials (P < 0.001). No 
difference in TT performance was apparent between treatments in the Tmp condition, 
with times of 30.6 ± 2.2 min and 30.6 ± 1.9 min recorded in the placebo and 
bupropion trials respectively (P = 0.954). When exercise was performed in a warm 
environment, subjects completed the TT 9 % faster in the bupropion trial (36.4 ± 5.7 
min) than in the placebo (39.8 ± 3.9 min; P = 0.046). 
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Figure 6.1: Time trial performance in the four experimental trials. a, b, c, d denote a 
significant difference from corresponding values in pla18, bup18, pla30 and bup30 
trials respectively (P < 0.05). 
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Figure 6.2: Individual percent changes in exercise perfonnance in the bupropion trial 
relative to the placebo trial in temperate (A) and wann (B) conditions. 
As the TT required the completion of a predetennined amount of work, the time taken 
to complete the protocol was directly related to the power output maintained 
throughout this period. TT power output was significantly higher during the Tmp 
trials (P = 0.001; Figure 6.3), with a similar workload maintained throughout the 
duration of the trial. Mean power output in temperate conditions was 275 ± 36 W and 
279 ± 35 W in the placebo and bupropion trials respectively (P = 0.531). Mean power 
output was greater throughout the bupropion trial in the wann (234 ± 35 W) than 
during the placebo trial in the same environmental conditions (211 ± 23 W). From the 
start of the TT in the heat, power output was reduced below the predetennined 
starting value, but the reduction was not as pronounced in the bupropion trial. 
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Figure 6.3: Time trial power output in Tmp (A) and Wrm (B) conditions. * (P < 0.05) 
denote a significant difference between the placebo trial and the corresponding time 
point on the bupropion trial. 
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Core temperature at rest was not different between trials (P = 0.107; Figure 6.4). 
Exercise produced a progressive increase in core temperature in all trials (P < 0.001). 
Ambient temperature influenced TeOTe (P = 0.003), with values significantly elevated 
in the warm trials above those recorded in temperate conditions after 50 minutes of 
Ex 1, with this difference maintained throughout the TT and into the recovery. There 
was no apparent effect of bupropion on TeOTe during Ex I, but core temperature was 
significantly higher on bupropion during the TT in both temperate and warm 
conditions. At the end of the performance test core temperature was elevated in 
bupropion trials in both temperate (plal8 39.2 ± 0.2 °c, buplS 39.4 ± 0.3 °C; 
P = 0.010) and warm (pla30 39.7 ± 0.3 °C, bup30 40.0 ± 0.3 °C; P = 0.017) 
environmental conditions. 
Weighted mean skin temperature increased rapidly from the onset of exerCise, 
reaching a plateau after 20 minutes exercise in all trials (Figure 6.5). Skin temperature 
was higher throughout both trials at 30°C than during exercise in IS °c (p < 0.001), 
but was not influenced by bupropion (P = 0.3S6). There was a tendency for Tskin to be 
higher during the bup30 trial than in the pla30 (P = 0.099), but this failed to reach 
significance at any point. 
The change in body mass experienced during exercise, corrected for fluid intake, was 
significantly greater during trials in the warm (pla30 3.03 ± 0.56 kg, bup30 3.02 ± 
0.54 kg) when compared to the temperate conditions (plalS 2.10 ± 0.32 kg, buplS 
2.02 ± 0.43 kg; P < 0.001). 
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Figure 6.4: Core temperature responses to the experimental protocol in Tmp (A) and 
Wrm (B) conditions. * (P < 0.05) and ** (P < 0.01) denote a significant difference 
between the placebo trial and the corresponding time point on the bupropion trial. 
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Figure 6.5: Weighted mean skin temperature responses to the experimental protocol 
in Tmp (A) and Wrm CB) conditions. 
Heart rate was higher in the warm when compared to values recorded during the 
corresponding trial in temperate conditions (P < 0.001). During Exl heart rate was not 
affected by the drug treatment, but values were higher throughout the performance 
123 
Chapter 6 DA I NA reuptake inhibition and exercise 
test with bupropion in the warm (bup30) compared to the same period in the placebo 
trial (pla30). 
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Figure 6.6: Heart rate responses to the experimental protocol in Tmp (A) and Wrm 
CB) conditions. * (P < 0.05) and ** (P < 0.01) denote a significant difference between 
the placebo trial and the corresponding time point on the bupropion trial. 
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Figure 6.7: Rating of perceived exertion during exercise in Tmp (A) and Wrm (B) 
conditions. 
Ambient temperature did not influence RPE during exercise, although there was a 
tendency for perceived exertion to be higher towards the end of Ex I in 30 QC (P = 
0.072; Figure 6.7). Bupropion had no effect on perceived exertion (P = 1.000). The 
subjects' rating of perceived thermal stress is shown in Figure 6.8. Compared to the 
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temperate trials, perceived thennal stress was significantly higher when exercise was 
perfonned in warm conditions (P < 0.001), but during the TT neither RPE nor 
perceived thennal stress was different between environmental conditions. No 
difference in the subjects' thennal stress was apparent between drug treatments in 
either temperate or warm conditions (P = 0.785). 
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Figure 6.8: Perceived thennal stress during exercise In Tmp CA) and Wnn CB) 
conditions. 
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Table 6.1: Blood lactate concentrations (mmoI.L·') during exercise during the Tmp 
and Wrm trials. a, b, c, d denote a significant difference from corresponding values in 
plalS, buplS, pla30 and bup30 trials respectively (P < 0.05). 
0 30 60 TT End ReelS 
plal8 1.18 ± 0.20 1.48 ± 0.52 1.36 ± 0.48 5.17 ± 1.39 cd 2.65 ± 1.35 
bupl8 1.14 ± 0.20 1.81 ± 0.65 1.72 ± 0.48 5.08 ± 1.47 cd 2.51 ± 0.95 
pla30 1.20 ± 0.29 2.04 ± 0.71 2.14 ± 0.79 2.34 ± 0.66 ab 1.33 ± 0.29 d 
bup30 1.54 ± 0.58 1.80 ± 0.52 1.81 ± 0.79 3.33 ± 1.56 ab 1.85 ± 0.54 c 
Blood lactate at rest and during Ex I was not different between ambient temperatures, 
but was significantly elevated at the end of the TT in the temperate trials (P < 0.05). 
Drug ingestion did not influence the blood lactate concentrations (P = 0.225). 
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Figure 6.9: Serum prolactin concentration at rest and during exercise. a, b, c, d denote 
a significant difference from corresponding values in plalS, buplS, pla30 and bup30 
trials respectively (P < 0.05). 
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There was no difference between trials in serum prolactin concentration at rest 
(P = 0.480; Figure 6.9). Ambient temperature altered the prolactin response to the 
experimental protocol (P < 0.001), with higher circulating concentrations observed at 
the end of Ex 1 and upon completion of the target amount of work in the heat. Serum 
prolactin was not influenced by bupropion at rest or during exercise (P = 0.173). 
Compared to resting values, no change in circulating prolactin was apparent during 
Ex 1 in temperate conditions, but a marked elevation was measured at the end of the 
TT and recovery period. Prolactin concentrations were elevated throughout exercise 
in warm conditions. Ambient temperature did not appear to influence circulating 
cortisol concentrations (P = 0.191; Figure 6.10). There was a difference in resting 
cortisol measured before the start of exercise between trials (P = 0.019), with post-hoc 
analysis identifying a difference between pla30 and bup30 trials (P = 0.016). Cortisol 
concentrations were not different between trials at any other point. Circulating serum 
cortisol increased progressively throughout exercise in all trials, with this increase 
continuing into the recovery (P < 0.001). 
350 
300 
~ 
~ 250 
E 
Cl 
c 200 
-
"0 
III 
1:: 
0 150 (J 
100 
50 
Dpla18 
.bup18 
I!I pla30 
.bup30 
c 
o 30 60 End Rec15 
Time (minutes) 
Figure 6.10: Serum cortisol concentration at rest and during exercise. a, b, c, d denote 
a significant difference from corresponding values in pla18, bup 18, pla30 and bup30 
trials respectively (P < 0.05). 
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Figure 6.11: Plasma adrenocorticotropic hormone (ACTH) concentration at rest and 
during exercise. a, b, c, d denote a significant difference from corresponding values in 
plal8, bupl8, pla30 and bup30 trials respectively (p < 0.05). 
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Figure 6.12: Serum growth hormone (GH) concentration at rest and during exercise. 
a, b, c, d denote a significant difference from corresponding values in plal8, bupl8, 
pla30 and bup30 trials respectively (P < 0.05). 
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Changes in plasma ACTH are presented in Figure 6.11. Plasma ACTH increased 
progressively throughout exercise in all trials (P = 0.005). ACTH concentrations at 
rest were increased by bupropion (P = O.03S). Ambient temperature influenced 
circulating ACTH, with levels significantly higher during exercise in the heat at the 
end Ex I. At the end of the performance test plasma ACTH was higher in the bup IS 
trial (215 ± SI ng.L-1) than in the plalS trial (155 ± 61 ng.L-\ P = 0.02S). While 
serum growth hormone was increased 7 to 20-fold throughout exercise (P < 0.001; 
Figure 6.11), the environmental conditions (P = 0.131) and drug treatment (P = 0.223) 
did not influence the growth hormone response to the trial. 
Table 6.2: Percentage changes in blood (BV), plasma (PV) and red cell (CV) 
volumes relative to the 0 time point. a, b, c, d denote a significant difference from 
corresponding values in plalS, buplS, pla30 and bup30 trials respectively (P < 0.05). 
30 60 TT End ReelS 
BV plalS -4.5 ±2.S -3.5 ± 2.0 c -6.1 ± 2.9 -O.S ± 2.3 d 
buplS -4.3 ± 2.6 -2.S ± 2.3 c -5.3 ± 2.4 -0.6 ± 1.3 d 
pla30 -5.6 ± I.S -6.3 ± 1.4 ab -6.7 ± 1.7 -2.7 ± 1.0 
bup30 -4.4 ± 2.3 -5.3 ± 2.9 -6.4 ± 1.3 -3.4 ± 1.4 ab 
PV plalS -7.6 ± 4.0 -5.S ± 3.4 c -10.9 ± 4.0 -1.6 ± 3.4 d 
buplS -7.2±4.5 -4.9 ± 3.9 c -9.7 ± 3.5 -0.9 ± 2.4 d 
pla30 -9.6 ± 2.6 _10.4±2.l ab -11.5 ± 2.S -4.1 ± 1.9 
bup30 -7.5 ± 3.9 -S.7 ± 4.4 -10.5 ± 1.9 -5.5 ± 2.2 ab 
CV plalS 0.0 ± 1.6 -0.3 ± 1.1 0.7 ± 1.5 0.3 ± 1.5 
buplS -0.2 ± 1.1 0.0 ± 1.2 0.9 ± I.S -0.2 ± 1.2 
pla30 0.2 ± 1.1 -0.4 ± 1.0 0.3 ± 1.2 -0.7 ± 1.0 
bup30 0.3 ± 1.1 -0.2 ± 1.2 -0.3 ± 0.9 0.0 ± 1.6 
130 
I~ 
Chapter 6 DA / NA reuptake inhibition and exercise 
Compared to resting values, both blood (P < 0.001) and plasma (P < 0.001) volumes 
were significantly reduced during exercise and after a 15 minute recovery period. 
There was a difference in blood and plasma (P = 0.005) volume changes between 
environmental conditions (P = 0.003), with post hoc analysis identifying differences 
at the end of Ex I and following the recovery. Bupropion did not influence blood (P = 
0.132), plasma (P = 0.080) or red cell (P = 0.897) responses to the experimental 
protocol. 
6.5 - Discussion 
The present study investigated the effect of acute administration of a dual dopamine I 
noradrenaline reuptake inhibitor on performance, thermoregulation and hormonal 
responses to exercise in temperate and warm environments. While a number of 
studies have attempted to enhance exercise performance through the manipulation of 
central catecholaminergic neurotransmission in temperate conditions (Chinevere et 
aI., 2002; Meeusen et aI., 1997; Piacentini et aI., 2004; Struder et aI., 1998), this is the 
first study to evaluate the effect a dual DA I NA reuptake inhibitor in warm ambient 
temperatures. Evidence suggests that exercise-induced hyperthermia may reduce 
motivation and drive to continue exercise, potentially contributing to the reduced 
capacity to perform prolonged exercise when ambient temperatures are elevated. 
Additionally, DA and NA have been implicated in the control of thermoregulation 
(Hasegawa et aI., 2000; Lee et aI., 1985; Lipton and Clark, 1986). 
The results of the present study demonstrate that performance of a relatively short (30 
- 45 minutes), pre-Ioaded TT was improved by bupropion when exercise was 
performed in warm ambient conditions, but no ergogenic benefit was apparent in a 
temperate environment. The 9 % increase in performance observed in the warm was 
accompanied by higher TT heart rate and the attainment of a significantly higher core 
temperature at the completion of the TT compared to values measured during the 
placebo trial under the same environmental conditions. Despite these differences no 
change in blood lactate or subjective feelings of perceived exertion and thermal 
discomfort were apparent between the pla30 and bup30 trials. 
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While there is good evidence that amphetamine, a potent DA agonist, can enhance 
exercise capacity (Chandler and Blair, 1980; Gerald, 1978), the failure to observe a 
performance effect at 18 QC in the present study supports the findings of recent studies 
investigating nutritional and pharmacological manipulation of catecholaminergic 
neurotransmission (Chinevere et aI., 2002; Meeusen et aI., 1997; Piacentini et aI., 
2004; Struder et aI., 1998). Recently the influence of bupropion on exercise 
performance and the hormonal response to a 90 minute TT has been investigated 
(Piacentini et aI., 2004). While there were slight differences in the exercise protocol, 
the drug administration protocol in the present study was identical to that employed 
by Piacentini et al. (2004). The authors also reported no effect of bupropion on 
exercise performance in temperate environmental conditions (18 QC). 
Bupropion is a relatively weak, but selective, DA and NA reuptake inhibitor, with 
potency twice as great for DA than NA, while it shows little affinity for the 5-HT 
system (Holm and Spencer, 2000). Peak plasma concentrations are found 3 hours after 
ingestion, with the concentration of hydroxybupropion and threohydrobupropion, 
bupropion's major metabolites reaching peak concentrations 6 hours post-ingestion. 
While animal studies suggest that bupropion acts primarily through its effect on DA 
reuptake (Nomikos et aI., 1989), the hormonal responses observed by Piacentini and 
colleagues (2004) led the authors to suggest that the central action of bupropion in 
humans was mediated largely through the noradrenergic system. This suggestion is 
supported by clinical studies (Cooper et aI., 1994), and the observation that drugs 
acting exclusively on DA appear not produce an appreciable antidepressant effect 
(Nestler et ai, 200 I). The discrepancy between human and animal data appears to 
result from differences in drug metabolism, with the metabolite hydroxybupropion not 
produced in rodents. This metabolite acts primarily on the NA transporter (Piacentini 
et aI., 2003a). 
Core temperature was not influenced by the drug treatment during the initial 60 
minute period of fixed-intensity exercise (Exl), but marked differences were evident 
during the TT under both temperate and warm conditions. It appears that the elevated 
core temperature towards the end of the TT in the bup30 trial can be explained by an 
elevated metabolic heat production, occurring as a result of the maintenance of a 
higher power output throughout the TT. It is interesting to note that only two (of nine) 
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subjects attained a temperature of 40.0 QC or greater during the pla30 trial, whereas 
seven breached this value when bupropion was administered (bup30 trial). It is not 
clear why a difference in core temperature was apparent between drug and placebo 
trials under temperate conditions, as no difference in power output was measured. 
Bupropion has recently been reported to possess thermogenic properties (Liu et aI., 
2002) possibility relating to its amphetamine-like structure (Nestler et aI., 2001), and 
catecholaminergic neurotransmission may influence thermoregulation during exercise 
(Hasegawa et aI., 2000). This may explain the different core temperature response 
during the TT in temperate conditions, but does not explain why no change in core 
temperature was measured during Ex 1 and in the warm trials. 
There is some limited evidence increased dopaminergic activity increases tolerance to 
exercise in the heat (Bridge et aI., 2003). It is possible to suggest that bupropion 
administration in the heat acted on central DA and NA neurotransmission to maintain 
motivation and arousal, enabling the subjects to continue to sustain a high power 
output despite approaching, and in some cases breaching, the critical core temperature 
proposed by Nielsen et al (1993). Attainment of a critical core temp has been 
suggestf:d to result in a loss of drive to continue exercise (Nielsen, 1992) and has been 
associated with increased perception of effort (Nybo and Nielsen, 2001b), altered 
brain activity (Nielsen et aI., 2001) and reduced maximal muscle activation (Nybo and 
Nielsen, 2001a), all of which have been suggested to contribute to the development of 
fatigue and may serve as a protective mechanism limiting further heat production 
(Nielsen, 1992). This could indicate that subjects taking bupropion before exercise in 
a warm environment were capable of pushing into a potential 'danger zone' close to 
critical core temperature without, or significantly dampened, negative feedback from 
the CNS. 
While Piacentini and co-workers (2004) failed to report a performance effect 
following bupropion, a marked difference in the hormonal response to exercise was 
apparent, suggesting that the drug administration produced an effect on central 
neurotransmission. Increased dopaminergic neurotransmission is associated with an 
inhibition of pituitary hormone release, with the exception of growth hormone 
(Checkley, 1980; Van de Kar, 1997). Regulation of hormone release by NA is 
complicated by the type of adrenoceptor subtype activated, with conflicting responses 
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produced by alpha and beta receptors. As stated earlier, it appears that bupropion acts 
primarily through changes to NA neurotransmission, making it difficult to predict 
expected changes to hormone release. Acute bupropion supplementation has been 
previously reported to increase the ACTH and cortisol response to exercise, while not 
influencing prolactin and growth hormone concentrations (piacentini et ai, 2004). 
Although it is difficult to ascertain the effect of acute drug administration due to 
potential autoreceptor-mediated negative feedback (Artigas et aI., 1996), recent 
animal studies have given an insight into the effect of acute doses on 
neurotransmission and the central regulation of hormone release (Piacentini et aI., 
20OJa; Piacentini et aI., 2003b). The effects and implications of acute vs chronic drug 
administration are described in detail in Chapter 8. 
Changes in circulating prolactin concentrations have been widely employed as a 
peripheral marker of serotonergic activity (Struder and Weicker, 2001; Van de Kar, 
1997), but its reliability has been questioned (Meeusen et aI., 2001b; Piacentini, 
2003). Interpreting changes in plasma prolactin as an index of 5-HT activity may be 
misleading as prolactin release from the pituitary gland is governed through an 
complex interaction between a number of neurotransmitters rather than by serotonin 
alone (Meeusen et aI., 2001a). In the present study, serum prolactin concentrations 
were significantly elevated during exercise in the heat, but bupropion ingestion did 
not alter this response. A relationship between core temperature and circulating 
prolactin has been widely reported (Melin et aI., 1988; Pitsiladis et aI., 2002; 
Radomski et aI., 1998; Strachan, 2002), and it has been proposed that serotonergic 
activity may be upregulated during combined exercise and heat stress (Pitsiladis et aI., 
2002). As changes in core temperature and HP A-hormone secretion are primarily 
regulated by the hypotbalamus, it appears that brain temperature during exercise may 
be causally related to the release of hormones from the pituitary gland (Radomski et 
aI., 1998). 
In contrast to previous reports (Brenner et aI., 1997; Strachan, 2002) serum cortisol 
concentrations were not influenced by the ambient conditions. Brenner and colleagues 
reported a marked elevation in circulating cortisol concentration when moderate-
intensity exercise was performed in warm (40 QC) compared to temperate (23°C) 
conditions. A failure to observe a difference in cortisol between environmental 
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conditions in the present investigation may be due to the attainment of relatively high 
core temperatures (> 39 QC) in the temperate trial, with clamping of body temperature 
previously demonstrated to abolish exercise-induced cortisol secretion (Cross et aI., 
1996). As previously reported (Piacentini et aI., 2004) bupropion did not significantly 
influence the serum cortisol or growth hormone response, whereas plasma ACTH was 
elevated at the end of the TT in temperate ambient conditions. There was a tendency 
for ACTH to be higher in the heat with bupropion at this time point, but this 
difference failed to reach statistical significance due to the large intra-subject 
variability. 
Two important findings arise from this study: 1) subjects completed a pre-loaded time 
trial 9 % faster when bupropion was taken before exercise in a warm environment 
compared to a placebo treatment. This ergogenic effect was not apparent at 18 QC. 2) 
Seven (of 9) subjects attained core temperatures equal to, or greater than, 40.0 °C in 
the BUP trial, compared to only two during the placebo trial. This occurred without 
any apparent change in the subjects' perceived exertion or thermal sensation. It is 
possible to suggest that this drug may enable an individual to dampen or override 
inhibitory signals arising from the CNS to cease exercise due to hyperthermia, and 
continue to maintain a high power output. The present findings should be noted as the 
International Olympic Committee (lOC), removed this drug from the list of prohibited 
substances in January 2003. 
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7.1 - Abstract 
Seven active males were recruited to examine changes in serum SI OOb, a proposed 
peripheral marker of BBB permeability, following water immersion and prolonged 
exercise in temperate (Tmp) and warm (Wrm) conditions. Subjects were seated 
immersed to the neck in water at 35.0 ± 0.1 QC (Tmp) or 39.0 ± 0.1 QC (Wrm) for 30 
min. Subjects then entered a room maintained at either 18.3 ± 1.8 QC (Tmp) or 35.0 ± 
0.3 QC (Wrm) and completed 60 min cycle exercise at 60 % Y0 2 peak. Serum S100b 
was elevated after exercise in the Wrm trial (+0.12 ± 0.10 Ilg.L·\ P = 0.02), but not 
after the Tmp trial (P = 0.238). Water immersion and exercise elevated core 
temperature by 2.1 ± 0.5 QC to 39.5 ± 0.3 QC at the end of exercise in the Wrm trial 
compared to a 0.9 ± 0.2 QC increase during the Tmp trial (P < 0.001). Weighted mean 
skin temperature was higher throughout the Wrm trial (P < 0.001). Body mass loss 
was significantly influenced by the experimental conditions (Tmp 0.70 ± 0.14 kg, 
Wrm 1.79 ± 0.35 kg; P < 0.001). Heart rate (P < 0.001), as well as blood glucose 
(P < 0.001) and lactate (P < 0.001), were elevated during exercise in the warm 
environment. Ratings of perceived exertion (P < 0.001) and thermal discomfort 
(P < 0.001) were markedly higher throughout the Wrm trial than in the Tmp trial. The 
results of this study demonstrate that serum SI OOb was elevated following water 
immersion and prolonged exercise in a warm environment, suggesting that BBB 
permeability may be altered. Changes in BBB integrity may contribute to the 
development of central fatigue during prolonged exercise by disturbing CNS 
homeostasis. 
7.2 - Introduction 
The blood-brain barrier (BBB) is a dynamic structure consisting of microvascular 
endothelial cells, characterised by the presence of tight junctions and restricted 
vesicular transport (Kandel et aI., 2000). The foot processes of surrounding astrocytes 
and the presence of pericytes reinforce these tight junctions. The BBB functions 
through these specialised structures to maintain a stable environment for the CNS by 
tightly regulating the exchange of molecules between the CNS and the peripheral 
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circulation. When the BBB is intact diffusion is largely restricted, with transport 
mediated through a series of selective molecular carrier systems specific to a wide 
range of substances, including glucose, amino acids, vitamins, electrolytes and 
peptides (Saunders et aI., 1999). Further information regarding the structure and 
function of the BBB can be found in Chapter 1. 
The BBB is largely resistant to changes in permeability, but there are situations where 
the function of the BBB may become compromised. A number of physiological 
disturbances have been demonstrated to result in BBB dysfunction, including 
bacterial and viral infections (Chaudhuri, 2000), brain tumours, stroke and traumatic 
brain damage (Greenwood, 1991) and the extreme stress of warfare (Hanin, 1996). 
Either acute or chronic changes to the permeability of this barrier may allow the entry 
or exit of species that can affect the metabolism of the brain and consequently 
influence a wide range of homeostatic mechanisms. Additionally, changes in BBB 
permeability associated with disorders mentioned above may result in secondary 
neuronal damage, thus further complicating the condition. Paradoxically, the opening 
of the BBB is desirable in the treatment of some conditions to allow the delivery of 
therapeutic agents into the CNS that would typically not cross the intact BBB 
(Rapoport, 2000). 
There is some evidence that prolonged exercise may lead to increased BBB 
permeability. Animal studies have established that the BBB can be widely disrupted 
following 30 minutes forced swimming exercise (Sharma et aI., 1991; Sharma et aI., 
1996). These changes were found to be relatively acute, with normal BBB function 
restored 2 hours after the end of exercise. A number of physiological responses 
occurring during prolonged exercise may potentially lead to a change in BBB 
function, with the development of hyperthermia (Sharma and Dey, 1987; Wijsman 
and Shivers, 1993), an upregulation in central serotonin synthesis (Sharma et aI., 
1991; Sharma et aI., 1996), increased circulating ammonia concentrations (Mans et 
aI., 1983) and an increased production of pro-inflammatory cytokines (de Boer and 
Breimer, 1998) all suggested as possible factors contributing to this response. 
At present, it is not clear how an increase in BBB permeability may influence 
exercise. Some increase in the exchange of substances across the barrier is probably 
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desirable during exerCise, to facilitate the transport of metabolites and other 
substances into the CNS when cerebral blood flow is elevated. However, a marked 
disturbance in BBB function during exercise may adversely affect normal brain 
function and contribute to the development of central fatigue by altering the transport 
kinetics of neurotransmitter precursors (Chaouloff, 1997) or allowing the 
accumulation of unwanted molecules in the CNS (Shivers and Wijsman, 1998). 
An increase in the permeability of the BBB can result in a detectable leakage of 
substances from the blood into CNS. This forms the basis of many conventional 
methods employed to monitor BBB integrity, with the accumulation of plasma 
proteins (e.g. albumin) in the brain and cerebrospinal fluid (CSF) used as an indicator 
of changes in BBB permeability using lumbar puncture and tracer-imaging 
techniques. The possibility that CNS-specific proteins may breach the BBB in areas 
of dismption and leak into the peripheral circulation has also been recently 
considered. Kapural and colleagues (2002) proposed that the appearance of CSF-
specific proteins, in particular SI OOb, in the circulation might be used as a relatively 
non-invasive peripheral marker of BBB function. 
S 100b is a low molecular weight (21 kDa) calcium-binding protein expressed 
predominantly within the CNS by astrocytes and Schwann cells. While the precise 
function of SI OOb within the CNS is not well understood at present, it is thought to 
play roles in the modulation of intracellular signal transduction, neuronal 
development, and cerebral energy metabolism (Zimmer et aI., 1995). It is typically 
found in low concentrations in the semm of healthy individuals, with a CSF to semm 
concentration ratio of approximately 18 : I (Reiber, 2001), thus BBB opening would 
be expected to significantly elevate semm concentrations (Kapural et aI., 2002). S 100 
proteins are cleared from the peripheral circulation by the kidneys and appear in the 
urine, with a semm half-life of around two hours (Ali et aI., 2000). As brain trauma is 
known to result in a marked elevation in CSF SI OOb concentrations and damage to the 
brain is typically accompanied by a breakdown in barrier function (Marchi et aI., 
2003), semm SI OOb has been widely employed in a clinical setting as a peripheral 
marker of neuronal damage. The application ofSl00b as a peripheral marker of brain 
damage and BBB disruption is discussed in detail in Chapter 1. 
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The aim of the present investigation was to determine whether a combination of water 
immersion and prolonged exercise in temperate and warm environmental conditions 
results in a change in circulating concentrations of serum SI OOb. As the development 
of whole-body hyperthermia was hypothesised to increase BBB permeability pre-
exercise water immersion was included to accelerate the change in core temperature 
during the warm trial. 
7.3 - Methods 
Subjects. Seven healthy males (age 25.7 ± 5.0 y, height 1.76 ± 0.08 rn, mass 77.1 ± 
5.0 kg, VO, peak 4.1 ± 0.2 L.min·l) were recruited to take part in this study. All 
subjects were taking part in regular endurance exercise, but were not accustomed to 
exercise in a warm environment at the time of the study. Prior to volunteering to 
participate all subjects received written details outlining the nature of the study. 
Following any questions regarding the protocol, a written statement of consent was 
signed. The protocol described in this Chapter received approval from the 
Loughborough University Ethics Board. 
Experimental protocol. All subjects completed a preliminary test to determine peak 
oxygen uptake (VO, peak), a familiarisation trial and 2 experimental trials. The 
preliminary test is described in Chapter 2, and was used to determine the power 
output required to elicit 60 % VO, peak. The familiarisation trial mirrored exactly the 
warm trial and was undertaken to ensure the subjects were accustomed to the protocol 
and environmental conditions employed throughout the investigation. Experimental 
trials were completed under either temperate (Tmp) or warm (Wrm) conditions. The 
experimental trials were administered in a randomised order separated by at least 7 
days to minimise the development of heat acclimation. Instructions for the 
standardisation of pre-trial dietary and physical activity conditions are outlined in 
Chapter 2. 
All experimental trials commenced in the morning following an overnight fast, other 
than the ingestion of -500 mL of plain water at least 90 minutes before the start of the 
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trial. Upon arrival in the laboratory, a rectal thennister was positioned by the subject 
10cm beyond the anal sphincter. Temperature thennisters were attached to the skin 
surface at four locations (chest, tricep, thigh, calf) and a heart rate telemetry band was 
positioned. Post-void, nude body mass was detennined after positioning of the probes 
to allow ease of measurement following water immersion. Subjects were seated for 15 
minutes in a comfortable environment (24 - 26 QC) with one hand immersed in wann 
water (42 QC) for 10 minutes to enable arterialised venous blood to be drawn. A 21 g 
cannula was introduced into a superficial foreann vein to enable repeated blood 
sampling whilst at rest and during exercise. Two resting 7.5ml blood samples were 
drawn (-5 and 0 min), and baseline measurements of temperature and heart rate (HR) 
were made at 5 minute intervals. 
Subjects then entered a water tank and sat for 30 minutes immersed to the neck with 
the exception of the cannulated foreann. Water temperature was maintained at either 
35 ± 0.1 QC or 39 ± 0.1 QC in the temperate and wann trials respectively. Core and 
skin temperatures and heart rate were recorded at 5 minute intervals during 
immersion, and the subject's perceived thennal stress was assessed every 10 minutes. 
During the final minute of water immersion a blood sample was drawn (post-Im), 
after which the subject left the water tank and towelled dry. Nude body mass was then 
re-measured to detennine sweat losses occurring during the period of immersion. 
Subjects then dressed in shorts and shoes. 
Subjects entered a climatic chamber maintained at either 18.3 ± 1.8 QC (Tmp trial) or 
35.0 ± 0.3 QC (Wnn trial) and began a bout of cycle exercise (Gould Corival 300, 
Groningen, Holland) corresponding to 60 % VO, peak for 60 minutes. During both 
trials the relative humidity was 60 ± 5 %. The time between leaving the water tank 
and commencing exercise in the climatic chamber was around 5 minutes. Blood 
samples (7.5 mL) were drawn during exercise at 15 minute intervals. Throughout 
exercise core and skin temperatures and heart rate were recorded every 5 minutes. 
Ratings of perceived exertion and thennal stress were obtained at 10 minute intervals. 
Expired gas was collected and analysed at 20 minute intervals using the Douglas bag 
method. These data were used to estimate rates of substrate oxidation and energy 
expenditure. In accordance with local ethics guidelines, trials were prematurely 
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stopped if a subject's rectal temperature reached 40.0 °C. Following the cessation of 
exercise, subjects were returned to a comfortable environment where recovery was 
monitored for 15 minutes and a post-exercise body mass was measured. 
Blood handling and analysis. Blood samples collected throughout the experimental 
protocol were drawn into dry syringes with 2.5 mL dispensed into tubes containing 
K2EDTA and the remaining 5 mL into plain tubes. Percentage changes in blood, 
plasma and red cell volumes relative to the second resting sample were determined 
using haemoglobin and spun packed cell volumes. Deproteinised whole blood was 
used for determination of blood glucose (God-PAP, Randox, Co.Antrim, UK) and 
lactate concentrations (Maughan, 1982). The remaining EDTA-treated blood was then 
spun to yield plasma and stored frozen at -20°C for the analysis of FFA (Roche 
Diagnostics, Mannheim, Germany). The 5 mL sample added to a plain tube was kept 
on ice until the end of each trial before being centrifuged to yield serum. One aliquot 
of serum was kept frozen at -20°C for the analysis of SI OOb using a commercially 
available enzyme-linked immunosorbant assay (ELISA; Sangtec Medical, Bromma, 
Sweden). The second aliquot was refrigerated at 4 °c and used for the determination 
of serum electrolytes: serum Na+ and K by flame photometry (Coming 410C, New 
York, USA), cr concentrations were obtained through coulometric titration (Jenway 
PCLM 3, Essex, UK) and osmolality by freezing point depression (Gonotec Osmomat 
030, YS!, Farnborough, UK) within 7 days of each trial. 
7.4 - Results 
One subject was prematurely stopped due to a high core temperature after 52 minutes 
exercise during the Wrm trial in accordance with local ethics guidelines. The final 
exercise blood sample was drawn at this point and the recovery was monitored as 
usual. This subject's data were included in all analyses outlined in this Chapter. 
Changes in serum S 100b are presented in Figure 7.1. Serum concentration of SI OOb 
was not different at rest between trials, with values of 0.06 ± 0.04 /lg.L·! and 0.07 ± 
0.05 /lg.L·! measured in the Tmp and Wrm trials respectively (p = 0.372). A 2.6-fold 
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increase in SI OOb was apparent following water immersion and prolonged exercise in 
the Wrm trial (+0.12 ± 0.10 Ilg.L·I; P = 0.02), with no change apparent after the Tmp 
trial (P = 0.238). Two subjects who experienced no change in serum SI OOb in either 
trial were primarily responsible for the large variation SI OOb observed following 
exercise. 
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Figure 7.1: Serum S100b at rest (0) and at the end of exercise (Ex60) in the Tmp and 
Wrm trials. b denotes a significant difference from the 0 time point in the Wrm trial 
(P < 0.05). * (P<0.05) denotes a significant difference between the Tmp trial and the 
corresponding time point in the Wrm trial. 
Expired gas data collected during exercise are presented in Table 7.1. Exercise V0 2 
was elevated in the Wrm trial compared to values during the Tmp trial (P = 0.049), 
but post-hoc analysis did not identify a difference at any time point. A progressive 
reduction in RER was apparent during the Tmp trial, reaching significance at the end 
of exercise (P = 0.042). No change in RER was observed during the Wrm trial (P = 
0.567), but it was not different from the Tmp trial at the end of exercise (Tmp 0.87 ± 
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0.02, Wnn 0.92 ± 0.07; P = 0.151). Rates of CRO (p = 0.294) and fat (P = 0.943) 
oxidation were not different between trials. 
Table 7.1: Oxygen uptake, RER, CRO and fat oxidation during exercise in the Tmp 
and Wnn trials. a and b denote a significant difference from the 20 minute time point 
in the Tmp and Wnn trials respectively (p < 0.05). 
20 40 60 
\T02 (L.min·l) Tmp 2.29 ± 0.22 2.35 ± 0.20 2.30 ± 0.20 
Wnn 2.36 ± 0.15 2.46±0.13 2.36 ± 0.29 
RER (no units) Tmp 0.91 ± 0.03 0.90 ±0.03 0.87 ± 0.02 a 
Wnn 0.90 ± 0.01 0.89 ± 0.04 0.92 ± 0.07 
CRO Oxidation (g.min·1) Tmp 2.18 ± 0.38 2.14 ± 0.27 1.75 ± 0.28 
Wnn 2.09 ± 0.16 2.15±0.51 2.33 ± 0.65 
Fat Oxidation (g.min·1) Tmp 0.33 ± 0.15 0.38 ± 0.14 0.50 ± 0.07 
Wnn 0.40 ± 0.06 0.43 ± 0.16 0.39 ± 0.21 
Core temperature at rest was not different between trials (P = 0.253; Figure 7.2A). 
Water immersion produced an increase in core temperature during the Wnn trial. In 
contrast, no change in core temperature was observed during water immersion in the 
Tmp trial. Exercise produced a marked increase in core temperature in both trials, 
with a plateau apparent after 30 minutes in the Tmp trial compared to a near linear 
increase in the Wnn trial. Core temperature was elevated by 2.1 ± 0.5 °C to 39.5 ± 0.3 
°C at the end of exercise in the Wnn trial compared to a 0.9 ± 0.2 °C increase during 
the Tmp trial (P < 0.001). There was no apparent association between the change in 
S100b and the change in core temperature, with correlation coefficients calculated as 
-0.318 (P = 0.486) for the Tmp trial and -0.021 (P = 0.965) for the Wnn trial. 
Weighted mean skin temperature was different between trials throughout the period of 
water immersion, during exercise and the recovery (P < 0.001; Figure 7.28). 
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Figure 7.2: Change in core (A) and weighted mean skin (B) temperature at rest, 
during water immersion and exercise. a and b denote a significant difference from the 
pre value in the Tmp and Wrm trials respectively (P < 0.05). * (P < 0.05) and ** 
(P < 0.01) denote a significant difference between the Tmp trial and the 
corresponding time point in the Wrm trial. 
Body mass loss during the experimental protocol was greater in the Wrm than in the 
Tmp trial (P < 0.001). Thirty minutes immersion in water maintained at 35 QC (Tmp 
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trial) produced no change to body mass, whereas subjects lost 0.46 ± 0.17 kg during 
Wrm trial (P = 0.001). At the end of exercise body mass losses of 0.70 ± 0.14 kg and 
1.79 ± 0.35 kg were recorded in the Tmp and Wrm trials respectively (P < 0.001). 
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Figure 7.3: Heart rate at rest, during water immersion and exercise. a and b denote a 
significant difference from the Pre value in the Tmp and Wrm trials respectively 
(P < 0.05). * (P < 0.05) and ** (P < 0.01) denote a significant difference between the 
Tmp trial and the corresponding time point in the Wrm trial. 
Heart rate was significantly influenced by the environmental conditions (P < 0.001; 
Figure 7.3). Warm water immersion resulted in a marked elevation in HR above the 
Tmp trial, with this difference maintained throughout exercise and the recovery. Heart 
rate at the end of exercise in the Tmp trial was 138 ± 8 beat.min'l compared to 174 ± 
I1 beat.min'l during the Wrm trial (P < 0.001). 
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Figure 7.4: Rating of perceived exertion during exercise. a and b denote a significant 
difference from the Ex 1 0 min value in the Tmp and Wrm trials respectively 
(P < 0.05). * (P < 0.05) and ** (P < 0.01) denote a significant difference between the 
Tmp trial and the corresponding time point in the W rm trial. 
Throughout the Wrm trial RPE was elevated above the Tmp trial (P < 0.001; Figure 
7.4). Perceived exertion increased with time during both trials, reaching values of 
12 ± 0 and 16 ± 2 in the Tmp and Wrm trials respectively. Perceived thermal stress 
was relatively stable during the Tmp trial, with little change apparent during water 
immersion or exercise (Figure 7.5). In the Wrm trial the subjects' perceived thermal 
discomfort progressively increased and was persistently higher than values obtained 
in the Tmp trial (P < 0.001). 
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Figure 7.S: Perceived thermal stress during water immersion and exercise. a and b 
denote a significant difference from the Im I 0 value in the Imp and Wrm trials 
respectively (P < 0.05). * (P < 0.05) and ** (P < 0.01) denote a significant difference 
between the Imp trial and the corresponding time point in the Wrm trial. 
Ihe blood glucose and lactate response to the experimental trials are presented in 
Figure 7.6. Blood glucose concentrations were not different at rest between conditions 
(P = 0.457) and at no point during either the Imp (P = 0.097) or Wnn (P = 0.171) trial 
were blood glucose concentrations different from resting levels. Throughout exercise 
in the Wrm trial, blood glucose was significantly elevated above corresponding values 
in the Imp trial. A 30 minute period of water immersion did not influence blood 
lactate concentrations. Lactate concentrations were elevated above rest during 
exercise in both trials and maintained significantly higher during the Wnn trial 
(P < 0.001). 
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Figure 7.6: Blood glucose (A) and lactate (B) concentrations at rest, during water 
immersion and exercise. a and b denote a significant difference from the -5 min value 
in the Tmp and Wrm trials respectively (P < 0.05). * (P < 0.05) and ** (P < 0.01) 
denote a significant difference between the Tmp trial and the corresponding time 
point in the Wrm trial. 
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Plasma FFA concentrations are shown in Figure 7.7. There was no difference in 
plasma FFA at rest between trials (P = 0.459). While FFA concentrations did not 
change significantly during exercise, there was a marked increase apparent after 15 
minutes recovery with this response more pronounced in the Wrm trial. 
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Figure 7.7: Plasma free-fatty acid concentration at rest, during water immersion and 
exercise. a and b denote a significant difference from the ImlO value in the Tmp and 
Wrm trials respectively (P < 0.05). * (P < 0.05) and ** (P < 0.01) denote a significant 
difference between the Tmp trial and the corresponding time point in the Wrm trial. 
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Table 7.2: Serum sodium (Na+; mmolrl), potassium (K+; mmoI.L-1), chloride (er; 
mmoI.L-1) and osmolality (Osm; mOsmol.kg-l ) at rest, following water immersion and 
during exercise. a and b denote a significant difference from the Pre value in the Tmp 
and Wrm trials respectively (P < 0.05). * (P < 0.05) and ** (P < 0.01) denote a 
difference between the Tmp and the corresponding time point in the Wrm trial. 
Pre Post-Im ExlS Ex30 Ex4S Ex60 ReelS 
Na+ 
Tmp 141 ± 141 ± 142 ± 143 ± 142 ± 143 ± 142 ± 3 2 3 3 2 2 2 
Wrm 140± 141 ± 142 ± 143 ± 143 ± 142 ± 141 ± 2 2 1 2 2 2 2 
K+ 
Tmp 5.0± 4.9± 5.5 ± 5.8 ± 5.5 ± 5.7 ± 4.7 ± 0.2 0.4 0.2 " 0.6 0.2 0.3 0.4 
Wrm 5.1 ± 5.1 ± 5.8 ± 5.9 ± 6.0 ± 6.0 ± 5.0 ± 0.3 0.3 0.4 bO 0.4 b 0.3 bOO 0.4 b 0.6 
er Tmp 105 ± 105 ± 107± 107 ± 107 ± 107 ± 106 ± 2 2 2 2 2 2 2 
Wrm 105 ± 106± 107± 106 ± 108 ± 107 ± 105 ± 1 1 1 2 2 2 3 
Osm Tmp 290± 291 ± 297± 296± 299± 297 ± 293 ± 3 2 4" 4" 5" 4" 2 
Wrm 289± 292 ± 296± 300± 300± 302 ± 298± 4 2 3 b 5 b 5 b 4 b 3" 
The environmental conditions did not alter the serum Na+, er or osmolality response 
to the experimental protocol (Table 7.2). Serum K+ during exercise in the Wrm trial 
was elevated above corresponding values in the Tmp trial (P = 0.004). Serum Na+ did 
not change throughout the experimental protocol in either the Tmp or Wrm trial. 
Serum K+ and osmolality were significantly increased above resting values during 
exercise in both experimental trials. 
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Table 7.3: Percentage change in blood (BV), red cell (CV) and plasma (PV) volumes 
relative to the -5 min value. a and b denote a significant difference from the -5 min 
time point in the Tmp and Wrm trials respectively (p < 0.05). * (P < 0.05) and ** 
(P < 0.01) denote a significant difference between the Tmp trial and the corresponding 
time point in the Wrm trial. 
Pre Post-I m Ex15 Ex30 Ex45 Ex60 Reel 5 
BV Tmp 1.1± 5.2 ± -4.5 ± -5.2 ± -5.5 ± -6.1 ± -1.6 ± 0.7 1.5" 0.7 a 0.5 " 0.6 " 0.7 " 1.3 
Wrm 0.4± 1.7± -5.1 ± -5.7 ± -6.0± -6.1 ± -3.S ± 1.4 2.1 ** 0.7 b O.S b 0.9 b LOb 1.1 b** 
CV Tmp 0.2 ± 0.2± -1.0 ± -1.4 ± -2.0± -2.7± -1.1 ± 1.2 1.4 O.S 1.4 2.0 1.5 1.9 
Wrm 0.1 ± -1.4 ± -2.1 ± -2.7 ± -3.1 ± -3.0± -2.6 ± 1.7 2.9 2.0 1.5 2.2 2.0 3.0 
PV Tmp I.S ± 9.1 ± -7.2 ± -7.6 ± -S.1 ± -S.5 ± -2.0 ± 1.3 3.2 " 1.3" 1.2 " O.S" 1.2" 1.9 
Wrm 0.6 ± 4.0 ± -7.S ± -S.3 ± -S.9 ± -S.9± -5.3 ± I.S 4.5 ** 2.3 b LOb 2.0 b 1.2 b 2.4 b 
Percentage changes in blood volume were different between trials (P = 0.039), with 
post-hoc analysis identifying a larger change in the Wrm trial following water 
immersion and the post-exercise recovery only (Table 7.3). No differences in blood 
volume were apparent whist at rest or during exercise. Percentage changes in red cell 
and plasma volumes were not different between trials. The experimental protocol 
produced a fall in blood and plasma volumes during both trials, with a marked 
reduction apparent from the first exercise blood sample (Ex 15). There was no further 
change in blood or plasma volume throughout exercise. 
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7.5 - Discussion 
Exercise-induced hyperthennia has been suggested to result in a reduction in 
motivation and drive to continue exercise, and this may to some extent explain the 
reduction in prolonged exercise capacity apparent when ambient temperatures are 
high (Nielsen, 1992). Recent work has demonstrated that hyperthermia results in a 
reduction in sustained maximal muscle activation (Nybo and Nielsen, 200Ia), altered 
brain activity (Nielsen et aI., 2001) and elevated perceived exertion (Nybo and 
Nielsen, 200Ib), but the underlying neurobiological mechanism(s) responsible for 
these changes are not clear. The present study examined the possibility that BBB 
penneability may be altered following water immersion and exercise in warm 
conditions. 
The main observation to arise from the present study was the marked elevation in 
serum SI OOb following exercise in a wann environment. This response was not 
apparent following exercise in temperate conditions. Increased serum concentrations 
of SI OOb have been reported following osmotic opening of the BBB (Kapural et aI., 
2002), with the appearance of this CNS-specific protein in the peripheral circulation 
up to serum concentrations of 0.34 Ilg.L-1 proposed as a peripheral marker of BBB 
penneability (Marchi et aI., 2003). A small increase in BBB penneability may be 
beneficial to brain metabolism during exercise, facilitating the exchange of substances 
when cerebral blood flow is increased. However, a marked change to BBB integrity 
may affect nonnal brain function and influence the development of central fatigue 
during prolonged exercise by altering the transport kinetics of neurotransmitter 
precursors (Chaouloff, 1997) or allowing the accumulation of unwanted substances in 
the CNS (Shivers and Wijsman, 1998). 
Previous reports of changes in BBB penneability with exercise have employed a 
forced swimming model in rats (Sharma et aI., 1991; Sharma et aI., 1996). The 
increased permeability reported in these studies was only observed in young rats « 10 
weeks), with no change apparent in older animals (> 30 weeks). The BBB is a 
dynamic structure capable of adapting to repeated exposure to hyperthennia and other 
physiological stresses, with conditioning enabling the barrier to behave nonnally 
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(Shivers and Wijsman, 1998). In the present investigation no association was apparent 
between changes in serum S100b and the age of the subjects (r = -0.04, P = 0.939), 
but this was an homogenous group. Forced swimming places an animal under severe 
stress and has been associated with marked alterations to serotonin and dopamine 
metabolism, the appearance of haemorrhagic spots on the wall of the stomach and the 
excretion of faecal pellets (Sharma et aI., 1996). It is important to note that the 
breakdown in BBB permeability reported in the series of studies by Sharma and 
colleagues was particularly severe and widespread, with the extravasation of an 
albumin-tracer complex (Evans blue and 13I I_sodium) into the brain. Any change in 
BBB permeability in humans occurring during exercise is unlikely to be as dramatic. 
While it is accepted that the BBB integrity can be altered by a wide range of 
physiological disturbances, the molecular and cellular mechanisms behind these 
changes in vivo are not clear at present (Gloor et aI., 2001). Factors that may be 
important in changes to BBB permeability during exercise in a warm environment, 
include the development of hyperthermia (Sharma and Hoopes, 2003; Shivers and 
Wijsman, 1998), changes to central serotonergic neurotransmission (Sharma et aI., 
1991; Sharma et aI., 1996), hyperammonaemia (Mans et aI., 1983) and an 
upregulation in pro-inflammatory cytokine production (de Boer and Breimer, 1998). 
Prolonged exposure to physiological and psychological stress has been demonstrated 
to result in widespread BBB disruption in humans (Hanin, 1996). The data collected 
during the present study (RPE, perceived thermal stress, heart rate) suggest subjects' 
found the warm trial significantly more difficult to complete. It appears likely that the 
stress encountered during the temperate trial may have been insufficient to produce a 
marked change in BBB function. 
Whole-body hyperthermia induced by prolonged exposure to passive heat stress has 
been demonstrated to result in impaired BBB integrity in rats (Sharma and Dey, 1987; 
Wijsman and Shivers, 1993), but no change was reported in a study using dogs 
(Katsumura et aI., 1995). The apparent difference in BBB response between these 
species is not clear, but may relate to methodological differences. In the present study 
the Wrm trial resulted in a marked and sustained increase in core (rectal) temperature, 
with levels elevated above 39 QC during the final 25 minutes of exercise and 
throughout the recovery period, compared to a mean core temperature of 38.3 QC at 
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the end of exercise in the Tmp trial (Figure 7.2A). Additionally, brain temperature, a 
more representative measure of the thermal load placed on the brain capillary 
network, is thought to be persistently maintained at least 0.2 QC above core 
(esophageal) temperature during exercise in a warm environment (Nybo et aI., 2002). 
The failure to observe a significant relationship between changes in S 100b and core 
temperature was unexpected, but was largely due to 2 subjects failing to display any 
change in serum SI OOb despite a marked increase in core temperature. 
It has been suggested that serotonin may be important in mediating changes in BBB 
integrity during both exercise and exposure to hyperthermia (Sharma and Hoopes, 
2003), with the administration of p-chlorophenylalanine (a tryptophan hydroxlase 
inhibitor) reported to prevent exercise-induced BBB breakdown (Sharma et aI., 1996). 
Serotonin is a potent vasoactive agent, known to act on both central and peripheral 
blood vessels (Cohen et aI., 1996). While there is some limited evidence that 
serotonergic neurotransmission is increased during exercise in a warm environment 
(Pitsiladis et aI., 2002), this is not supported by data examining cerebral tryptophan 
uptake using arterial-venous difference across the brain (Nybo et aI., 2003). This does 
not discount a role for serotonin in mediating exercise-induced changes in BBB 
function, but it is likely that a complex interaction of neuromodulators is involved in 
permeability control during exercise. 
In contrast to previous work conducted by Galloway and Maughan (1997), VO, was 
significantly elevated during exercise in a warm environment (Table 7.1), but similar 
findings have been previously reported (Fink et aI., 1975). It is widely accepted that 
exercise in a warm environment is associated with an increased reliance on CHO 
utilisation, resulting from an increased sympatho-adrenal response (Febbraio, 2001). 
While rates of CHO oxidation estimated from expired gas failed to support this 
suggestion, there was a tendency for CHO utilisation to be elevated above the Tmp 
condition by the end of exercise in the Wrm trial. 
The reduced temperature gradient between the skin and the ambient air in the Wrm 
trial would be expected to result in an increased skin blood flow and a greater 
dependence on evaporative heat loss (Rowell, 1974). Heart rate was clearly elevated 
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throughout the period of water immersion and during exercise in the Wrm trial when 
compared to the Tmp trial, supporting this suggestion. The marked difference in body 
mass losses experienced between trials indicate sweat production was increased. No 
differences in blood and plasma volume changes during exercise were apparent 
between trials despite the marked differences in sweat losses. These data suggest that 
a greater proportion of the fluids lost during the warm trial were likely to have been 
derived from other vascular compartments, including the interstitial and intracellular 
water compartments to maintain blood volume (Costill et aI., 1976; Galloway and 
Maughan, 1997; Nose et aI., 1988). 
While SI OOb has been widely employed in a clinical setting as a peripheral marker of 
brain damage and more recently BBB disruption, it is important to consider the 
potential limitations of this technique. In a similar manner to the use of plasma 
prolactin as a marker of serotonergic neurotransmission, the measurement of a 
peripheral marker is indirect and may not accurately reflect changes occurring within 
the CNS. Kanner and colleagues (2003) have reported a strong association between 
the extent and time-course of BBB disruption measured using gadolinium-enhanced 
MRI and changes in serum SI OOb, supporting the use of this marker as an effective 
peripheral marker of BBB permeability. While the beta subunit of this protein is 
highly specific to the CNS (Ali et aI., 2000), it has been found to be expressed in 
small quantities in peripheral tissues including bone, heart and adipose tissue (Zimmer 
et aI., 1995). Recent work suggests that SI OOb is liberated into the circulation only 
when significant trauma occurs to these tissues (Anderson et aI., 2001; Pelinka et aI., 
2003). Additionally, potentially small openings in the BBB may not allow SI OOb to 
leak into the peripheral circulation. Thus, it is possible that subtle changes in BBB 
permeability may not be detected using this technique. 
The present study has demonstrated that serum SI OOb is elevated following prolonged 
exercise in a warm environment, suggesting that BBB permeability may be altered. 
Previous animal studies have also observed a marked increase in BBB permeability 
following forced swimming exercise. The development of hyperthermia, an 
upregulation in central serotonin synthesis, increased circulating ammonia 
concentrations and an increased production of pro-inflammatory cytokines has all 
been suggested as possible factors contributing to this response. These findings may 
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be important for two reasons: 1) a change in BBB integrity during exercise may 
disturb normal brain function and contribute to the development of central fatigue. 2) 
Serum SI OOb is now being employed as an index of brain trauma in individuals who 
suffer head injuries during sports (Mussack et aI., 2003; Otto et aI., 2000). Changes in 
the permeability of the BBB to this protein marker may give misleading results in 
exercising individuals. 
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8.1 - Background 
The capacity to perform prolonged exercise is significantly reduced when exercise is 
performed in a warm environment (Galloway and Maughan, 1997; Parkin et aI., 
1999). Additionally, distance covered during a 30 minute cycle time trial is also 
reduced when ambient temperature was increased from 23 to 32 QC (Tatterson et aI., 
2000). In contrast to temperate conditions, fatigue during exercise in high ambient 
temperatures does not appear to be adequately explained by the depletion of muscle 
glycogen, or by cardiovascular and fluid balance factors (Nielsen and Nybo, 2003; 
Strachan and Maughan, 2002), suggesting that fatigue may be mediated through 
mechanisms residing within the CNS. Recent studies have provided evidence that 
hyperthermia profoundly influences brain function during exercise, resulting in 
altered brain activity (Nielsen et aI., 2001), reduced voluntary activation of muscle 
during sustained contractions (Nybo and Nielsen, 200 I a) and an increased perception 
of effort (Armada-Da-Silva et aI., 2004; Nybo and Nielsen, 2001 b). At present the 
neurobiological mechanism(s) behind these changes are not apparent. There is limited 
evidence that serotonin may be important to the development of fatigue during 
prolonged exercise in a warm environment (Mittleman et aI., 1998; Pitsiladis et aI., 
2002), through the mechanism proposed by Newsholme and colleagues (1987). The 
aim of the work described in this thesis was to examine the possible roles of 
serotonergic and catecholaminergic neurotransmission and changes in BBB 
permeability in an attempt to further elucidate the role of the CNS in the development 
of fatigue during exercise in a warm environment. 
8.2 - Nutritioual manipulation of serotonin-mediated fatigue during exercise in a 
warm environment 
Since the proposal of the serotonin-based hypothesis of fatigue (Newsholme et aI., 
1987), a number of investigations have sought to manipulate central 
neurotransmission during prolonged exerCise through the provIsion of 
pharmacological agents and dietary supplements. Nutritional strategies employed 
have included the ingestion of amino acids (BCAA, TRP, TYR) or CHO to alter the 
cerebral uptake of neurotransmitter precursors. At present evidence for a benefit of 
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BCAA ingestion in temperate conditions is poor (Blomstrand et aI., 1995; Blomstrand 
et aI., 1997; Davis et aI., 1999; Hassmen et aI., 1994; Madsen et aI., 1996; Struder et 
aI., 1998; van Hall et aI., 1995). Differences in protocol (Davis and Bailey, 1997), co-
ingestion with CHO (Calders et aI., 1999) and the timing of pre-exercise BCAA 
ingestion may partially explain this failure to detect an ergogenic effect, but it is 
possible that the development of fatigue during prolonged exercise under temperate 
conditions is adequately explained by peripheral mechanisms of fatigue (e.g. muscle 
glycogen depletion). 
To date, only one published investigation has examined the effect of BCAA ingestion 
on prolonged exercise in a warm environment. Mittleman and colleagues (1998) 
reported a 14 % increase in exercise capacity following BCAA ingestion when 
exercise was performed at 34°C. In the absence of any significant peripheral effects, 
the findings are consistent with the hypothesis that the supplementation regimen 
limited the transport of TRP across the BBB and consequently attenuated the 
exercise-induced increase in serotonergic activity. The exercise intensity employed in 
this study was relatively low (40 % VO, max), resulting in little change to core 
temperature. It remains to be seen whether these positive findings can be reproduced 
when exercise is performed at higher intensity, resulting in greater heat production 
and the attainment of higher core temperatures. The aim of Chapters 3 and 4 was to 
further examine the effect of acute BCAA ingestion on prolonged exercise capacity in 
a warm environment. 
In contrast to previous findings (Mittleman et aI., 1998), but in agreement with a 
number of studies undertaken in temperate conditions (Blomstrand et aI., 1995; 
Blomstrmd et aI., 1997; Davis et aI., 1999; Galiano et aI., 1991; Madsen et aI., 1996; 
Struder et aI., 1998), the results of Chapters 3 and 4 fail to support the suggestion that 
BCAA ingestion delays fatigue during prolonged exercise. This occurred despite a 
marked reduction in the plasma concentration ratio of f-TRP to BCAA before and 
during exercise. The magrritude of this plasma amino acid response was similar to 
(Chapter 3), or greater than (Chapter 4) that observed by Mittleman and colleagues 
(1998). In accordance with Mittleman's findings, supplementation produced no effect 
on cardiovascular and thermoregulatory measures or perception of effort and thermal 
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stress. In addition, the ingested amino acids did not markedly alter blood glucose and 
lactate, or plasma FF A concentrations. Although plasma NH3 concentrations were 
elevated following BCAA ingestion throughout exercise in Chapter 4, the levels 
measured were not thought to be high enough to negatively influence cerebral or 
muscle metabolism (Gibala, 2001). As the first BCAA study (Chapter 3) employed a 
similar supplementation regimen and exercise was performed under comparable 
environmental conditions to this previous work, it is possible that the failure to 
observe any ergogenic benefit in the present study may have been related co-ingestion 
of BCAA with CRO and / or the relatively short duration of exercise 
The ingestion of CRO has been reported to independently limit the development of 
central fatigue by attenuating the exercise-induced increase in plasma FFA and f-TRP 
concentrations, consequently producing a dose-dependent suppression of the plasma 
concentration ratio of f-TRP to BCAA (Davis et aI., 1992). The Mittleman study used 
a polydextrose (a low-energy sugar substitute) placebo, whereas subjects in the 
present study ingested between 65 - 130 g CRO depending on exercise time. Despite 
this apparent difference between protocols, the plasma concentration ratio of f-TRP to 
BCAA during the placebo trials were remarkably similar, perhaps suggesting that the 
ingestion of this quantity of CRO was not sufficient to significantly alter circulating 
plasma amino acids. Although, plasma FF A concentrations at exhaustion in the 
present study were lower than those reported previously by Mittleman and co-workers 
(1998), possibly as a result of the shorter exercise duration and the ingestion ofCRO. 
Furthermore, the relatively short duration of exercise before fatigue (-60 minutes), 
may have been an important factor in the failure to observe a difference in exercise 
capacity. Recent evidence suggests that increased activity of the serotonergic 
neurones may only become important in the development fatigue when the duration of 
exercise is greater than two hours (Nybo et aI., 2003). This suggestion is partially 
supported by the observation that extracellular 5-RT concentrations were only 
elevated following 60 minutes treadmill exercise (Gomez-Merino et aI., 200Ia), but 
this delayed response was only when the animals were fed prior to exercise (Meeusen 
et aI., 1996). Time to fatigue in the study conducted by Mittleman et al. (1998) was 
between 130 and 170 minutes, compared to times of between 43 and 101 minutes 
recorded in Chapter 3. The increased exercise intensity resulted in a elevated heat 
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production and a significant elevation in core temperature resulting in a relatively 
short exercise time. 
To further investigate the influence of BCAA ingestion on the capacity to perform 
prolonged exercise in a warm environment, a second study was undertaken using a 
modified protocol to further explore the positive findings of Mittleman et al (1998). 
As a time delay may exist between changes in peripheral amino acid availability and 
the cerebral uptake of f-TRP (Curzon and Knott, 1974), the pre-exercise ingestion 
period was extended from 45 minutes (as employed in Chapter 3) to 120 minutes. By 
reducing the exercise intensity (to 50 % V0 2 peak) and ambient temperature (to 30 
QC) exercise time was significantly extended (placebo 103.9 ± 26.9 min; BCAA 111.0 
± 29.2 min; range 59 to 157 minutes). In addition, exercise was preceded by an 
exercise and dietary regimen designed to reduce glycogen availability and effectively 
simulate the metabolic conditions typically found late in exercise to accelerate 
changes in serotonergic neurotransmission. 
Again, the findings of this study fail to support an effect of BCAA ingestion in 
delaying fatigue during prolonged exercise in a warm environment, but there was 
some evidence of individual sensitivity to the supplementation. In the light of the 
results of Mittleman et al. (1998), it is not clear why no significant benefit was 
apparent in this second BCAA study (Chapter 4). While evidence for the involvement 
of central 5-HT in the development of fatigue during prolonged exercise in the heat is 
limited (Strachan, 2002), the results of Chapter 4 suggest that fatigue was delayed in 
some subjects following the supplementation regimen, whereas others exhibited little 
or no effect. The enhancement of exercise capacity in these individuals was greater 
than the calculated day-to-day variability in the exercise protocol (CV = 12.7 %). This 
may indicate that a degree of individual variation exists in the sensitivity to 
manipulation of central neurotransmission. Support for this suggestion is provided by 
recent work examining the cerebral balances of amino acid precursors during exercise 
(Nybo et aI., 2003). A net uptake of TRP across the brain following moderate-
intensity exercise was apparent in only 50 % of subjects, despite a marked elevation 
in plasma f-TRP. Additionally, it is recognised that platelet 5-HT transporter density 
(Strachan and Maughan, 1998; Struder et aI., 1999) and the prolactin response to a 
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buspirone challenge (Bridge et aI., 2003b; Jakeman et aI., 1994; Marvin et aI., 1998) 
vary widely between individuals. 
A major limitation when interpreting the findings of precursor loading / manipulation 
studies is the degree of uncertainty regarding the fate of cerebral uptake. This makes it 
almost impossible to evaluate whether the manipulations have produce the desired 
effect on the cerebral TRP balance and whether changes in precursor uptake translate 
into functional alterations to extracellular neurotransmitter release. While recent data 
from Nybo et al. (2003) failed to detect a difference in TRP uptake between 
environmental conditions this does not rule out a possible upregulation of the 
serotonergic system when exercising in a warm environment. The exchange between 
arterial and venous blood across the brain does not give an indication of rates of 
synthesis and the balance between monoamine storage and synaptic release, 
particularly as it is becoming clear that precursor availability is not the sole 
determinant of neurotransmitter synthesis (Bequet et aI., 2002; Cooper et aI., 2003). 
Although this work is novel and informative, it is important to note that these data are 
several steps removed from the site of action (5-HT neurons) resulting in conclusions 
based largely on a degree of speculation. This is a common feature of all central 
fatigue research (Davis and Bailey, 1997). 
The work described in Chapter 5 examined the magnitude and time-course of changes 
in plasma amino acids at rest following meals containing added CHO or fat. In 
contrast to a number of previous reports (Fernstrom et aI., 1975; Fernstrom and 
Wurtman, 1971; Pan et aI., 1982) both meals failed to significantly alter the plasma 
concentration ratio of f-TRP to BCAA or total-TRP to BCAA compared to pre-
ingestion values. It appears that the presence of a small quantity of protein in both 
meals limited any change to circulating concentrations of BCAA and TRP, although 
the protein content of the meals was significantly smaller than that administered in 
investigations examining the addition of protein to meals (Fernstrom and Wurtman, 
1972; Paul et aI., 1996). The ingestion of CHO-containing meals has been previously 
reported to alter mood and mental function (Spring et aI., 1986; Young, 1991), but in 
the light of the amino acid data, it is not surprising that the meals failed to alter 
subjective feelings of tiredness, alertness and concentration. 
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The effectiveness of nutritional strategies at altering central neurotransmission and 
consequently mood, mental function and perception of fatigue has been questioned. 
Fernstrom (2000) has suggested that dietary manipulation is unlikely to produce 
significant alterations to neurotransmission, particularly compared to the magnitude of 
change possible following the administration of pharmacological agents, including 
SSRls. Feeding studies in monkeys have demonstrated that a 13- to 26-fold change in 
the plasma concentration ratio of f-TRP to BCAA was necessary to induce a change 
in central serotonergic activity (Leathwood and F ernstrom, 1990). Clearly changes of 
this magnitude have not been possible with the strategies employed in Chapters 3, 4 
and 5 of this thesis, but it should be noted that these observations were primarily 
based on brain homogenate preparations. Pre-exercise infusion of valine (Gomez-
Merino et aI., 2001b) and TRP (Meeusen et aI., 1997) has been demonstrated to limit 
and amplify the exercise-induced increase in extracellular 5-HT concentrations 
respectively. The apparent discrepancy between these human and animal findings 
may be potentially explained by differences in the regulation of central 
neurotransmitter homeostasis between species. 
8.3 - Importance of catecholaminergic neurotransmission to exercise 
performance in a warm environment 
In a follow up to the studies presented in Chapters 3 and 4, the role of 
catecholaminergic neurotransmission in the development of fatigue during prolonged 
exercise was investigated. There appears to be a plethora of evidence accumulating to 
support the involvement of the catecholaminergic neurotransmitters in the fatigue 
process. Early animal studies suggest that prolonged exercise (Bailey et aI., 1992) and 
exposure to stress (Palkovits et aI., 1975) may partially deplete DA in some brain 
regions, potentially contributing to the development of fatigue (Davis, 2000). The 
attainment of high core temperatures has been associated with reduced motivation and 
drive to continue exercise (Bruck and Olschewski, 1987; Nielsen, 1992; Nielsen and 
Nybo, 2003) and a relationship between a measure of dopaminergic function and 
tolerance to exercise in a warm environment has been reported (Bridge et aI., 2003b). 
Additional support for an involvement of catecholamines in the development of 
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fatigue comes from studies investigating the effects of amphetamines on exercIse 
capacity (Chandler and Blair, 1980; Gerald, 1978). 
Chapter 6 examined the effect of an acute dose of bupropion, a dual DA / NA 
reuptake inhibitor, on the perfonnance of a preloaded time trial under temperate (18 
QC) and wann (30 QC) ambient conditions. Subjects completed the target amount of 
work 3.4 minutes quicker following the bupropion administration, representing a 9 % 
improvement in perfonnance. The failure to observe a perfonnance benefit at 18 QC, 
is consistent with the suggestion that central neurotransmission plays a limited role in 
the development of fatigue under temperate environmental conditions. 
The drug did not alter the cardiovascular or thennoregulatory response to exercise in 
the heat during the initial 60 minute bout of fixed-load exercise. As the time taken to 
complete the TT is directly related to the power output maintained during this period, 
it is clear that the drug enabled subjects to maintain a higher workload with no 
apparent difference in perceived exertion and thennal stress. This latter point is 
interesting as core temperature during the bupropion trial was significantly higher 
towards the end of the TT, almost certainly as a direct consequence of the elevated 
heat production. At the completion of the TT protocol, two (of nine) subjects attained 
a rectal temperature of 40.0 QC or greater during the placebo trial in the wann, 
whereas seven subjects breached this value when bupropion was administered. This 
could indicate that bupropion enabled subjects to push into a potential 'danger zone' 
without any negative feedback from the CNS. The mechanism behind the difference 
in core temperature apparent between treatments in temperate conditions is not clear 
at present. 
These findings appear to support the suggestion that increased catecholaminergic 
activity is important in the tolerance to exercise in a wann environment (Bridge et aI., 
2003b), and that the maintenance of low central ratio of 5-HT to DA is associated 
with feelings of arousal and motivation, consequently favouring increased 
perfonnance (Davis and Bailey, 1997). As serotonergic and catecholaminergic 
projections innervate areas of the hypothalamus, a decrease in the ratio ofS-HT to DA 
activity may be expected to delay fatigue when core temperature is elevated 
(Gandevia, 2001). Bupropion administration in the heat may have acted on central DA 
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and NA neurotransmission to maintain motivation and arousal, effectively dampening 
or overriding inhibitory signals arsing from the CNS to cease exercise due to 
hyperthermia. This enabled the subjects to continue to sustain a high power output 
despite approaching, and in some cases breaching, the critical core temperature 
proposed by Nielsen et al (1993). The concept of critical core temperature will be 
discussed in Section 8.5. 
The potential danger of this situation was apparent during the 1967 Tour de France 
cycle race, where the successful British cyclist Tom Simpson collapsed and died from 
heat-related illness on the Mont Ventoux climb after taking amphetamines to enhance 
his performance. This may be important as bupropion has an amphetamine-like 
structure, acting centrally through similar neurochemical mechanisms (e.g. inhibiting 
catecholamine reuptake), although at a lower potency. 
Exercise in the heat significantly increases plasma prolactin release (Bridge et aI., 
2003a; Pitsiladis et aI., 2002; Radomski et aI., 1998; Strachan, 2002), a response that 
was apparent in Chapters 4 and 6. As plasma prolactin has been widely employed as a 
peripheral index of central S-HT activity (Struder and Weicker, 2001; Van de Kar, 
1997), that has led to the suggestion that serotonergic activity may be upregulated 
under conditions of heat stress (Pitsiladis et aI., 2002). Recent evidence suggests that 
the regulation of prolactin release is complex, so this assumption may not be correct 
(Meeusen et aI., 2001; Piacentini, 2003). Given that the hypothalamus is the central 
regulator of both core temperature and pituitary hormone secretion, it has been 
suggested that an increase in brain temperature may directly result in the induction of 
hormone release during exercise (Radomski et aI., 1998). The present results appear 
to support this suggestion, with not only a progressive increase in plasma prolactin 
apparent throughout exercise at 30 QC, but also a significant increase at the end of the 
TT at 18 QC when core temperature was also elevated above 39.0 QC. Elevated mean 
skin temperature has also been proposed as a stimulus for prolactin release, modulated 
through peripheral temperature receptors (Bridge et aI., 2003a). In contrast to these 
findings plasma prolactin continued to increase throughout exercise under both 
temperate and warm conditions despite weighted mean skin temperature remaining 
relatively stable. 
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At present the central response to acute doses of drugs influencing central 
neurotransmission is not clear in humans; this is clearly an issue for all studies 
employing pharmacological agents to manipulate central neurotransmission. While 
there is good evidence from animal studies employing brain microdialysis to suggest 
that extracellular concentrations of both DA and NA are elevated following bupropion 
administration (piacentini et aI., 2003), the effects in humans may not be so clear cut 
particularly as the metabolism ofbupropion is different between rats and humans (see 
Chapter 6 for details). While there does not appear to be information regarding the 
acute effects of agents influencing DA and NA, evidence from clinical studies 
suggests that an acute dose of a 5-HT reuptake inhibitor (SSRI) may produce little 
change in extracellular neurotransmitter concentrations, due to a reduction in cell 
firing rate caused by autoreceptor-mediated feedback inhibition (Artigas et aI., 1996). 
This is reflected by the observation that between 4-6 weeks SSRI administration is 
typically required to observe a therapeutic benefit in depressive patients. However, at 
this stage it is not clear how combined exposure to exercise, heat stress and a 
pharmacological agent influences central neurotransmission through the control of 
neurotransmitter release, reuptake and metabolism. 
8.4 - BBB permeability during exercise 
The suggestion that the BBB may be compromised during prolonged exercise is not 
new. Work conducted by Sharma and colleagues (1991, 1996) demonstrated a 
transient breakdown in barrier function following 30 minutes of forced swimming in 
rats. This response was attributed to increased brain 5-HT, with the administration of 
agents to reduce serotonergic activity found to abolish this response. As strenuous 
exercise produces a widespread disturbance of physiological homeostasis, there are a 
number of factors that may contribute to a change in BBB permeability. These include 
the development of hyperthermia (Sharma and Dey, 1987; Wijsman and Shivers, 
1993), increased circulating ammonia (Mans et aI., 1983) and adrenaline (Abdul-
Rahrnan et aI., 1979) concentrations and the production of pro-inflammatory 
cytokines (de Boer and Breimer, 1998). At present the importance of changes in BBB 
permeability during exercise is not clear. A small increase in barrier permeability 
during exercise may be desirable to facilitate the transport of metabolites, such as 
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glucose and lactate, and other substances into the CNS when cerebral blood flow is 
elevated. However, a marked disturbance in BBB function during exercise may 
adversely affect normal brain function and contribute to the development of central 
fatigue by increased brain-blood interfacing. 
The work presented in Chapter 7 investigated changes in serum SI OOb following 
combined water immersion and prolonged exercise in temperate and warm 
environments. A significant elevation in serum SI OOb was apparent following 
exercise in the warm environment, with no such response apparent in the temperate 
trial. No subject exceeded a serum SI OOb concentration of 0.34 Ilg.L-1 at the end of 
exercise. This value was proposed as the maximal value to suggest BBB opening by 
Marchi and colleagues (2003), with levels greater than this associated with neuronal 
damage. In the light of the findings of Kapural and co-workers (2002), these data may 
indicate that BBB permeability is increased during exercise in the heat, potentially 
playing an important role in the mechanisms of fatigue that operate in prolonged 
exercise. Disturbance in BBB function is often associated with impaired brain 
function, potentially impacting on the operation of the organism as a whole (Sharma 
and Hoopes, 2003). A marked change in BBB permeability during exercise may limit 
an individual's capacity to perform prolonged exercise by modifying the transport 
kinetics of neurotransmitter precursors and other metabolites or allowing the 
accumulation of unwanted substances in the CNS. 
While serum SI OOb is now widely employed in a clinical setting as a diagnostic tool 
for the assessment of brain damage/injury (see Chapter I) and more recently BBB 
dysfunction (Marchi et aI., 2003), a number of factors must be first be considered 
when interpreting these data. There is the possibility that changes in serum levels of 
this protein may have arisen from extra-cerebral sources (e.g. bone and adipose 
tissue), although this is doubtful as it appears that significant tissue trauma is 
necessary for SlOOb to be liberated into the circulation (Anderson et aI., 2001; Pelinka 
et aI., 2003). As S 100 proteins are cleared from the peripheral circulation by the 
kidneys, with a serum half-life of around 2 hours (Ali et aI., 2000), the change 
observed following exercise may have resulted from reduced renal clearance. 
Prolonged exercise, in particular under conditions of heat stress, is associated with a 
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marked reduction in renal blood flow (Rowell, 1974), but there is some evidence that 
extraction of protein remains high during strenuous exercise (Castenfors et aI., 1967). 
Follow up studies may benefit from the measurement of urinary S 100b at rest and 
after exercise to confirm the effects of exercise on SI OOb clearance. Additionally, 
small openings in the BBB may not allow CNS-specific proteins to leak into the 
peripheral circulation. Thus, it is possible that subtle changes in BBB permeability 
may not be detected using this technique (Bailey et aI., 2004). 
Despite these considerations, serum SI OOb is now being employed as an index of 
brain trauma occurring during sporting competition (Mussack et aI., 2003; Otto et aI., 
2000). These results indicate that an increase in serum concentration SI OOb is 
apparent following exercise at high ambient temperatures, which could result in an 
incorrect assessment of brain trauma in exercising individuals. 
8.S - Evidence for critical core temperature 
Attainment of a critical core temperature has been suggested to result in a loss of 
drive to continue exercise, potentially serving as a CNS-mediated protective 
mechanism limiting further heat production (Nielsen et aI., 1993; Nielsen and Nybo, 
2003). Work conducted by Gonalez-Alonso et al. (1999) reported an inverse 
relationship between core temperature at the outset of exercise and time to exhaustion, 
with fatigue occurring when oesophageal temperature reached -40.0 QC. Additionally, 
exercising goats reduced their speed, or refused to move, when the brain temperature 
was increased to > 42 QC, when body temperature was maintained at 40 QC (Caputa et 
aI., 1986). While there appears to be good evidence in support of this hypothesis, 
some individuals fatigue during exercise in the heat long before attaining values of 
39.5 QC (Sawka et aI., 1992). During the studies reported in Chapters 3 and 4, there 
was a considerable variation in the rectal temperature at fatigue (38.6 - 40.1 QC) with 
good agreement apparent between the values attained in the placebo and BCAA trials. 
The well-trained cyclists recruited in the bupropion study (Chapter 6) reached 
temperatures of between 39.4 to 40.4 QC at the end of the TT. Some of the variation 
between studies may be attributed to the intimate knowledge of their upper limits in 
trained cyclists (Chapter 6) compared to the physically active volunteers studied in 
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Chapters 3 and 4. Differences in the protocol employed between studies may also 
account for some of this discrepancy. Motivation to continue exercise is different 
when there is a defined end-point to focus on (e.g. completion of a TT), compared to 
an open-ended test such as a fixed-intensity ride to volitional exhaustion. 
A wide variety of methods have been employed as an index of core temperature, 
including rectal, oesophageal, tympanic, and more recently the use of a telemetry pill 
(Moran and Mendal, 2002; Saltin and Hermansen, 1966). When considering the 
influence of hyperthermia on the CNS, brain temperature, particularly the temperature 
of the blood perfusing the anterior hypothalamus, is clearly the most important factor. 
Venous heat removal from the brain is reduced during exercise with hyperthermia 
(Nybo et aI., 2002). This coupled with an increased brain heat production has been 
demonstrated to result in an elevation in cerebral heat storage. This response was not 
altered by cooling of the head, despite this intervention reducing facial skin and 
tympanic temperatures. The results of this study suggest that brain temperature is 
thought to be maintained at least 0.2 QC above oesophageal temperature during 
exercise as a result of inadequate heat release. The exercise studies described in this 
thesis (Chapters 3, 4, 6 and 7) employed rectal temperature as an index of core 
temperature. This method is widely employed and has been demonstrated to give an 
accurate representation of the temperature of the body's core during prolonged 
exercise, despite a lag in response time (Moran and Mendal, 2002). Rectal 
temperature during exercise has been reported to be slightly higher (-0.1 QC) than 
oesophageal measures (Moran and Mendal, 2002; Saltin and Hermansen, 1966) and 
may therefore give a reasonable representation of brain temperature during sustained 
constant-load exercise, although the dynamics of change are expected to be markedly 
different. 
8.6 - Summary and conclusions 
The balance of evidence suggests that neurobiological mechanisms of central fatigue 
are not important in trained subjects during prolonged exercise in temperate 
conditions, with muscle glycogen depletion thought to limit exercise capacity. There 
is, however, some evidence that serotonin-mediated fatigue may be important in ultra-
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endurance events, where exercise is perfonned at a low intensity for many hours 
(Nybo et aI., 2003). This is not to suggest that the brain has no role in fatigue whilst 
exercising in temperate conditions. Psychology can influence exercise perfonnance 
and ultimately an individual has to make a conscious decision to cease exercise 
(Kayser, 2003). When exercise is perfonned in high ambient temperatures, the 
development of central fatigue is thought to be accelerated, leading to a loss of drive 
to continue (Bruck and Olschewski, 1987; Nielsen, 1992; Nielsen and Nybo, 2003). 
Exercise-induced hyperthennia has been demonstrated to reduce sustained muscle 
activation (Nybo and Nielsen, 2001a), alter brain activity (Nielsen et aI., 2001) and 
mcrease perceived exertion (Annada-Da-Silva et aI., 2004; Nybo and Nielsen, 
2001b). The studies contained in this thesis attempted to uncover some of 
neurobiological mechanisms behind these responses and to examine strategies to 
prolong exercise in a wann environment. 
The results of Chapters 3 and 4 fail to support the suggestion that BCAA ingestion 
before and during exercise can delay the development of fatigue m a wann 
environment. It is doubtful that a single neurotransmitter system IS uniquely 
responsible for the development of central fatigue as originally proposed by 
Newsholme and colleagues (1987). While 5-HT IS implicated in virtually all 
physiological and psychological processes, it is often found to be ultimately 
responsible for nothing (Jacobs and Azmitia, 1992). Its wide distribution throughout 
the brain and regular discharge pattern suggests that its importance lies in exerting a 
modulatory influence on other monoamine systems (Cooper et aI., 2003; Gandevia, 
2001), and in this way it may indirectly influence exercise perfonnance. 
Dopamine and noradrenaline play a crucial role in motor control, arousal and 
motivation and have been proposed to be important in fatigue (Davis and Bailey, 
1997) and the tolerance to exercise in wann conditions (Bridge et ai., 2003b). The 
results of chapter 6 suggest that these monoamine systems are important in the 
development of central fatigue during exercise in the heat, and may dampen inhibitory 
signals from the CNS to reduce heat production, allowing perfonnance to be 
maintained. On the basis of the present results and those of others (Bridge et aI., 
2003b) DA and NA are emerging as important mediators of central fatigue during 
prolonged exercise in the heat. 
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While mechanisms of fatigue involving central neurotransmission have been widely 
investigated in recent years, potential changes in BBB function during exercise have 
received relatively little attention. The appearance SI OOb, a CNS-specific protein, in 
the peripheral circulation has recently been explored as a peripheral marker of BBB 
integrity. Water immersion and exercise in warm conditions produced a marked 
increase in serum SI OOb, suggesting that BBB permeability may be increased 
(Chapter 7). It is important to recognise the limitations of this peripheral marker, and 
further work is required to clarify the significance of changes in circulating SI OOb 
during exercise. 
Attempts to simplify the complexity of the involvement of CNS in behavioural and 
physiological responses rarely meet with success (Femstrom et ai, 1983). 
Neurotransmitter systems acting within the CNS are not mutually exclusive and it is 
probable that a complex interaction between neurotransmitters and changes in BBB 
function, as well as factors not considered in this thesis such as brain glycogen 
depletion (Dalsgaard et aI., 2002; Nybo et aI., 2003), all contribute to the development 
of fatigue during prolonged exercise in a warm environment. 
Key points: 
1) In contrast to the findings of Mittleman and co-workers (1998), acute BCAA 
ingestion does not appear to influence exercise capacity in a warm 
environment. 
2) Acute bupropion administration improved exercise performance in the heat, 
with no effect evident in temperate conditions. This response was attributed to 
the maintenance of motivation to continue exercise despite the attainment of 
high core temperatures. 
3) Serum S 100b was increased following water immersion and exercise under 
warm conditions. These findings suggest that BBB permeability is disrupted, 
although there are a number of factors to consider when interpreting these 
results. 
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Appendix I - Data contained in figures throughout the 
thesis 
The data contained in this appendix is the numerical data presented in the figures 
displayed throughout the thesis. All data is presented at mean ± standard deviation 
unless otherwise stated. 
Chapter 3 - Branched-chain amino acid supplementation during 
prolonged exercise in a warm environment 
Figure 3.1: Individual exercise times to exhaustion (minutes) and percent changes in 
exercise capacity between the placebo and BCAA trials 
Subject Placebo BCAA 0/0 change 
60.6 62.4 2.9 
2 100.7 90.5 ·11.3 
3 51.7 55.0 6.0 
4 52.8 75.7 30.2 
5 53.0 53.2 0.4 
6 45.1 49.9 9.6 
7 75.9 72.2 -5.1 
8 46.7 43.4 -7.6 
Mean±SD 60.8 ± 18.8 62.8 ± 15.7 3.1 ± 13.0 
Figure 3.2: Plasma BCAA concentration ()lmoI.L-1) at rest and during exercise 
Placebo 
BCAA 
-45 
446 ± 120 
444 ± 128 
o 
422 ± 117 
1287 ± 252 
15 
370 ± 125 
984 ± 200 
30 45 Ex 
393± 120 354± 109 351 ±89 
1146±399 1231±407 1166±511 
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Figure 3.3: Change in core (Teor.) and weighted mean skin (Tskin) temperature eC) at 
rest and during exercise 
Pr. 5 10 15 20 25 30 35 40 45 Ex 
Too" Placebo 37.4 37.2 37.4 37.6 37.8 38.0 38.1 38.3 38.5 38.6 39.1 
±0.2 ±0.3 ±0.3 ±0.3 ±0.4 ± 0.4 ±0.4 ±0.4 ±0.4 ±0.4 ± 0.6 
BCAA 37.3 37.2 37.4 37.5 37.7 38.0 38.1 38.3 38.4 38.5 39.2 
± 0.3 ±0.3 ± 0.4 ±0.4 ± 0.4 ±0.5 ±0.4 ± 0.5 ± 0.5 ±0.4 ±0.6 
T5kill Placebo 32.9 34.6 35.5 36.1 36.3 36.5 36.7 36.9 37.0 37.2 37.5 
±1.1 ± 0.8 ±0.8 ± 0.7 ±0.6 ± 0.7 ± 0.7 ± 0.7 ± 0.8 ± 0.8 ±0.4 
BCAA 32.2 34.4 35.3 36.0 36.2 36.4 36.5 36.7 37.0 37.2 37.4 
±0.7 ±0.4 ± 0.6 ± 0.6 ±0.5 ± 0.5 ± 0.5 ±0.5 ±0.6 ±0.7 ±0.6 
Figure 3.4: The heart rate (b.min- I ) response at rest and during exercise in a warm 
environment 
Pre 5 10 15 20 25 30 35 40 45 Ex 
Placebo 61 135 143 146 155 159 163 168 172 171 182 
±9 ± 17 ± 17 ±17 ± 15 ±16 ±17 ±17 ± 18 ± 14 ±11 
BCAA 59 134 142 144 149 158 162 167 172 174 185 
±9 ± 14 ± 15 ± 15 ±16 ± 13 ±17 ± 17 ± 15 ± 17 ± 12 
Figure 3.5: Change in RPE and thermal stress during the placebo and BCAA trials 
10 20 30 40 Ex 
RPE Placebo 12 ± I 13 ± I 15 ± 2 16 ±2 19 ± I 
BCAA 12 ± I 13 ± I 14 ± I 15 ± 2 18 ± I 
TS Placebo 2±1 4±1 5±2 5 ±2 8 ± I 
BCAA 2±1 3±1 5±1 5 ± I 8±1 
l<"igure 3.6: Blood glucose (mmoI.L- I ) and lactate (mmoI.L- I ) concentrations at rest 
and during exercise. 
-45 0 15 30 45 Ex 
Glucose Placebo 5.6 ± 0.4 6.3 ± 0.8 3.7 ± 0.4 5.0 ± 0.8 6.0 ± 0.9 6.0 ± 0.9 
BCAA 5.5 ± 0.4 6.0 ± 0.7 3.6 ± 0.2 4.9 ± 0.4 5.5 ± 0.7 6.2 ± 1.1 
Lactate Placebo 1.2 ± 0.2 2.0 ± 0.2 3.3 ± 2.0 3.8 ± 2.0 3.2 ± 0.7 4.7 ± 2.4 
BCAA 1.0 ± 0.5 1.9 ± 0.3 3.2 ± 2.2 3.6 ± 2.2 3.4±1.4 4.5 ± 2.0 
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Chapter 4 - Branched-chain amino acid supplementation during 
prolonged exercise in a warm environment after a regimen 
designed to reduce muscle glycogen 
Figure 4.1: Individual exercise times to exhaustion (A; minutes) and percent changes 
in exercise capacity (B) between the placebo and BCAA trials. 
Subject Placebo BCAA % change 
106.7 106.3 -0.4 
2 88.4 109.9 24.3 
3 113.3 103.8 -9.2 
4 80.7 78.4 -2.9 
5 58.1 71.1 22.4 
6 123.6 144.5 16.9 
7 117.3 117.1 -0.2 
8 143.0 156.6 9.5 
Mean±SD 103.9 ± 26.9 111.0 ± 29.2 7.6 ± 12.6 
Figure 4.2: Plasma BCAA (mean ± SD; ~moI.L-I), f-TRP (median ± range; ~moI.L-I) 
concentrations at rest and during exercise. 
-120 -60 0 15 30 45 60 Ex 
BCAA Placebo 535 492 475 504 496 505 499 497 
± 128 ± 91 ± 91 ±87 ± 104 ± 124 ± 101 ± 84 
BCAA 531 1298 1601 1169 1211 1300 1454 1653 
± 117 ± 184 ± 185 ± 173 ± 207 ± 151 ± 155 ± 128 
f-TRP Placebo 5 5 6 6 7 7 7 14 
(3 - 6) (3 - 6) (3 -7) (3 -7) (4 - 10) (6 - 11) (5 -11) (9 - 26) 
BCAA 6 5 4 5 5 6 7 12 
(2 - 8) (2 -6) (3 - 6) (3 - 6) (4 - 6) (3 - 8) (5 - 10) (9 - 19) 
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Figure 4.3: Changes in the plasma concentration ratio of f-TRP to BCAA (median ± 
range) at rest and during exercise 
-120 -60 0 15 30 45 60 Ex 
Placebo 0.009 0.011 0.011 0.010 0.013 0.013 0.016 0.027 
(0.005 - (0.007 - (0.006 - (0.007 - (0.009 - (0.011 - (0.011 - (0.016 -
0.010) 0.012) 0.015) 0.015) 0.021) 0.024) 0.024) 0.053) 
BCAA 0.010 0.003 0.002 0.004 0.004 0.004 0.004 0.007 
(0.005 - (0.002 - (0.002 - (0.003 - (0.003 - (0.003 - (0.003 - (0.006-
0.015) 0.005) 0.004) 0.005) 0.005) 0.005) 0.006) 0.012) 
Figure 4.4: Change in core (A) and weighted mean skin (B) temperature CC) at rest 
and during exercise. 
Pr. 10 20 30 40 50 60 Ex 
Tru~ Placebo 37.3 37.4 37.8 38.0 38.2 38.3 38.4 38.9 
± 0.2 ±0.2 ±0.2 ±0.2 ±0.2 ± 0.2 ± 0.2 ±0.5 
BCAA 37.3 37.4 37.8 38.0 38.2 38.3 38.4 38.9 
±0.2 ±0.2 ± 0.1 ± 0.1 ±0.2 ± 0.2 ± 0.1 ±0.5 
Tslcin Placebo 33.0 34.6 35.4 35.6 35.7 35.8 35.9 36.1 
± 0.7 ±0.6 ±0.6 ±0.5 ±0.6 ±0.4 ±0.4 ±0.6 
BCAA 32.9 34.4 35.3 35.6 35.6 35.6 35.6 35.8 
± 0.6 ±0.4 ±0.3 ±0.3 ±0.4 ±0.4 ± 0.4 ±0.7 
Figure 4.5: Heart rate (beats.min- I ) at rest and during exercise. 
Pr. 10 20 30 40 50 60 Ex 
Placebo 58±10 126±13 130±10 133±9 137±6 139±9 141±1O 156±15 
BCAA 56±8 120±10 127±1I 129±1O 136±1O 138±9 142±1I 159±13 
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Figure 4.6: Rating of perceived exertion (RPE) and thennal stress (TS) during 
exercise. 
10 20 30 40 50 60 Ex 
RPE Placebo 12 ± I 12 ± 0 13 ± I 13 ± I 14 ± I 14 ± I 19 ± I 
BCAA 12 ± I 12 ± I 12 ± I 13 ± I 14 ± I 15 ± I 19 ± I 
TC Placebo 8±1 9±1 10 ± I 10 ± I 11 ±2 11 ± 2 12 ± 2 
BCAA 9 ± 1 9±2 1O± 2 1O±2 11 ±2 11 ± 2 13 ± I 
Figure 4.7: The relationship between the change in plasma FFA (mmol.L-') and 
plasma f-TRP (flmol.L-') during the placebo and BCAA trials 
Subject Placebo Placebo BCAA BCAA 
M"FA M-TRP M"FA M-TRP 
1.24 21 1.18 13 
2 0.35 6 0.58 6 
3 1.06 11 0.85 5 
4 0.25 7 0.58 4 
5 0.45 10 0.33 7 
6 0.39 6 0.44 7 
7 1.06 14 0.87 7 
8 0.66 5 0.71 6 
Figure 4.8: Plasma NH3 (mmol.L-') during the placebo and BCAA trials. 
-120 0 15 30 45 60 
Placebo 69.5 68.5 83.8 85.5 87.6 84.4 
±24.3 ± 19.5 ±22.6 ± 39.1 ± 33.8 ±24.7 
BCAA 63.6 84.2 120.0 123.5 126.8 135.2 
± 14.9 ±26.2 ± 27.3 ± 14.5 ± 20.2 ± 13.8 
Figure 4.9: Plasma prolactin concentration (ill.L-') at rest and at the point of 
exhaustion in the placebo and BCAA trials. 
Placebo 
BCAA 
Pre 
190.0± 151.2 
211.5±92.1 
Ex 
733.9 ± 408.6 
775 ± 394.4 
Ex 
94.7 
± 17.7 
134.7 
±6.8 
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Chapter 5 - Acute changes to the plasma concentration ratio of f-TRP to 
BCAA following the ingestion of carbohydrate and fat rich 
meals in man 
Figure 5.1: Resting plasma BCAA (A; /-lmol.L-1) and f· TRP (B; /-lmol.L-1) responses 
to the CRO and fat meals 
0 30 60 120 180 240 
BCAA CRO 393 ± 58 414 ± 73 335 ± 61 335 ± 63 337 ± 34 342 ±45 
Fat 404 ±45 422 ± 69 470 ± 66 434 ± 55 402 ±43 403 ± 39 
f-TRP CRO 5 ±2 6±1 5±1 5±1 5±1 5±1 
Fat 5±1 6±1 5±1 5±1 5±1 5 ± I 
Figure 5.2: Changes in the plasma concentration ratio off-TRP to BCAA in response 
to the CRO and fat meals 
0 30 60 120 180 240 
CRO 0.013 0.015 0.016 0.015 0.015 0.015 
± 0.005 ± 0.004 ± 0.004 ± 0.005 ± 0.004 ± 0.005 
Fat 0.013 0.015 0.011 0.011 0.012 0.013 
± 0.003 ± 0.002 ± 0.002 ± 0.002 ± 0.002 ± 0.003 
Figure 5.3: Resting plasma total-TRP (A; /-lmol.L-1) and changes in the plasma 
concentration ratio of total-TRP to BCAA (B) in response to the CRO and fat meals 
0 30 60 120 180 240 
TRP CHO 54 ± 10 59 ± 11 55 ± 11 53 ± 10 53±9 52 ± 10 
Fat 53 ± 7 59 ± 8 57±6 53 ±7 50±7 48 ± 6 
TRP:BCAA CRO 0.138 0.144 0.167 0.161 0.159 0.153 
± 0.019 ± 0.018 ± 0.029 ± 0.027 ± 0.029 ± 0.028 
Fat 0.132 0.143 0.122 0.122 0.128 0.119 
± 0.008 ± 0.019 ± 0.009 ± 0.18 ± 0.019 ± 0.012 
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Chapter 6 - Dopamine / Noradrenalin reuptake inhibition and exercise 
performance in temperate and warm environments 
Figure 6.1: Time trial performance (minutes) in the four experimental trials 
Trial Time 
Placebo 18 'c 30.6± 2.2 
Bupropion 18 'c 30.6 ± 1.9 
Placebo 30 'c 39.8 ± 3.9 
Bupropion 30 'c 36.4 ± 5.7 
Figure 6.2: Individual percent changes in exercise performance in the bupropion trial 
relative to the placebo trial in temperate (A) and warm (B) conditions 
Subject Temperate Warm 
-2.0 -8.2 
2 3.5 4.3 
3 4.9 4.3 
4 4.0 6.8 
5 -2.9 5.4 
6 0.7 21.6 
7 -12.1 22.5 
8 4.5 24.2 
9 1.0 14.1 
Figure 6.3: Time trial power output in the Tmp (A) and Wrm (B) trials (Watts) 
TTO TT5 TTlO TTl5 TT20 TT25 End 
plal8 279 ± 27 289 ± 42 283 ±44 270 ± 44 269 ± 37 274± 38 296 ± 47 
bup18 279 ± 27 294 ± 30 275 ± 31 276 ± 36 276 ± 40 272± 39 291 ± 44 
pl.30 279 ± 27 215±32 214 ± 30 204 ± 16 207 ± 28 203 ± 25 233 ±42 
bup30 279 ± 27 254 ± 39 237 ± 45 226 ± 35 228 ± 34 229 ± 35 277 ± 65 
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Figure 6.4: Core temperature CC) responses to the experimental protocol in Tmp (A) 
and Wrm (B) trials 
-10 o 10 20 30 40 50 60 TTlO TT20 End ReelS 
pla18 37.1 37.1 37.4 37.8 38.1 38.3 38.4 38.5 38.5 38.8 39.2 38.2 
± 0.3 ± 0.3 ± 0.3 ± 0.3 ± 0.2 ± 0.2 ± 0.2 ± 0.3 ± 0.3 
bup18 37.2 37.2 37.5 37.8 38.2 38.4 38.5 38.6 38.7 
±0.3 ±0.3 ±0.3 ±~3 ±0.3 ±0.3 ±0.3 ±0.3 ±0.3 
pla30 37.0 37.0 37.4 37.8 38.2 38.5 38.8 39.0 39.1 
±~ ±~ ±02 ±0.2 ±0.2 ±~2 ±~ ±~ ±0.3 
bup30 37.1 37.1 37.4 37.9 38.3 38.6 38.8 39.0 39.2 
± 0.2 ± 0.2 ± 0.4 
39.1 39.4 38.2 
± 0.2 ± 0.3 ± 0.5 
39.3 39.7 38.6 
± 0.3 ± 0.3 ± 0.4 
39.5 40.0 39.0 
±0.3 ±0.3 ±0.3 ±~3 ±0.2 ±0.2 ±0.2 ±0.3 ±~3 ±0.3 ±0.3 ±0.6 
Figure 6.5: Weighted mean skin temperature (QC) responses to the experimental 
protocol in Tmp (A) and Wrm (B) conditions 
-10 o 10 20 30 40 50 60 TT10 TT20 End ReelS 
pla18 31.3 30.9 31.7 33.3 33.7 33.7 33.6 33.7 33.2 33.6 33.5 30.7 
±0.7 ±0.7 ± 1.2 ± 1.1 ±0.8 ±0.8 ±0.8 ±0.8 ± 1.1 
bup 18 31.3 30.8 31.5 33.2 33.6 33.4 33.4 33.6 33.1 
pla30 
bup30 
± 0.5 ± 0.6 ± 0.8 ± 0.9 ± 0.9 ± 1.0 ± 1.1 ± 1.1 
33.0 33.4 35.2 35.8 35.8 35.8 35.8 35.9 
±0.7 ±0.5 
33.4 33.9 
± 0.4 ± 0.3 
35.3 35.8 
± 0.4 ± 0.4 ± 0.6 ± 0.7 
36.0 36.2 36.2 36.2 
±1.3 
35.8 
± 0.6 
36.1 
± 1.0 ± 1.1 
33.5 33.5 
±1.2 
35.8 
±0.6 
36.2 
±1.2 
35.8 
±0.8 
36.2 
1.3 
31.1 
1.3 
34.4 
0.9 
34.4 
± 0.6 ± 0.5 ± 0.5 ± 0.5 ± 0.5 ± 0.5 ± 0.6 ± 0.7 ± 0.8 ± 0.8 ± 1.1 1.2 
Figure 6.6: Heart rate (beats.min- I ) responses to the experimental protocol in Tmp 
(A) and Wrm (B) conditions 
-10 o 10 20 30 40 50 60 TTlO TT20 End ReelS 
pla18 65 62 
± 10 ± 5 
bup18 68 69 
± 8 ± 8 
pla30 66 66 
±8 ±6 
bup30 73 73 
141 143 144 146 148 
±8 ±8 ±10 ±9 ±ll 
144 149 149 150 151 
±8 ±8 ±9 ±1O ±1O 
148 153 158 162 165 
± 10 ± 9 ± 10 ± 10 ± 10 
152 157 159 165 166 
146 
±8 
151 
±9 
165 
±9 
168 
± 8 ± 12 ± 12 ± 9 ± 10 ± 10 ± 10 ± 9 
172 
±8 
173 
±9 
172 
±8 
179 
174 
±6 
177 
±8 
173 
±8 
179 
180 
±6 
181 
±8 
178 
±7 
183 
90 
±8 
93 
±9 
94 
±8 
106 
±9 ±IO ±12 ±5 
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Figure 6.7: Rating of perceived exertion during exercise in Tmp CA) and Wrm CB) 
conditions. 
15 30 45 60 TTlO TT20 End 
pl.IS 12 ± I 12 ± I 12 ± I 12 ± I 15 ± I 16 ± I 17 ± I 
buplS 12 ± 0 12 ± I 12 ± I 12 ± I 15 ± I 16 ± I 17 ± I 
pl.30 12 ± I 13 ± I 14 ± 2 14 ± 2 16 ± I 16 ± I 17 ±2 
bup30 12 ± I 13 ± I 13 ± 2 14 ± 3 16 ± 2 16 ± I 17 ± 2 
Figure 6.8: Perceived thermal stress during exercise in Tmp CA) and Wrm CB) 
conditions. 
15 30 45 60 TTlO TT20 End 
pl.IS 2±2 2±1 3±1 3±2 4±1 4±2 5±2 
buplS 2 ± I 2±2 3±2 3±2 4±2 5±2 5±2 
pl.30 3 ± I 4±2 4±2 5±2 6±2 6±2 6±2 
bup30 3±2 4 ±2 5±2 5±2 5±2 6±2 7±2 
Figure 6.9: Serum prolactin concentration Cng.mL·1) at rest and during exercise 
0 30 60 End ReelS 
pl.IS S.O ± 1.9 7.6 ± 2.0 S.0±2.1 26.0 ± 14.2 23.1 ± S.9 
buplS 7.6 ± 2.7 7.9 ± 2.0 9.3 ± 2.4 29.0 ± 13.1 24.1 ± 6.0 
pl.30 7.0 ± 1.5 13.4 ± 6.4 2S.3 ± 14.7 43.2 ± 19.5 31.2± 11.S 
bup30 7.6 ± 2.7 14.7 ± S.4 2S.1 ± 13.4 46.4 ± 14.7 35.S ± S.9 
Figure 6.10: Serum cortisol concentration Cng.mL-1) at rest and during exercise 
0 30 60 End Reel 5 
pl.IS 132.1 ± 46.3 141.S ± 3S.6 176.S ± 51.1 220.S ± 37.0 262.3 ± 36.2 
buplS 146.2 ± 29.4 147.3 ± 3S.7 16S.2 ± 55.4 233.4 ± 56.7 260.2 ± 45.2 
pl.30 111.4±34.7 120.6± 50.0 IS1.3 ± 3S.6 252.S ± 53.9 265.1 ± 52.2 
bup30 150.6 ± 25.7 160.0 ± 2S.9 204.3 ± 46.4 269.3 ± 27.3 2S7.S ± 40.4 
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Figure 6.11: Plasma adrenocorticotropic hormone concentration (ng.L·') at rest and 
during exercise 
0 30 60 End ReelS 
pl.18 26.6 ± 11.4 43.3 ± 15.0 54.3 ± 21.8 154.6 ± 60.9 101.4 ± 67.9 
bupl8 38.4 ± 27.5 54.0 ± 27.0 71.7 ± 35.7 215.3 ± 81.4 112.8 ± 44.4 
pl.30 23.1 ± 11.6 53.9 ± 25.7 109.7 ± 57.2 173.9 ± 86.3 87.2 ± 25.2 
bup30 37.9 ± 10.1 66.9 ± 24.7 114.0 ± 50.9 227.0 ± 68.2 105.2 ± 37.9 
Figure 6.12: Serum growth hormone concentration (mIU.L-') at rest and during 
exercise 
0 30 60 End ReelS 
pl.18 1.5 ± 4.0 5.0 ±2.7 7.3 ± 4.7 24.0 ± 11.9 10.7 ± 6.2 
bupl8 1.1 ± 2.6 5.2 ± 3.6 7.6 ± 4.6 32.5 ± 17.7 14.5 ± 6.5 
pl.30 1.3 ± 3.4 10.6 ± 8.3 16.4±9.1 25.4 ± 13.6 10.4 ± 5.9 
bup30 0.6± 0.7 9.5 ± 8.0 13.8 ± 9.6 30.5 ± 15.6 13.4 ± 7.2 
Chapter 7 - Serum SI OOb, a proposed marker of blood-brain barrier 
permeability, and prolonged exercise in temperate and warm 
environments in man 
Figure 7.1: Mean serum SI OOb (J.lg.L-') whilst at rest (0) and at the end of exercise 
(Ex60) in the Tmp and Wrm trials. 
Trnp 
Wrm 
o 
0.06 ± 0.04 
0.07 ± 0.05 
Ex60 
0.12 ± 0.13 
0.19±0.12 
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Figure 7.2: Change in core (A) and weighted mean skin (B) temperature (OC) at rest, 
during water immersion and exercise 
Pre ImIO Im20 Im30 10 20 30 40 50 60 ReelS 
Too" Tmp 37.4 37.3 37.2 37.2 37.6 38.0 38.2 38.2 38.3 38.3 38.0 
±0.2 ±0.2 ±0.2 ±0.2 ± 0.2 ± 0.1 ± 0.1 ± 0.1 ± 0.1 ± 0.1 ±0.2 
Wrrn 37.5 37.5 37.7 38.1 38.2 38.5 38.8 39.1 39.4 39.5 39.1 
±0.3 ±0.3 ±0.3 ±0.2 ±0.2 ±0.2 ±0.2 ±0.3 ± 0.3 ±0.3 ±0.3 
Tskin Tmp 32.6 34.3 34.5 34.5 28.7 30.0 30.8 31.2 31.4 31.3 32.1 
±0.5 ±0.5 ± 0.5 ±0.5 ±1.3 ±1.5 ±1.4 ±1.3 ± 1.2 ±1.3 ± 0.6 
Wrrn 32.8 37.1 37.4 37.8 36.0 36.4 36.5 36.7 36.9 37.1 34.0 
±0.7 ± 0.7 ±0.6 ±0.4 ±0.4 ±0.3 ±0.3 ± 0.3 ±0.2 ± 0.2 ±0.2 
Figure 7.3: Heart rate (beats.min,l) at rest, during water immersion and exercise 
Pre ImlO Im20 Im30 10 20 30 
Tmp 61 61 58 57 131 137 136 
± 10 ±7 ±7 ±9 ±9 ±8 ± II 
Wrrn 67 76 89 89 158 166 170 
±11 ± 14 ±8 ±7 ± 14 ± 12 ± 10 
Figure 7.4: Rating ofperceived exertion during exercise 
Tmp 
Wrrn 
10 
11 ± I 
\3 ± I 
20 
II ± I 
14 ± I 
30 
12 ± I 
14 ± 2 
40 
12 ± I 
15 ± 2 
40 
141 
±9 
176 
± 10 
50 
137 
±8 
176 
± 12 
50 
12 ± I 
16 ±2 
60 
138 
±7 
174 
± II 
Figure 7.5: Perceived thermal stress during water immersion and exercise 
Tmp 
Wrrn 
ImlO 
O±I 
3 ± I 
Im20 
O±I 
3 ± I 
Im30 
O±I 
4±1 
10 
1±2 
4±1 
20 
I ± I 
5±2 
30 
2±1 
5±2 
40 
2±1 
6±2 
50 
2 ± I 
6±2 
ReelS 
76 
±8 
101 
± 15 
60 
12 ± 0 
16 ± 2 
60 
2±1 
6±2 
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Figure 7.6: Blood glucose CA; mmol.L-') and lactate CB; mmol.L-') concentrations at 
rest, during water immersion and exercise 
-5 0 Post-Im 15 30 45 60 ReelS 
Glucose Tmp 5.2 ± 5.3 ± 4_9 ± 4_9 ± 4_9 ± 4.9± 4.8± 5.2 ± 
0.3 0.4 0.3 0.2 0.4 0.4 0.3 0.4 
Wrrn 5.3 ± 5.4 ± 5.0± 5.4 ± 5.5 ± 5.6± 5.5 ± 5.8 ± 
0.7 0.5 0.4 0.3 0.4 0.4 0.5 0.5 
Lactate Tmp 0.8 ± 0.7± 0.7 ± 2.5 ± 2.1 ± 1.8 ± 1.4 ± 0.8 ± 
0.2 0.2 0.2 0.8 0.7 0.6 0.2 0.2 
Wrrn 0.8 ± 0.8 ± 0.9 ± 3.4 ± 2.9 ± 2.9± 2.5 ± 1.5 ± 
0.3 0.3 0.2 0.9 0.9 0.7 0.4 0.4 
Figure 7.7: Plasma free-fatty acid concentration Cmmol.L-') at rest, during water 
immersion and exercise 
-5 0 Post-Im 15 30 45 60 ReelS 
Tmp 0.31 0.31 0.29 0.20 0.24 0.31 0.41 0.72 
± 0.11 ± 0.11 ± 0.12 ±0.08 ±O.IO ± 0.14 ±0.23 ± 0.28 
Wrrn 0.33 0.33 0.35 0.25 0.32 0.40 0.58 1.13 
± 0.15 ±0.14 ± 0.20 ± 0.15 ± 0.19 ±0.22 ±0.36 ± 0.40 
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Appendix II - Fluorimetric determination of tryptophan 
1 - Introduction 
Tryptophan (TRP) is an essential amino acid found in protein-rich dietary sources 
(meats, nuts, milk, eggs etc). It is unique amongst amino acids as around 80 - 90 % of 
TRP circulates in the blood loosely bound to albumin (McMenamy and Onciey, 
1958), with the remaining fraction circulating in a free form (f-TRP). While 
tryptophan fulfils a number important functions within the body, its role in the 
synthesis of the neurotransmitter, serotonin has received the greatest attention. In 
recent years the determination of circulating concentrations of plasma TRP has been 
an important step in the understanding of neurochemistry and has helped elucidate the 
role of serotonin in a number of psychiatric disorders. Many of the methods currently 
employ to determine plasma TRP typically require access to sophisticated and 
expensive instruments. Enzymatic methods are often many times cheaper to run, but a 
number of problems have been encountered with these techniques. 
A number of methods have been developed to measure TRP fluorimetrically, through 
the conversion of TRP to the fluorophore, norharman (Bloxam and Warren, 1974; 
Denckla and Dewey, 1967; Eccieston, 1973; Wood et aI., 1977). This is achieved by 
heating TRP in acid conditions in the presence of varying concentrations of 
formaldehyde and ferric chloride. While these assay methods have been previously 
employed to determine TRP concentrations in a number of previous investigations, 
we were unable to produce consistent and physiologically valid values in our 
laboratory environment. This problem has been widely reported (Bloxam and Warren, 
1974; Eccieston, 1973; Wood et ai., 1 977), and is probably the reason for the 
numerous revisions of the original method proposed by Denkla and Dewey (1967). 
The aim of the present method was to adapt the original fluorimetric method (Denckla 
and Dewey, 1967), in the light of subsequent revisions, to produce consistent (low 
variability) values for both free and total-TRP in our current laboratory environment. 
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2 -Methods 
Principle. The assay is based on the oxidative fonnation of norhannan from 
tryptophan by Ferric chloride (FeCh) in the presence of fonnaldehyde. The reaction is 
optimised by the presence of an acid medium and exogenous heat. See Denkla and 
Dewey (1967) for a detailed overview of the biochemical reaction. 
Reagents and apparatus required. All chemicals and biochemicals were obtained 
from Sigma (poole, UK) or BDH (Poole, UK). A filter fluorimeter (Locarte LF 8-9: 
Locarte, London, UK) with standard pyrex glass curvettes was used for the 
measurements. The excitation (373 nm) and emission (452 nm) wavelengths were 
isolated using filters. 
A tryptophan stock standard (250 Ilmol.L,I) was prepared by diluting 5.1 mg TRP in 
lOO mL O.IN NH40H (Denckla and Dewey, 1967). Appropriate working standard 
solutions were prepared immediately prior to each assay run as described in Table I. 
Table 1: Preparation of working standards for both free- and total-TRP analysis. 
TRP Concentration 5 Ilmol.L,1 10 Ilmol.L,l 25 Ilmol.L'l 50 Ilmol.L,l 
Stock sol (mL) 0.1 0.2 0.5 1.0 
Diluent (mL O.IN NH40H) 4.9 4.8 4.5 4.0 
Immediately prior to perfonning the assay, sufficient reaction mixture to run all 
standards and samples in duplicate, was prepared as follows; 
per mL of 0.3N PCA 2 % fonnaldehyde 
6 mmol FeCI3 
Sample collection and handling. Blood samples were collected at rest and during 
exercise via an indwelling venous cannula placed into a superficial forearm vein. 
Collected blood was immediately dispensed into tubes containing lithium heparin. 
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Following centrifugation to obtain plasma, 0.5 mL of plasma was placed into a tubes 
with a 12 kDa cellulose triacetate filter (Whatman, Maidstone UK) and spun for 2 h at 
-400g in a refrigerated (4 QC) fixed angle centrifuge. The resultant ultrafiltrate and the 
remaining whole plasma was stored at -20 QC for determination of f-TRP and total-
TRP respectively. 
f-TRP method. 2 mL of reaction mix was dispensed into plain pyrex tubes, to which 
20 ilL of blank, standard or ultrafiltrate was added. The tubes were firmly capped and 
the thoroughly mixed before incubating at 100 ± 1 QC for 1 h. Samples were then left 
to cool before decanting into fluorimeter tubes to be read. The exposure of the 
samples, and in particular the standards, to the FeCh was kept to a minimum prior to 
incubation « 10 min), to reduce the loss ofTRP (see the discussion). 
Total-TRP method. 20 ilL of whole (un filtered) plasma was deproteinised in 2 mL 
of ice-cold reaction mixture, and spun for 10 min in a centrifuge at 4000 rev.min'l. 
The supernatant was then dispensed into plain pyrex tubes. While the plasma samples 
were in the centrifuge, the standards were prepared to minimise the exposure of the 
standards to FeCh prior to incubation. The tubes were then firmly capped and the 
solution thoroughly mixed before incubating at 100 ± I QC for 1 h. Samples were then 
left to cool before decanting into fluorimeter tubes to be read. 
3 - Results and Discussion 
The enzymatic determination of plasma free- and total-TRP has been widely 
employed in both clinical and exercise based literature, yet problems have been 
reported with existing methods. This has lead to a number of revisions to the original 
methods. The assay described in this appendix is primarily based on a modification of 
the methods proposed by Bloxam and Warren (1974) and Eccleston (1973). 
Free- and total-TRP concentrations and CV s obtained using the present method were 
compared to values obtained using the widely employed method proposed by Bloxam 
and Warren (1974) and Eccleston (1973). A comparison of the results obtained are 
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presented in Table 2, based on the determination of 20 resting, overnight fasted 
samples. 
Table 2: Mean free- and total-TRP concentrations and variability expressed as 
coefficient of variation (CV) for the Bloxam and Warren (1974), Ecclestone (1973) 
and present methods. 
Method 
Bloxam and Warren 
Eccleston 
Present method 
f-TRP 
13.6 
4.3 
4.6 
TRP 
43 
43 
CVf-TRP 
(%) 
45.9 
2.1 
1.6 
CVTRP 
(%) 
1.6 
1.9 
It is clear from the present results that the modification of the original method by 
Bloxam and Warren (1974) failed to yield values within the normal physiological 
range. This value may have been influenced by the large variability in the technique, 
with a meaningful standard curve often difficult to construct. This would also 
significantly reduce the sensitivity of the assay. Similar observations have been 
previously reported by other laboratories (Wood et aI., 1977), yet this method has 
been routinely employed in a number of clinical and exercise based studies. 
The fluorimetric TRP method originally proposed by Denkla and Dewey (1967) and 
subsequently modified by Bloxam and Warren (1974) was based on the conversion of 
TRP to norharman, by heating in acid conditions in the presence of formaldehyde and 
ferric chloride (FeCb). Briefly, samples were deproteinised in trichloroacetic acid 
(TCA) with formaldehyde and FeCb added to the supernatant before incubation. The 
major problems encountered with this method relate to the use of TCA as the acid 
medium and the concentration of FeCI3 (Eccleston, 1973). During the incubation 
period, CO2 is liberated from TCA making it impossible to use stoppers to limit 
evaporative fluid losses. The original method requires this lost fluid to be replaced at 
the end of the heating step by adding an appropriate quantity of TCA before reading 
the fluorescence. This is both inconvenient and an obvious source of error. The 
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presence of FeCh may cause quenching, causing a progressive loss of TRP (Bloxam 
and Warren, 1974). This response only appears to occur in the standards (plasma TRP 
appears to be preserved;) and may result in distortion of the calibration curve. 
Changes implemented by Eccleston (1973) supplemented TCA with 30 % perchloric 
acid (PCA) added to distilled water, allowing the tubes to be capped during 
incubation. Thus preventing the evaporative loss and a potential source of error. The 
final concentration of FeCh was also halved to reduce the breakdown of the TRP 
present in the standards, yet still producing a linear relationship between TRP 
concentration and fluorescence. 
The present method further develops these previous methods by reducing the final 
concentration of PCA from 10 % to 2.5 %. This change in the acid medium did not 
appear to influence the TRP values obtained, with similar values for free- and total-
TRP measured between the present method and Eccleston's (see Table 2). The use of 
a more dilute PCA solution would also cut reagent costs. Additionally, a reaction 
mixture containing the appropriate concentrations of PCA, formaldehyde and FeCh 
was prepared, to which the ultrafiltrate and whole plasma samples were added. This 
process significantly reduced the number of pipetting steps and time taken to prepare 
the assay, limiting the exposure of TRP to FeCh prior to incubation that may 
influence the values obtained. 
The standard curve was found to be linear to 100 IlmoI.L-'. This assay may also be 
suitable for the determination of higher plasma concentrations, but these were not 
considered in the preparation of this method. 
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Appendix III - Thermal Sensation Scale 
-10 Cold impossible to bear 
-9 
-8 Very cold, shivering hard 
-7 
-6 Cold, light shivering 
-5 
-4 Most areas of body feel cold 
-3 
-2 Some areas of body feel cold 
-1 
0 Neutral 
1 
2 Some areas of body feel warm 
3 
4 Most areas of body feel hot 
5 
6 Very hot, uncomfortable 
7 
8 Extremely hot, close to limit 
9 
10 Heat impossible to bear 
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Appendix IV - Subjective Feeling Questionnaire 
Subject: Trial: Time: Date: 
Subjective Feeling 
How tired do you feel now? 
Not at all tired Very tired 
How alert do you feel now? 
Not at all alert Very alert 
How well can you concentrate now? 
Not at all well Very well 
How does your head feel now? 
Not at all sore Very sore 
214 

\ 
\ 
11 
I 
